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Introduction 
Introduction 
Submitted for publication in revised form as: 
Cholesterol lowering and atherosclerosis. Clinical benefit and possible 
mechanisms: an update. 
A.A. Kroon, A.F.H. Stalenhoef 
The results of several lipid lowering randomized trials were released during the 
past years and have confirmed the lipid hypothesis. Reduction of cholesterol by 
potent drugs in clinically symptomatic or asymptomatic patients with above 
average cholesterol levels will substantially reduce the risk of coronary events. 
The present article gives a review of potent cholesterol lowering treatments and 
discusses developments in cholesterol lowering treatment in relation to recent 
primary and secondary prevention studies. Additionally, possible mechanisms of 
retardation of the atherosclerotic process and different outcome measures for 
future regression studies are summarized. 
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Introduction 
Cardiovascular diseases are the major cause of death in the Western societies. In the 
Netherlands 40% of all deaths in 1993 were caused by cardiovascular diseases, of 
which 40% were ischemic heart disease and 23.5% cerebrovascular disease. The 
ability to prevent the development of atherosclerosis or, alternatively, to induce a 
decrease in the severity of established atherosclerotic plaques, often referred to as 
regression, has major implications for public health. 
The validity of the lipid hypothesis has been debated for more than 40 years. 
The relation between total cholesterol and low density lipoprotein (LDL) cholesterol 
levels and the incidence of coronary artery disease (CAD) and peripheral vascular 
disease (PVD) is now well established [1-5]. Epidemiologic studies have shown 
parallel, age-related trends of atherosclerotic lesions in the abdominal aorta, carotid, 
and coronary arteries [6-8]. Since the beginning of the 1980s many primary and 
secondary prevention trials, predominantly conducted in men with hyperchol-
esterolemia, have shown that lipid lowering regimens result in reduction of 
angiographic lesions and are associated with a decreased incidence of atherosclerotic 
events [9-42]. Most of these trials have shown slowing or arrest of progression of 
coronary atherosclerosis. Reports concerning femoral atherosclerosis are more scarce 
[12,21,23,24,29,32,33]. In several more recent clinical trials on plasma lipid regula-
tion measurements of carotid artery intima-media thickness (IMT) have been in-
cluded, since coronary and carotid atherosclerosis share coronary events as their 
major cause of morbidity and mortality [43-46]. Indeed, most of these studies have 
also shown a slowing of progression of IMT during lipid lowering treatment. 
The common denominator of most of these trials is reduction of LDL choles-
terol [47]. With the introduction of more potent cholesterol lowering agents, the 
HMG-CoA reductase inhibitors, the effects of lipid lowering on coronary and total 
mortality have been confirmed solidly, changing the lipid hypothesis into evidence 
[48]. In this introduction the background of cholesterol lowering treatment will be 
discussed in relation to atherosclerosis regression studies. In addition, outcome 
measures for lipid lowering studies are discussed, and an outline of the studies of the 
present thesis will be given. 
Cholesterol lowering treatments 
HMG-CoA reductase inhibitors 
Three-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase is an enzyme 
that catalyses the rate limiting step in the cholesterol biosynthesis [49]. HMG-CoA 
reductase inhibitors reduce serum cholesterol levels by inhibiting the endogenous 
synthesis of cholesterol, thereby upregulating LDL receptors especially in the liver 
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[50,51]. This leads to an increased removal from plasma of LDL as well as the 
precursors of LDL, intermediate density lipoproteins (IDL). This dual mechanism of 
decreased production and increased removal of LDL causes large reductions in serum 
cholesterol concentrations. Over the past few years numerous studies have shown the 
efficacy and safety of four HMG-CoA reductase inhibitors currently available: 
lovastatin, simvastatin, pravastatin, and fluvastatin. A reduction of total cholesterol 
ranging from 23-45% (mean 30%) can be achieved, due to a 26-42% (mean 35%) 
reduction of LDL-cholesterol. This effect is accompanied by a 11-32% (mean 20%) 
decrease in serum triglycerides and a 8-13% (mean 8%) increase of high density 
lipoprotein (HDL) cholesterol [52,53]. Some reports have shown an increase in 
lipoprotein(a) [Lp(a)] levels during treatment with these so-called statins, ranging 
from 8-12% [38,54].On a milligram basis simvastatin is twice as potent as pravastatin 
and lovastatin and four to eight times as potent as fluvastatin [55,56]. The 
nonapproved drug atorvastatin has been reported to decrease LDL-cholesterol by up 
to 60% and reduce triglyceride levels by up to 40% [57]. In general, HMG-CoA 
reductase inhibitors are well tolerated and side effects are neither serious nor frequent 
[52]. Apart from increases in liver enzyme levels greater than threefold the upper 
normal limit, which occur in approximately 1 % of statin-treated patients, the myopa-
thy syndrome (elevation of creatine kinase activity above tenfold the upper normal 
limit plus muscle pain or weakness) is the only side effect worth mentioning. The 
incidence of myopathy during monotherapy with statins is approximately 1 in 1000 
[58], although the combination with other treatments might amplify this risk [59]. In 
animal studies, treatment with HMG-CoA reductase inhibitors has been shown to 
retard the development of atherosclerosis [50,60-62]. Moreover, until now intensive 
lipid lowering using HMG-CoA reductase inhibitors is the most effective in terms of 
inducing plaque regression and consequently reducing the number of clinical events 
in men with established CAD and PVD [26,27,33,36,38-42,45,46]. Recently, a 
prospectively planned meta-analysis that pooled data from four studies treating men 
and women with 10 to 40 mg per day pravastatin for 2-3 years, showed that a de-
crease of LDL-cholesterol of 28% from baseline was associated with 62% reduction 
of the combined incidence of nonfatal and fatal myocardial infarction [63]. Moreover, 
statins may have stabilizing and protective effects on atherosclerotic lesions, by 
making them less vulnerable to fissure and rupture, and by restoring the 
hypercholesterolemia-induced endothelial dysfunction [64,65]. 
LDL-apheresis 
Alternative approaches of cholesterol lowering have been performed by portacaval 
shunting, liver transplantation and plasmapheresis [66-68]. The latter has been shown 
to reduce mortality of CAD [69]. New techniques have been developed to replace 
plasmapheresis, which remove apolipoprotein (apo) B-containing lipoproteins from 
plasma extracorporally. These methods make use of immuno-absorption columns, 
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chemical affinity columns, precipitation with heparin at low pH, and double filtration 
techniques [70-74]. Continuous LDL-apheresis using dextran sulfate cellulose col­
umns selectively removes apo B-containing particles from plasma by specific affinity 
between dextrans and apo В [72]. The performance of regular apheresis permits the 
achievement of lower levels of LDL-cholesterol, which are usually not possible to 
attain with drug therapy alone [75-78]. Adverse events from LDL-apheresis are 
infrequent and similar to any extracorporeal treatment. They mainly include hypoten­
sion and chills, which have been reported with frequencies ranging between 0.2 to 
1.1% and 0.3 to 6.0%, respectively [75,78]. LDL-apheresis has shown to change 
peripheral and cerebral hemodynamics favourably by short-term improvements of the 
rheological properties of whole blood and probably also by restoring the endothelium-
dependent vasodilation [79,80]. The application of this method may offer opportuni­
ties in the prevention of progression, or even inducing regression of atherosclerosis 
as has been shown in selected patients with a primary hyperlipidemia and established 
CAD or PVD [32,81-87]. 
Clinical trials 
In 1994, convincing evidence for the value of lipid lowering therapy in reducing 
clinical CAD events has been published in a meta-analysis of 28 randomized con­
trolled, primary- and secondary-prevention trials by Law et al. [88]. The analysis 
indicated that in men 55 to 64 years of age, a 10% decrease in total cholesterol 
produced a 7% reduction in ischemic events during the first 2 years of the trial, a 
22% reduction during years 2 to 5, and a 25% reduction after 5 years of the trial. 
These findings are consistent with a lag period between the initiation of therapy and a 
reduction in clinical events. 
Primary prevention trials 
The early primary prevention trials were too small to demonstrate significant changes 
in mortality [89]. The Lipid Research Clinics Coronary Primary Prevention Trial (LRC-
CPPT), a 10-years placebo-controlled study in 3806 men with elevated cholesterol 
[14,15], and the 5-years Helsinki Heart Study (HHS), in 4081 men with elevated LDL 
and/or very low density lipoprotein (VLDL) cholesterol [19], both showed a reduction 
in coronary events after long-term treatment with cholestyramine and gemfibrozil, 
respectively (Table 1). The investigators of the LRC-CPPT showed that each 1% 
reduction in serum cholesterol would result in an approximately 2% reduction in the 
risk of CAD [15]. After the disappointing results on mortality of the very large World 
Health Organization Clofibrate Trial [9], the LRC-CPPT and the HHS actually initiated 
the wide acceptance of the favourable effects of lipid lowering treatment on cardiac 
mortality or CAD incidence, although much debate was raised by the increase in non-
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Table 1. Primary prevention studies 
Study number mean study total non-fatal all CAD non-CAD 
[ref.no.] of patients duration (yr) cholesterol MI events mortality 
LA-VA 
[89] 
WHO-
clofibrate [9] 
LRC-CPPT 
[14] 
HHS 
[19] 
WOS-COPS 
[42] 
846 
10627 
3806 
4081 
6595 
7 
5.3 
7.4 
5 
4.9 
-13% -32% -23% n.c. 
-26%* -20%* +36%* 
-19% -19%* +33% 
-10% -36% -34%* +25% 
-20% -31%* -31%* -11% 
Data represent percent changes of the intervention group versus the control group. MI, 
myocardial infarction; CAD, coronary artery disease; n.c, not changed; *, statistically 
significant change 
cardiac mortality (Table 1). This excess of deaths in the intervention groups has been 
explained by the use of fibrates, but also by an overestimation due to intention-to-treat 
analyses and not adjusting for the regression dilution bias and the surrogate dilution 
effect [90-92]. To overcome some of the limitations of the LRC-CPPT, in which the 
decrease in cholesterol was less than expected due to poor compliance to the study-
drug, or of the HHS, which used an agent less effective in lowering cholesterol, the 
West of Scotland Coronary Prevention Study (WOSCOPS) was designed using one of 
the HMG-CoA reductase inhibitors (Table 1) [42]. In this double-blind, randomized, 
placebo-controlled trial 6,595 men between 45 and 64 years of age with a mean LDL-
cholesterol of 5.0 mmol/L were treated with 40 mg per day pravastatin or placebo for a 
mean of 4.9 years. LDL-choIesterol was lowered on the average by 26% and the major 
endpoint, death from CAD or nonfatal myocardial infarction showed a significant 
relative reduction of 31%, whereas overall mortality was reduced by 22% without 
excess of noncardiovascular deaths. This study unequivocally showed that primary 
prevention with a well tolerated and potent drug, in a population at relatively low risk 
for CAD and no history of myocardial infarction, is effective and may also have major 
impact for healthcare costs. The clinical benefits of lipid-regulating therapy in primary 
prevention trials forgoing WOSCOPS have been less dramatic and a matter of constant 
debate. However, hypercholesterolemic individuals without established CAD represent 
an important population who will eventually die or become disabled by a coronary 
event. Several studies are underway, which may provide more information on the bene-
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fits and risks of several treatment modalities in the primary prevention of CAD [93]. 
Secondary prevention trials 
The Scandinavian Simvastatin Survival Study (4S) provided definitive evidence of the 
benefit of lowering LDL-cholesterol in patients with established CAD [39]. In this 
double-blind, randomized, placebo-controlled study, 4444 men and women with 
serum total cholesterol levels between 5.5 and 8.0 mmol/L were allocated to 20 to 
40 mg per day simvastatin or placebo. After a median treatment period of 5.4 years, 
LDL-cholesterol was lowered by on the average 35%, and the total mortality was 
reduced by 30% because of a CAD mortality rate reduction of 42% in the 
simvastatin-treated patients. Evidently, lipid lowering in a population at high risk of 
coronary events is even more effective in reducing coronary and total mortality. 
Since the separation of cholesterol lowering trials into those studying primary and 
those studying secondary prevention has little foundation in coronary pathology, 
WOSCOPS and 4S indicate that more aggressive lipid lowering further reduces the 
progression of CAD. Indeed, renewed meta-analysis of randomized cholesterol 
lowering trials has shown a regression line between CAD and total mortality versus 
the percent of cholesterol reduction, indicating that further lowering of total choles-
terol concentrations is associated with a decreased mortality [90]. Only recently, the 
Familial Hypercholesterolaemia Regression Study [87], the first randomized, con-
trolled study using LDL-apheresis was published. Biweekly LDL-apheresis plus 
40 mg per day simvastatin aggressively decreased LDL-cholesterol levels by 53%, 
which was significantly different from the 44% reduction induced by 40 mg/day 
simvastatin plus 20 g per day colestipol or 16 g per day cholestyramine. Despite these 
differences in LDL-cholesterol reduction, the mean percent diameter stenosis of the 
coronary arteries and the number of patients classified as progressors and regressors 
after 2 years of treatment did not differ significantly between the two groups. Al-
though LDL-cholesterol was further lowered than in any of the above mentioned 
studies, the differences between the two treatment groups may have been too small 
and the intervention period too short to confirm the assumption that more aggressive 
lowering of LDL-cholesterol induced more reduction in CAD. As has been indicated 
by the meta-analysis of Law et al. [88], the greatest changes in atherosclerosis may 
be found after more than 2 years of intervention. Moreover, in a recent analysis of 
11 angiographic coronary atherosclerosis regression studies it was plotted that in 
patients with CAD, reduction of LDL-cholesterol by 44% for the duration of 2.6 
years should completely arrest the progression of the disease [94]. 
The extent of cholesterol lowering 
Current international guidelines for the secondary prevention of CAD in Europe and 
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the USA stipulate that LDL-cholesterol levels should be reduced to 3 to 3.5 mmol/L 
and to 2.6 mmol/L or below, respectively [95,96]. However, the recently published 
subgroup analysis of the 4S Study showed that percentage reductions in LDL-choles-
terol (32-37%) and decrease in relative risk of CAD (32-36%) were comparable and 
constant across all quartiles of baseline LDL-cholesterol, which ranged from below 
4.39 mmol/L in the lowest quartile to more than 5.39 mmol/L in the highest quartile 
[97]. This indicates that, at least in subjects with total cholesterol between 5.5 and 
8.0 mmol/L, the percentage reduction in LDL-cholesterol rather than its absolute 
level on treatment is determinant of clinical benefit, since subjects in the 4S study 
with LDL-cholesterol levels well above the recommended value showed the same 
reduction in CAD risk as those below these levels. Indeed, in the aforementioned 
analysis of 11 coronary atherosclerosis regression studies it has been shown that 
percent change in diameter stenosis of coronary arteries was correlated with percent 
change in LDL-cholesterol during the study and not with on-trial LDL-cholesterol 
concentrations [94]. These results, however, do not fit with the results of Harvard 
Atherosclerosis Reversibility Project (HARP), which studied the effect of intensive 
lipid lowering in 40 normocholesterolemic patients [34]. After 2.5 years of treatment 
with pravastatin and/or nicotinic acid and/or cholestyramine and/or gemfibrozil, to 
lower LDL-cholesterol, increase HDL-cholesterol, and decrease serum triglycerides, 
no differences in coronary atherosclerosis were observed between the controls (LDL-
cholesterol 3.59 mmol/L) and the actively treated subjects (LDL-cholesterol 2.23 
mmol/L) as measured by quantitative coronary angiography. These results were 
noted in the face of significant differences between the active and placebo groups: 
LDL -cholesterol -41%, HDL-cholesterol +13%, and triglycerides -26%. Although, 
HARP was a small study and the only negative angiographic regression study, these 
observations may reflect the importance of other risk factors in promoting progres-
sion of CAD. Consequently the issue of cholesterol lowering to recommended, fixed 
target values versus guidelines in percent reduction of baseline cholesterol levels is 
not solved yet and needs more studies. 
Mechanisms of cholesterol lowering in retardation of atherosclerosis 
Several mechanisms have been suggested by which lowering of LDL-cholesterol may 
confer clinical benefit, including stabilization of rupture-prone atherosclerotic lesions, 
decreased LDL-oxidizability, improvement of vascular endothelial function, and 
reduction of an inflammatory or immunologic response associated with atherosclero-
sis [98]. 
Plaque stabilization 
The culprit lesion causing thrombosis of the coronary arteries is thought to be a 
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30-50% Stenosis in the majority of cases. These early lesions, characterized by a 
lipid-rich core, a thin fibrous caps, few smooth muscle cells and fibroblasts, and a 
large number of foam cells particularly at the shoulders of the caps, are prone to 
rupture and lead to thrombotic occlusions and consequent clinical events [64,99]. 
Moreover, enhanced vasoconstriction potentially promotes plaque fissuring and 
ulceration, which may lead to thrombosis [100,101]. Evidently, there seems to be a 
dissociation between the results of angiographic studies and clinical outcome: lipid-
lowering therapy has shown to reduce the incidence of cardiovascular events without 
marked changes in coronary anatomy [102-104]. Therefore, it is most likely that 
treatment of hypercholesterolemia depletes the lipid core of early atheromatous 
plaques, and consequently stabilizes these lipid-rich lesions and prevents further 
complications such as intramural haemorrhage and intraluminal thrombosis, an 
assumption that has been demonstrated in the Canadian Coronary Atherosclerosis 
Intervention Trial (CCAIT) and the Stanford Coronary Risk Intervention Project 
(SCRIP) [36,104-106]. 
LDL-oxidizability 
Evidence exists to suggest that oxidative modification of LDL plays a key role in the 
development of atherosclerosis. It has been shown that LDL must undergo oxidative 
modification before it can be taken up by macrophages [98,107]. Oxidative modifica-
tion of LDL, which may be mediated by cell-surface receptors [108], converts it to a 
form recognized by the macrophage scavenger receptor [109], leading to its unlimited 
uptake and the formation of foam cells, an early hallmark of atherosclerotic plaques. 
In addition to promoting excess lipid accumulation, oxidized LDL may facilitate the 
progression of atherosclerotic lesion by disrupting the normal endothelial cell func-
tion [110]. The finding of oxidized LDL and lipid peroxides in areas of atheroscle-
rotic plaques and the observations that antioxidant treatment with probucol and 
vitamin E slows the progression of atherosclerosis in the animal model strongly 
support the role of LDL modification in atherogenesis [111-115]. However, a de-
crease in oxidative susceptibility alone is not sufficient to attenuate atherogenesis 
when cholesterol levels remain markedly elevated [116,117]. Recent evidence indi-
cates that oxidized LDL inhibits endothelium-dependent arterial relaxation by dimin-
ishing the release of vasoactive compounds such as endothelium-derived relaxing 
factor [118]. Moreover, in a case-control study of 270 subjects in the Helsinki Heart 
Study it has been shown that mean levels of antibodies against oxidized LDL were 
significantly higher in individuals who had a coronary fatal or nonfatal event com-
pared to controls [119]. 
Endothelial cell dysfunction 
The normal endothelium participates in the regulation of the vascular tone by releas-
ing substances with both anti-aggregating and vasodilating properties, such as 
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prostacyclin and endothelium-derived relaxing factor (EDRF), identified as nitric 
oxide (NO), and also substances with contracting properties, such as endothelin 
[120,121]. Early in the process of development of atherosclerosis increased reactions 
to contractile agonists and attenuated vasodilating responses have been observed 
[122]. It has been shown in animal models that the release of protective, anti-aggre-
gating and vasodilating substances is diminished in atherosclerotic vessels and also as 
a consequence of hypercholesterolemia per se [123-129]. In humans, coronary ath­
erosclerosis and hypercholesterolemia have also been associated with dysfunction of 
endothelium mediated vasomotion, which impairs coronary or myocardial blood flow 
and forearm blood flow [130-134]. Lipid lowering therapy has shown to improve the 
endothelium mediated vasomotion after relative short periods of time [135,136]. For 
example, Egashira et al. [135] demonstrated a significant improvement in coronary 
blood flow in response to acetylcholine infusion in patients with hypercholesterolemia 
and pravastatin therapy. Only recently, Anderson et al. [137] showed that the addi­
tion of antioxidant therapy with probucol to cholesterol lowering treatment with 
lovastatin improved acetylcholine-induced endothelium-dependent vasodilation signif­
icantly more than cholesterol lowering alone. Moreover, in this process of reversal it 
has been found that functional improvements of the coronary circulation precede the 
structural, anatomical improvements [138]. 
Reduction of inflammatory or immunologic response 
The initial inciting event in atherosclerosis is intimai lipid deposition, which is fol­
lowed by recruitment of inflammatory cells (monocytes and T-lymphocytes) into the 
intima, smooth muscle cell accumulation, and elaboration of collagen and matrix 
proteins by smooth muscle cells. These processes have been shown to be mediated by 
minimally modified LDL. They induce the expression of and interplay between 
adhesion molecules (selectins, ICAM-1, and VCAM-1), monocyte chemotactic 
proteins (e.g. MCP-1), growth factors (e.g. PDGF), and cytokines (IL-1, IL-4, IL-6, 
TNFa, and INFY)[H0,139,140]. It has been shown that systemic administration of 
oxidized LDL stimulates leucocyte adhesion and platelet aggregation to the vascular 
endothelium [141]. In both men and rabbits, autoantibodies are found which recog­
nize and selectively bind oxidized LDL [111]. Moreover, the titre of autoantibodies 
binding malondialdehyde-LDL was found to be an independent predictor of the 
progression of carotid atherosclerosis in man [142]. The proliferation of smooth 
muscle cells is promoted by a number of growth factors, including IL-1 β and IL-1 a, 
which are secreted by activated monocytes, macrophages, and endothelial cells [143]. 
Oxidized LDL has been shown to induce T-cell activation, which modulates the 
IL-1 ρ and tumour necrosis factor (TNFa) release [144], whereas IL-4 has been found 
to induce 15-lipoxygenase activity of human monocytes, inducing lipid peroxidation 
[140]. All these data indicate that several potential atherosclerosis reversal mecha­
nisms exist, of whom reduction of the number of LDL particles is a central one. 
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Outcome measures for future cholesterol lowering studies 
Quantitative Coronary Angiography (QCA) 
Quantitative methods for analyzing the extent of coronary atherosclerosis from 
arteriograms have been developed and extensively evaluated [145-148]. In lipid 
lowering trials, hard clinical endpoints such as improved survival and reduction of 
major cardiac events are generally accepted outcome measures, however, they re-
quire numerous patients over a long intervention period [14,19,23,39,42]. At the 
moment, QCA is the best surrogate endpoint for evaluation of lipid-lowering therapy 
in CAD [25-27,30,33-36,38,40,41] and has been shown to correlate strongly with 
future coronary events [149,150]. The application of QCA, however, has several 
limitations such as the diffuse character of coronary atherosclerosis, the complexity 
of stenosis geometry, the foreshortening in non-orthogonal views, the insufficient 
contrast staining and the limited resolution of the radiographic chain [151,152]. 
Moreover, there seems to be a dissociation between the results of angiographic 
studies and clinical outcome: lipid-lowering therapy has shown to reduce the inci-
dence of cardiovascular events without marked changes in coronary anatomy [153]. 
However, as discussed before, treatment of hypercholesterolemia has shown to 
stabilize minor atheromatous plaques by depleting the lipid core. Therefore, not the 
relatively small changes in angiographic lumen size, but plaque stabilization appears 
to decrease the risk of disruption and consequently the clinical events [104]. Given 
these small changes in the severity of lesions and the unclear clinical benefits of such 
changes, the addition of measurements that predict the functional significance of 
alterations in coronary stenosis seems important [154]. 
Assessment of regional myocardial perfusion 
The cumulative effects of all anatomical and functional abnormalities of the epicardial 
coronary arteries, in combination with possible dysfunction of conduit and resistance 
vessels, are responsible for the ultimate effect of atherosclerosis on myocardial blood 
flow. The regional myocardial blood flow assessed by digital subtraction angiography 
and followed by videodensitometric calculation of the hyperemic mean transit time 
(HMTT) of contrast has been shown to be an important functional measure for the 
hemodynamic consequences of vascular stenosis [155-157]. Moreover, it reflects the 
integrated flow capacity of the entire coronary arterial and arteriolar vascular system, 
which has also been shown by Gould et al. [158], using the noninvasive assessment 
of the myocardial perfusion by rest dipyridamole positron emission tomography. In 
one of the previously cited angiographic studies it was suggested that increased 
coronary flow induced by enhanced vasodilation after lipid lowering therapy may also 
involve the smaller resistance arteries of the myocardium [133]. This is in agreement 
with data after LDL-apheresis evaluating skeletal muscle and cerebral circulation 
after acute reduction of serum cholesterol levels [79,80], and data from positron 
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emission tomography [158,159]. So, in addition to the anatomical assessment of 
changes in the luminal encroachment by QCA, functional measurements of coronary 
flow should be added to evaluate the impact of lipid lowering interventions. 
Non-invasive assessments of CAD or PVD 
Intima-media thickness of the carotid artery 
In several more recent clinical trials on plasma lipid regulation and risk factor analy-
sis, measurements of carotid artery intima-media thickness (IMT) have been in-
cluded, since coronary and carotid atherosclerosis share coronary events as their 
major cause of morbidity and mortality [43-46]. The measurement of the IMT of the 
carotid artery has been shown to be a reproducible method for the analysis of early 
vascular lesions [160,161]. It has also been found that high-resolution B-mode ultra-
sonography of the carotid artery is an effective and accurate method in the assessment 
of atherosclerotic changes of the arterial wall [162-164]. This technique has now been 
applied in a number of studies and it has been shown that the IMT of the carotid 
artery reflects generalized atherosclerosis, indicated by its association with coronary 
and lower extremity atherosclerosis [165-171]. 
Ankle-arm index and femoral artery Doppler spectrum analysis 
Peripheral vascular lesions of the lower extremities can also be detected non-
invasive^ using ultrasound techniques. It has been shown that these techniques are 
important surrogate variables for clinical end-points in quantitative measurements of 
hemodynamically significant atherosclerotic manifestations [172]. The ankle/arm 
systolic pressure ratio at rest and during hyperemia is a reproducible method to 
determine the presence of arterial insufficiency in the lower limbs [173,174]. To 
differentiate between hemodynamic significant stenotic segments located in the 
aortoiliac or the femorotibial tract, measurement of this pressure ratio should be 
combined with the assessment of blood flow velocities in the common femoral artery 
obtained by Doppler spectrum analyses [175,176]. The combined use of both tech-
niques at rest and during reactive hyperemia has been shown to enhance the sensiti-
vity of detection of peripheral vascular atherosclerotic lesions [167,177]. 
Outline of the present thesis 
In this thesis we intended to study whether aggressive lipid lowering induces more 
retardation of the progression of atherosclerosis than conventional treatment. With the 
availability of LDL-apheresis we had the opportunity to compare the outcome of this 
relatively new method of lipid lowering with conventional drug therapy. 
We first studied the effect of long-term cholesterol lowering with pravastatin in an 
animal model for homozygous familial hypercholesterolemia (FH), Watanabe heritable 
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hyperlipidemic rabbits, and assessed changes in coronary and peripheral atherosclerosis 
as well as endothelium-dependent vasodilation (chapter 2). 
The main study of this thesis, the LDL-Apheresis Atherosclerosis Regression 
Study (LAARS), was an open, randomized, single center, prospective trial in primary 
hypercholesterolemic men with extensive CAD. In order to determine whether more 
aggressive lipid lowering with biweekly LDL-apheresis plus simvastatin exerted better 
an anti-atherosclerotic effect than conventional lipid lowering with simvastatin alone, 
42 subjects were treated for 2 years. The design of LAARS, the methods of follow-up, 
and some baseline characteristics of the patients are described in chapter 3. 
Treatments using selective LDL-apheresis remove large amounts of apo B-con-
taining lipoproteins from the body in a short time. Sawtooth-like alterations in lipopro-
tein concentrations are one of the most striking differences between patients undergoing 
repetitive LDL-apheresis and patients on conventional therapy. The efficacy of the 
treatment depends on the pre- and posttreatment lipid levels, and on the posttreatment 
return of lipids in plasma. Moreover, changes in the relative cholesterol and protein 
content may lead to compositional and conformational changes of the LDL particle, 
which may result in a different susceptibility to oxidation. Therefore, the kinetics of the 
rebound of LDL-apheresis and apheresis-induced changes in LDL-oxidizability were 
analyzed and described in chapters 4 and 5. 
The results of LAARS concerning the primary outcome variables, quantitative 
computer-assisted analyses of coronary angiograms and the videodensitometric mea-
surement of the regional myocardial blood flow are presented in chapters 6 and 7, 
respectively. Assessments of PVD are described in chapters 8 and 9. Chapter 8 de-
scribes the determination of the prevalence of hemodynamically significant PVD of the 
lower extremities in heterozygous FH patients of the outpatient lipid clinic of the 
University Hospital of Nijmegen, using noninvasive methods of assessment. In addi-
tion, the analyses of the secondary outcome measures of LAARS, the ultra-sonographic 
determination of change in PVD in the carotid arteries and the aortotibial tract, are 
described in chapter 9. 
Until recently, one of the main indications for LDL-apheresis was homozygous 
FH. Finally, in chapter 10 a case report of a female, homzygous FH patient, not a 
LAARS subject, who was treated with LDL-apheresis for more than 4 years, is pre-
sented as an example of the long-term effects of LDL-apheresis on coronary morbidity 
and mortality. 
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In 3-month-old homozygous Watanabe heritable hyperlipidemic (WHHL) rabbits the 
effect of treatment with the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase inhibitor pravastatin was studied for 9 months and related to the endothelial 
function of the coronary arteries of isolated hearts and rings of the distal abdominal 
aorta. Oral administration of pravastatin in doses up to 40 mg/kg per day significantly 
decreased plasma cholesterol by 51% in comparison to untreated WHHL rabbits. Basal 
coronary flow and bradykinin-induced increase in coronary flow in Langendorff hearts 
of the pravastatin-treated animals were significantly greater than the flow in the control 
animals, whereas the metacholine-induced relaxation of abdominal aortic rings was not 
different and attenuated in comparison to New Zealand white rabbits. The incidence of 
atherosclerotic lesions in four main coronary arteries and the aorta was significantly 
lower in the pravastatin treated animals (25.0% and 52.8%, respectively) than in 
untreated WHHL rabbits (34.1% and 80.0%, respectively). The mean percentage of 
narrowing in the aorta was also significantly lower in the pravastatin-treated group 
(12.0%) than in the controls (25.2%). Significant correlations were found between the 
extent of atherosclerotic lesions and the bradykinin-induced increase in coronary flow 
versus plasma total cholesterol levels. Thus, in this model, long term cholesterol 
lowering treatment with pravastatin starting at an early age retards the progression of 
plaque formation and preserves the endothelium-dependent relaxation of the coronary 
arteries. 
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Introduction 
Homozygous Watanabe heritable hyperlipidemic (WHHL) rabbits lack the low density 
lipoprotein (LDL) receptor due to a monogenic disorder [1]. Therefore, normal 
receptor-mediated clearance of LDL in vivo is impaired and consequently the grossly 
elevated serum cholesterol levels lead to atherosclerosis and xanthomatosis at 
premature age, which progress with aging [2,3]. The atherosclerotic lesions closely 
resemble those in humans, and therefore this animal serves as a unique model of 
familial hypercholesterolemia in men [1,2]. 
Atherosclerosis can alter vascular reactivity [4]. The normal endothelium 
participates in the regulation of the vascular tone by releasing substances with both 
anti-aggregating and vasodilating properties, such as prostacyclin and endothelium-
derived relaxing factor (EDRF), identified as nitric oxide (NO), and also substances 
with contracting properties, such as endothelin [5]. In the process of development of 
atherosclerosis, increased reactions to contractile agonists and attenuated vasodilating 
responses have been observed [6]. The release of protective, anti-aggregating and 
vasodilating substances is diminished in atherosclerotic vessels [7-9], and also as a 
consequence of hypercholesterolemia per se [9,10]. 
Evidence is emerging that oxidative modification of LDL is an important feature 
in the development of atherosclerosis [11]. Moreover, the accumulation of native and 
oxidatively modified LDL in atherosclerotic plaques [12,13] has been shown to impair 
endothelium-dependent vasodilation [14]. 
Pravastatin is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase, an enzyme that catalyses the rate limiting step in the cholesterol 
biosynthesis [IS]. In animal studies, treatment with HMG-CoA reductase inhibitors has 
been shown to retard the development of atherosclerosis [16-19]. 
In the present study, the effects of cholesterol lowering by long term administra-
tion of pravastatin was studied on the progression of atherosclerosis in WHHL 
rabbits. The results were related to measurements of the endothelial function in both 
coronary arteries of the isolated heart and in the isolated distal aorta from the same 
animal. 
Materials and Methods 
Animals 
Homozygous WHHL rabbits were bred by crossing and back-crossing with New 
Zealand white (NZW) rabbits [20]. They were housed individually in metal cages in a 
room maintained at constant temperature and humidity, and maintained on a regular 
diet (LK04, Hope Farms, Woerden, the Netherlands). Three-month-old animals 
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matched for sex and cholesterol, were divided into two groups. Ten rabbits were fed 
0.06% (w/w) pravastatin-enriched pelleted chow at 100 g per day (20 mg/kg per day) 
for the first 5 months of the study and 0.12% (w/w) pravastatin (40 mg/kg per day) 
from the sixth month to the end of the intervention at 9 months (group P; six males and 
four females). A second group of ten rabbits consumed unmodified LK04 pelleted 
chow and served as controls for progression of atherosclerosis (group C; six males and 
four females). Food intake was monitored daily for all groups. Body weights were 
determined every 4 weeks. 
Three animals from group Ρ died at the age of 6, 7 and 9 months, in the third, 
fourth and sixth months of the study respectively. The cause of death shown by autopsy 
was a Pasteurella multocida infection of the lungs and the upper respiratory tract. 
Measurements of endothelial function and the extent of atherosclerosis are presented 
for 17 animals. 
In order to compare the effect on endothelial function of the coronary arteries and 
a segment of the distal abdominal aorta, six 6-month-old NZW rabbits (three males and 
three females) were also studied as normal controls. 
Measurements of lipid levels 
After an overnight fast, blood samples were drawn from ear arteries for measurement of 
serum lipid levels every 4 weeks. Two series of baseline levels were taken. Plasma 
cholesterol and triglycerides were determined by enzymatic methods on a centrifugal 
analyzer using commercially available reagent for cholesterol (CHOD-PAP, no. 237574 
Boehringer, Mannheim, FRG) and triglycerides (Sera-PAK, Miles, Italy, cat. no. 6639). 
Determination of endothelial function 
After 9 months of treatment, the rabbits were anesthetized intravenously with 
6.0 mg/kg sodium pentobarbital. After heparin (1500 IU) was administrated intra­
venously, they were sacrificed by removing their heart and complete aorta from the 
ascending aorta to the ilial bifurcation. The heart was excised rapidly and put into icy 
saline. Retrograde perfusion of the aorta, essentially by the Langendorff method, was 
achieved immediately, as described in Ref. 21. Perfusion pressure was maintained 
constant at 60 mmHg by means of a microprocessor-controlled perfusion pump, which 
also calculated the coronary flow continuously. Left ventricular pressure was recorded 
by means of a cannula in the left ventricle. All hearts beat spontaneously. The standard 
perfusion medium used was a modified Tyrode solution, containing 10 mM glucose and 
equilibrated with 95% oxygen and 5% carbon dioxide. The temperature was kept 
between 37.5° and 38.0°C. A bipolar ECG and heart rate were recorded continuously. 
After a 15 min equilibration period using standard perfusion medium, basal coronary 
flow was determined. Next, a dose-response curve of bradykinin (10"'° - IO'7 M) was 
obtained. Seven different concentrations of bradykinin were studied in increasing 
sequence for each heart. After the administration of one concentration for 2 min, there 
26 
oooooooooo·· 
was a washout period of 5 min before the next concentration was administered. After 
another equilibration period of 15 min, endothelium-independent relaxation with 1 mM 
sodium nitrite was determined. 
For measurements of isotonic displacements, a portion of the distal abdominal 
aorta was used. The aorta was carefully removed and placed in an oxygen/carbon 
dioxide enriched Krebs' solution at constant pH. During the preparation, any contact 
with the luminal surface was avoided to preserve endothelial integrity. Rings of 2 mm 
in length were mounted in 10 ml organ baths, filled with Krebs' solution at 37.5°C. The 
rings were given a preload weight of 3.5 g and allowed to stabilize for 90 min, during 
which regular washings were performed. Thereafter, they were preconstricted with 
10 μΜ phenylephrine. Once a stable contraction level was established, endothelium-
dependent relaxations were evoked by adding cumulative concentrations of 
metacholine (ÎO'-IO"4 M bath concentrations). Subsequently, rings were washed and 
allowed to stabilize for 45 min. After the rings were preconstricted again as described 
above, endothelium-independent relaxations were induced by adding cumulative 
concentrations of sodium nitrite (10"M0'2 M). In this way, nine different concentrations 
of metacholine and sodium nitrite were studied. Relaxations were expressed as a 
percentage of change of the previously established contraction with phenylephrine. All 
experiments with the aortic rings were performed in duplicate. 
Measurement of atherosclerotic lesions 
Immediately after the rabbits were sacrificed, the aortas were fixed in 10% formalin. 
The hearts were fixed in 10% formalin at the end of the perfusion studies. Coronary 
atherosclerosis was examined as described by Watanabe et al [16]. Accordingly, the 
heart was cut in eight equal cross-sections of ventricle. The aorta was divided into three 
portions: the ascending aortic arch, the descending thoracic aorta and the abdominal 
aorta were cut in 8, 10 and 1 6 - 1 8 equal transverse segments, respectively. These 
cross-sections of the hearts and the aortas were embedded in paraffin and 5 μπι sections 
were stained with hematoxyline-eosin, Azan-Mallory and elastica-van Gieson. Luminal 
narrowing was assessed by computer-assisted stereologic point counting [22], using a 
Zeiss stereomicroscope which superimposed an integrated eyepiece graticule with 
168 intersection points of horizontal and vertical lines on the transverse segments of the 
vessels. The internal elastic lamina was taken as the original luminal border. The 
percentage of luminal narrowing was calculated from the ratio of the number of points 
lying on and within the area bounded by the internal elastic lamina and the points 
within the still patent lumen. Four coronary arteries were studied: the left anterior 
descending artery (LAD), the left circumflex artery (LCX), the left septal artery (LSP) 
and the right coronary artery (RCA). 
Statistical analysis 
Unless indicated otherwise, a one-way analysis of variance (ANOVA) was used to 
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analyze differences within group means. Differences in the mean value of the body-
weight, the lipid levels, the percent of narrowing of the atherosclerotic lesions in the 
aorta and the coronary arteries were tested for significance by Tukey's contrast method 
for multiple-comparison, in addition to the ANOVA. The relation of plasma total 
cholesterol to the extent of atherosclerotic lesions and coronary flow was quantified by 
using the Pearson product-moment correlation coefficient. A P-value of less than 0.05 
was considered to be significant. Statistical analyses were performed with procedures 
available in the SPSS software package (SPSS Inc., Chicago, IL). Results are expressed 
as means ± S.D., unless otherwise indicated. 
Results 
General characteristics 
There were no significant differences in age, sex distribution and body-weight between 
the comparative groups of WHHL rabbits (Table 1). During the first 6 months of the 
study, the pravastatin-treated group (P) and the control group (C) showed equal weight 
gain of about 400 g (19.1%). In the following months no increase in body weight was 
found, and no significant differences were present between the groups (Fig. 1). 
The food consumption was both constant and comparable between the groups. 
The content of pravastatin after preparation of the pelleted chow before and after 
doubling the dosage was 60 mg/100 g and 120 mg/100 g, respectively, showing a fully 
active inhibition of HMG-CoA reductase in comparison to 'spiked' control chow (Dr. R. 
Gregg, Bristol-Myers Squibb, Princeton, NJ). 
Plasma concentration of lipids 
Plasma concentrations of total cholesterol at the start of the study are given in Table 1. 
Table 1. Baseline characteristics of WHHL rabbits in the intervention group 
with pravastatin (P) and in the control group (C), and of NZW rabbits (NZW) 
which served as controls in the determination of the endothelial function at 
the end of the intervention period 
Group 
Ρ 
С 
NZW 
m/f 
6/4 
6/4 
3/3 
Age 
(months) 
3.5 
3.5 
6.0 
Weight (g) 
2183 ±260 
2335 ±350 
2700±225 
Tot.chol. 
(mmol/1) 
12.73±3.00 
11.26±1.67 
1.13±0.24 
Triglycerides 
(mmol/1) 
3.25 ±0.55 
3.86±1.19 
0.70±0.22 
Values are mean ± S.D.; m/f, number of males/females; Tot.chol., plasma total 
cholesterol. No significant differences are present between groups Ρ and С 
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Fig. 1. Body weight (left), total plasma cholesterol (centre) and plasma triglyceride levels (right) ofWHHL rabbits in the course of treatment 
with pravastatin (20 and 40 mg/kg per day, at age 3-8 and 8-12 months, respectively), compared to controls. Data represent the mean at each 
point. No significant differences are seen between the groups for body weight and triglycerides. Differences in total cholesterol: * Ρ < 0.001 
versus С 
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In comparison to baseline levels, group С showed an increase in plasma total 
cholesterol of 31.6% {P <0.001). This increase mainly occurred in the first 2 months of 
the study (Fig. 1). Administration of 20 mg/kg per day of pravastatin caused a mean 
difference in plasma total cholesterol of 42.1%, in comparison to the control group. 
Increasing the dose to 40 mg/kg per day of pravastatin, caused a further mean 
difference of plasma cholesterol levels of 54.7% at 12 months (Fig. 1). 
Both groups showed an identical mean change in plasma triglycerides: after the 
first 3 months of the study, all concentrations fell on average 36.6% (P <0.002) to a 
level between 2 and 3 mmol/L (Fig. 1). 
The six NZW rabbits, which served as normal controls in the determination of the 
endothelial function, had a mean plasma total cholesterol concentration of 1.13±0.24 
mmol/1 and mean plasma triglycerides of 0.70±0.22 mmol/1 (Table 1); their mean 
weight was comparable to that of the WHHL rabbits at the end of the study (Fig. 1) 
Determination of endothelial function 
The basal coronary flow in the hearts of the pravastatin-treated animals was 
significantly higher than in the controls and not significantly different from the NZW 
rabbits (Table 2). Coronary flow increase by bradykinin, which releases EDRF, was 
significantly enhanced in the hearts of the pravastatin-treated animals as compared to 
the controls (Fig. 2). The ratio of maximal bradykinin and sodium nitrite induced 
relaxation, a measure for endothelial relaxing capacity, was significantly higher in the 
pravastatin-treated animals than in the control hearts, and not significantly different 
from the ratio in the NZW rabbits (Table 2). 
In contrast, no differences in the metacholine induced relaxation of the abdominal 
aortic rings were observed between the pravastatin-treated animals and the controls. All 
these relaxations were significantly lower when compared than those obtained in the 
Table 2. Basal, maximal bradykinin and sodium nitrite induced coronary flow (ml/min) and 
the ratio of maximal bradykinin and sodium nitrite induced increase in coronary flow in 
WHHL rabbits (pravastatin-treated (P) and controls (C)), compared to normal NZW rabbits 
(NZW) 
Group 
Ρ 
С 
NZW 
η 
7 
10 
6 
Basal 
51.2±1.9* 
43.6±3.3 
56.3 ±2.9* 
Bradykinin 
68.3 ±1.9* 
53.3±3.8 
69.7±2.8' 
Nitrite 
67.3±2.3 
69.2±6.2 
67.114.8 
Bradykinin/ 
nitrite 
1.01 ±0.08* 
0.73±0.04 
1.07±0.08* 
Values are mean ± S.E.M.; n, number of rabbits in each group. 
Differences: * Ρ < 0.05 vs. С 
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NZW rabbits (data not shown). Sodium nitrite induced relaxation of the aortic rings 
were comparable in all three groups. 
We also studied the relationship between plasma total cholesterol levels at the end 
of the study and basal coronary flow, and end-of-study plasma total cholesterol levels 
and the maximal bradykinin induced increase in coronary flow, because the cholesterol 
level may be expected to be directly proportional to endothelium-dependent relaxation. 
The basal coronary flow showed no correlation with the plasma total cholesterol level, 
whereas a significant correlation was found between the bradykinin induced increase in 
coronary flow and the cholesterol levels in 17 WHHL rabbits (Table 3). 
Extent of atherosclerotic lesions 
At 12 months of age, atherosclerotic lesions of the aorta were predominantly found in 
the ascending and descending thoracic aorta (Table 4). In the pravastatin-treated 
rabbits, the mean percent of narrowing and the incidence of lesions on the cross-
sections of the aorta were significantly less in all areas than in the control group. 
The incidence of lesions and narrowing of coronary arteries are summarized in 
Table 5. Most stenoses were found in the LSP and maximal narrowing was 
predominantly observed at the origin of the four main coronary arteries. The incidence 
of all plaques was significantly lower in the pravastatin-treated rabbits than in the 
control rabbits. The incidence of proximal stenotic lesions at the origin of the coronary 
arteries was as high as 39.3% in the pravastatin-treated group and 65.0% in the control 
Increase in coronary flow ( m l / m i n ) 
20 
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Fig. 2. The dose-response curve of bradykinin on the coronary 
flow of the atherosclerotic WHHL rabbits (pravastatin-treated 
(PRA (n = 7)) and controls (WHHL (n=10)), and the normal NZW 
rabbits (NZW (n=6)). Data represent the mean (±S.E.M.) at each 
point. Differences: PRA vs. WHHL-controls, Ρ<0.05 
• PRA 
• NZW 
V WHHL 
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Table 3. Correlations between the plasma total cholesterol levels 
at the end of the study versus the basal and stimulated coronary 
flow, mean percentage of aortic and coronary stenosis, and 
incidence of the aortic and coronary stenosis in 12-month-old 
WHHL rabbits, pravastatin-treated (л=7) and untreated controls 
(л=10): the Pearson rank correlation (r) coefficients and their 
levels of significance (P) are given for each relation 
Total cholesterol (n= 
Coronary flow 
Basal 
17) versus 
Bradykinin induced increase 
Mean stenosis 
Aortic 
Coronary 
Incidence of stenosis 
Aortic 
Coronary 
r 
-0.165 
-0.426 
0.626 
0.423 
0.669 
0.571 
Ρ 
0.681 
0.028 
0.002 
0.029 
0.000 
0.004 
group (P < 0.05; Pearson's chi-square test). The mean stenosis in the pravastatin-treated 
animals showed a tendency towards less narrowing. Correlations between plasma total 
cholesterol levels at the end of the study and the extent of atherosclerotic lesions in both 
the aorta and the coronary vessels are shown in Table 3. Significant correlations were 
found between the mean aortic and coronary stenosis, and the incidence of aortic and 
coronary stenosis versus the cholesterol level. 
Discussion 
The aim of this study was to elucidate whether or not cholesterol lowering treatment 
with pravastatin could preserve endothelial function and retard the development of 
atherosclerosis in homozygous WHHL rabbits. 
Watanabe and Ito et al. have demonstrated that plasma total cholesterol levels in 
homozygous WHHL rabbits increase with maturation and decrease thereafter with 
increasing age during the first 12-24 months of life, whereas triglyceride levels 
gradually decline after the first month of life [23,24]. The initial rise in plasma total 
cholesterol of the control animals in the first 3 months of the present study is in 
agreement with these findings. No explanation was found for the drop in plasma 
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Table 4. Percentage of narrowing of atherosclerotic lesions (mean ± S.D. and range) and 
the incidence (%) of vascular lesions in the ascending thoracic, descending thoracic and 
abdominal aorta of 12-month-old WHHL rabbits, treated with pravastatin (P) and compared 
to untreated controls (C), analyzed with the point-counting method in transversal cross-
sections of the aorta 
Mean 
Range 
Inc. 
Mean 
Range 
Inc. 
Ascending 
21.4±19.4 
0-78.1 
82.1 (46/56)1 
36.0±7.9 
2.3-81.3 
100 (80/80) 
Descending 
8.2±9.8* 
0-69.9 
68.6 (48/70)1 
22.4±12.1 
0-79.7 
98 (98/100) 
Abdominal 
6.3 ±6.0' 
0-52.5 
31.0(39/136)' 
17.3±8.2 
0-75.0 
61.6(114/185) 
Total 
12.0±11.3* 
0-78.1 
52.8 (133/252)1 
25.2±8.1 
0-79.7 
80.0 (292/365) 
Inc., incidence (the values in parentheses indicate the number of injured arteries/the number 
of examined transversal cross-sections); n, number of rabbits in each group 
Differences in mean stenotic lesion: *Pi0.02 versus С 
Differences in incidence (Pearson's chi-square test): \Pi0.0001 versus С 
triglycerides of both the pravastatin-treated animals and the controls. 
Homozygous WHHL rabbits develop progressive aortic atherosclerosis in 100% 
after the first 5 months of life. The incidence of coronary atherosclerosis gradually 
increases with age, from 30% in immature (5-7 months) to 55% in advanced age 
(25-36 months) [3,24]. Treatment with the antioxidant probucol [25,26] and the 
cholesterol lowering HMG-CoA reductase inhibitors [16-19] have both shown to retard 
the development of atherosclerotic plaque formation. The inhibitory effect on 
atherosclerosis of the latter seems to be dose-dependent and more pronounced in young 
WHHL rabbits [16,19]. 
Therefore, we started this study with 3-month-old WHHL rabbits and used doses 
of pravastatin as high as 40 mg/kg per day, causing a 51% difference in plasma total 
cholesterol levels to a mean of 7.29 mmol/1. Indeed, a significant retardation of the 
progression of aortic atherosclerosis and a reduction of the number of lesions in the 
coronary arteries was found in the pravastatin-treated animals, as well as a tendency 
towards decrease of the plaque size of the coronary atherosclerosis. The coronary 
lesions were mainly located at the proximal portion of the coronary vessels. This 
pattern of distribution of coronary lesions is similar to those previously described 
[24,27]. 
In WHHL rabbits, the plasma cholesterol level required for the development of 
coronary atherosclerosis is higher than the level that causes aortic atherosclerosis, 
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probably because of structural differences between these two arteries [3,28]. Probably, 
the percentage reduction of total cholesterol will determine the amount of 
atherosclerosis that is retarded in either the coronary arteries or the aorta. Indeed, it has 
been shown that 28% reduction of total cholesterol by the administration of pravastatin 
sodium at a dose of 50 mg/kg per day in 3-month-old WHHL rabbits suppressed the 
progression of coronary atherosclerosis only [16], whereas treatment with the 
combination of 50 mg/kg per day pravastatin and cholestyramine in the diet reduced 
total cholesterol by 62%, and suppressed the progression of both coronary and aortic 
atherosclerosis [18]. Therefore, the retardation of the progression of atherosclerosis in 
the aorta in our study is in accordance with these previous studies [16,18], because the 
plasma total cholesterol levels in the pravastatin-treated animals were 51% lower 
(14.90 mmol/1 vs. 7.29 mmol/1). Moreover, in mature WHHL rabbits coronary 
atherosclerosis hardly developed when their total cholesterol levels at weaning were 
under 18 mmol/1 [3,29], whereas baseline levels in our study ranged between 11 and 13 
mmol/1 (Table 1). Therefore, the incidence of coronary atherosclerosis of 34% 
(Table 5) in the strain of WHHL rabbits we used, is less than reported elsewhere [3,19], 
and may explain the less pronounced effect of pravastatin treatment on retardation of 
the progression of coronary atherosclerosis in this study. 
It has been shown that aortic atherosclerotic preparations of WHHL rabbits have a 
Table 5. Percentage of narrowing of atherosclerotic lesions (mean ± S.D. and range) and 
the incidence (%) of vascular lesions in coronary arteries of 12-month-old WHHL rabbits 
treated with pravastatin (P) and compared to untreated controls (C), analyzed with the point-
counting method in 8 equal cross-sections of the ventricles 
Group 
Ρ 
л=7 
С 
л=10 
Mean 
Range 
Inc. 
Mean 
Range 
Inc. 
LAD 
7.7±9.3 
1.5-23.1 
19.6 
(U/56)* 
12.0±16.1 
0.7-50.7 
25.0 
(20/80) 
LSP 
13.4±14.4 
1.9-56.0 
28.6 
(16/56)· 
19.7±9.9 
1.0-78.1 
47.5 
(38/80) 
LCX 
10.2±14.2 
0.7-71.6 
26.8 
(15/56)· 
10.4±9.0 
0.7-80.2 
43.8 
(35/80) 
RCA 
6.5±5.8 
0.8-28.0 
25.0 
(14/56) 
8.5±8.9 
1.6-56.1 
20.0 
(16/80) 
All 
9.9±5.3 
0.7-71.6 
25.0 
(56/224)* 
12.6±7.5 
0.7-80.2 
34.1 
(109/320) 
Inc., incidence (the values in parentheses indicate the number of injured arteries/the number 
of examined transversal cross-sections); n, number of rabbits in each group. Differences in 
mean stenotic lesions are not significant. Differences in incidence (Pearson's chi-square 
test): * Ρ< 0.05 versus С 
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diminished endothelium-dependent relaxation in response to acetylcholine [7,8]. In 
addition, both in the hypercholesterolemic rabbit [9,10] and in men [30,31] it has been 
shown that hypercholesterolemia per se influences endothelial function and precedes 
the development of atherosclerosis, which may be caused by a decreased production or 
an increased inactivation of EDRF by native and oxidized LDL [14,32]. Only in short 
term studies with cholesterol-fed NZW rabbits has it been shown that administration of 
lovastatin, a HMG-CoA reductase inhibitor, improved the endothelial-dependent 
relaxation [9,10,33]. In our study, it was postulated that functional changes preceded 
the diminution of atherosclerosis predominantly due to cholesterol lowering. Indeed, 
the endothelium-dependent relaxation of the coronary arteries in the pravastatin-treated 
group was normal, and the bradykinin-induced increase in coronary flow was 
significantly correlated to the plasma total cholesterol level. Even so, 25% of the 
coronary cross-sections of the pravastatin-treated animals showed lesions in 
comparison to 34% in the control group. In contrast, a diminished endothelium-
dependent relaxation of the abdominal aortic rings of the pravastatin-treated group was 
found, whereas these parts of the aorta showed the most pronounced preservation of 
normal intima (incidence of atherosclerotic lesions of 31% in the pravastatin-treated 
animals versus 62% in the control group (Table 4)). Yet, despite pravastatin treatment, 
the WHHL rabbits had plasma total cholesterol levels still well above those in normal 
NZW rabbits. Therefore, these results suggest local differences between the aorta and 
the coronary arteries in susceptibility to endothelial dysfunction by high cholesterol 
levels. It can not be excluded that the preservation of normal intima was more complete 
in the coronary arteries, but several studies have shown that the plaque as a distance 
barrier to the diffusion of EDRF is not primarily responsible for changes in 
endothelium-dependent response [10,32]. Taking account of the structural differences 
between the aorta and the coronary arteries, the restoration of the endothelium-
dependent vasodilation in the aorta of this model may need more aggressive lipid 
lowering. 
In conclusion, the administration of pravastatin leads to retardation of the 
progression of atherosclerotic plaque formation in both coronary arteries and the aorta, 
and to the preservation of the endothelial function of the coronary arteries, due to its 
lipid lowering effect. These results are encouraging with regard to lipid lowering 
treatment in familial hypercholesterolemia in humans. 
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In this open, randomized, 2-years study in hypercholesterolemic men with severe 
coronary atherosclerosis, the effect of aggressive lipid lowering with LDL-apheresis 
plus simvastatin will be compared with conventional lipid lowering treatment with 
simvastatin alone. Treatments will be compared by means of quantitative coronary 
angiography and videodensitometric assessment of the coronary perfusion. Secondary, 
peripheral vascular disease of the carotid artery and the aorto-tibial tract will be fol-
lowed by ultrasonographic techniques. Changes in endpoints will be related to changes 
in lipid and lipoprotein levels. 
ooooooooo··· 
Introduction 
The relation between total cholesterol and LDL-cholesterol (LDL-C) levels and the 
incidence of coronary artery disease (CAD) en peripheral vascular disease (PVD) is 
well established [1-5]. Primary and secondary prevention trials, conducted in men with 
hypercholesterolemia, have shown that lipid lowering regimens result in reduction of 
angiographic lesions and are associated with a decreased incidence of atherosclerosis 
[6-31 ]. Most of these trials show slowing or arrest of progression of coronary and 
femoral atherosclerosis, although studies on the latter are scarce [32]. Until now, 
intensive lipid lowering in men with established CAD using HMG-CoA reductase 
inhibitors is the most effective in terms of inducing plaque regression and consequently 
reducing the number of clinical events [21,22,27,29-31,33]. Quantitative methods for 
analysing the extent of atherosclerosis from arteriograms have been developed and 
extensively evaluated [34-37]. The intrinsic limitations of coronary angiography to 
predict physiologic effects of coronary obstruction have been well documented [38]. 
Therefore, assessment of the functional significance of coronary stenosis seems impor-
tant. The videodensitometric assessment of the coronary perfusion has been shown to 
be an important functional indicator of the haemodynamic consequences of vascular 
stenosis [39-41]. 
Peripheral vascular lesions can be detected non-invasively using ultrasound 
techniques. The measurement of the intima-media thickness of the carotid artery has 
been shown to be a reproducible method for the analysis of early vascular lesions 
[42,43]. However, the combined use of Doppler-derived analysis of blood flow veloci-
ties in the common femoral artery and the ankle/arm systolic pressure ratio at rest and 
during reactive hyperemia has been shown to be a sensitive measure for the assessment 
of haemodynamically significant stenosis of the lower limb [44-46]. 
Continuous LDL-apheresis, using dextran sulfate cellulose columns, selectively re-
moves apolipoprotein-B-containing lipoproteins from plasma [47,48]. The application 
of this method of hypolipidaemic treatment may offer opportunities in the prevention of 
progression, or even inducing regression of coronary atherosclerosis in selected patients 
with a primary hyperlipidaemia and established CAD [49-51 ]. 
The LDL-Apheresis Atherosclerosis Regression Study (LAARS) was designed as 
an open, randomized, single-centre study to determine whether aggressive lipid lower-
ing with biweekly LDL-apheresis plus simvastatin, a potent HMG-CoA reductase 
inhibitor [52,53], exerts better anti-atherosclerotic effect then conventional lipid lower-
ing with simvastatin alone or in combination with a resin, in primary hypercho-
lesterolaemic men with extensive coronary artery disease [54]. Qualitative and quantita-
tive computer-assisted analyses of coronary angiograms and the videodensitometric 
measurement of the coronary perfusion are being employed at the start of the study and 
after 2 years of treatment. Secondary, ultrasonographic determination of PVD in the 
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carotid artery and aorto-tibial tract are to be performed at 1-year treatment intervals. 
From January 1990 to June 1992, 42 patients, from the Lipid and Cardiology 
clinics of the University Hospital of Nijmegen, were entered. In this report, we describe 
the design of the study, the methods of follow-up, and the baseline characteristics of the 
patients. 
Design of the study 
Men, aged between 30 and 67 years, who underwent diagnostic coronary angiography 
for angina pectoris were screened for eligibility. Included were patients with a mean of 
two successive serum total cholesterol determinations above 8.0 mmol/L or LDL 
cholesterol above 5.8 mmol/L, and a mean of two successive fasting serum triglyceride 
measurements below 5.0 mmol/L on a standard lipid lowering diet without other lipid 
lowering treatments, and extensive coronary atherosclerosis as shown on their coronary 
angiogram. Specific exclusion criteria are listed in Table 1. 
To perform the prerandomization evaluations and establish eligibility, three screening 
visits, spaced by a month were scheduled. The aims of the study and the protocol were 
explained at visit 1. Instructions about a cholesterol lowering diet equivalent to the 
American Heart Association phase I diet were given by a dietician, and all other lipid 
lowering treatments were stopped. At visits 2 and 3, blood was drawn for analyses of 
lipids, (apo)lipoproteins, and laboratory safety measures. Exercise tests and assess­
ments or peripheral vascular disease were performed in the meantime, as well as coro­
nary angiography (Figurel). After visit 3, the final decision with regard to eligibility 
was taken and written informed consent according to the Declaration of Helsinki was 
Table 1. LAARS exclusion criteria 
1. Left ventricular ejection fraction <0.35 (N=0.55-0.85) 
2. Myocardial infarction, PTCA or CABG within previous 3 months 
3. Cardiac arrhythmias 
4. Impaired hepatic function, or liver function tests with repeated values >30% above the 
normal range, hepatitis or biliary obstruction 
5. Impaired renal function with plasma creatinine к 150 цтоІ/L 
6. Homozygous familial hypercholesterolemia 
7. Secondary hyperlipidemias due to any cause 
8. Diabetes mellitus or fasting blood glucose ¿8.0 mmol/L 
9. Hypertension with diastolic blood pressure к 100 mmHg 
10. Heavy smokers (>10 cigarettes/day) 
11. Concurrent use of immunosuppressive drugs or fibrates 
12. Severe obesity with body mass index s30 kg/m2 
13. A history of alcohol or drug abuse 
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obtained. The patient was allocated at random to either biweekly LDL-apheresis plus 
simvastatin (40 mg/day) or simvastatin (40 mg/day) alone. Randomization was strati-
fied for total cholesterol and lipoprotein(a) (Lp(a)) levels, age, and coronary artery 
bypass graft status. 
LDL-apheresis has been performed with an automated system with two small-
sized dextran sulfate cellulose columns (MA-01 unit, Kanegafiichi Chemical industry 
Co., Japan). A plasma volume of 5000 mL was treated in each patient. The combination 
of LDL-apheresis and the HMG-CoA reductase inhibitor, simvastatin, can be expected 
to slow down the post-apheresis rebound in serum cholesterol due to increased choles-
terol synthesis, which permits prolongation of the intervals between the apheresis 
procedures [55,56]. A resin in the highest tolerable doses will be added to the treatment 
if (pre-apheresis) serum total cholesterol levels in two consecutive months remains 
above 8.0 mmol/L. 
Methods of follow-up 
Lipids, lipoproteins and laboratory safety measures 
Safety and tolerability of the treatment will be compared by means of medical and 
laboratory tests. In both groups, lipids, lipoproteins, blood chemistry, haematology, and 
routine urine analyses will be performed monthly. Apolipoprotein (apo)Al, apoB, and 
Lp(a) will be measured bimonthly. In the apheresis group, lipids and lipoproteins and 
some extra laboratory safety parameters will be measured biweekly, before and imme-
diately after LDL-apheresis. At each visit the patients are subjected to a brief physical 
examination and dietary instruction is repeated frequently. 
Serum total cholesterol and fasting triglycerides will be determined by enzymatic 
methods (CHOD-PAP, no. 237574, Boehringer Mannheim GmbH, FRG and Sera-
PAK, no. 6639, Miles, Italy, respectively). HDL-C is determined using the polyethyl-
ene glycol 6000 precipitation method [57]. LDL-C is calculated by subtraction. Sam-
diet randomization 
J 
-2 0 12 24 months 
Exercise test (ET) I ET II ET III 
Echo-doppler (ED) I ED II ED III 
Cor.angiography (CAG) I CAGII 
Randomization: LDL-apheresis plus medication or medication alone. 
Fig. 1. Diagram of study design 
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pies for apoAl, apoB, and Lp(a) will be initially stored at -80°C, and determined at the 
end of the study. ApoAl and apoB are quantified in serum by immunonephelometry 
and Lp(a) will be measured by a specific radioimmunoassay (apolipoprotein(a) RIA 
100, Pharmacia Diagnostics AB, Uppsala, Sweden) [58]. 
Exercise tests 
Replicate bicycle exercise tests (ET) will be performed at baseline, and after 12 months 
and 24 months. The ET is performed starting with a load of 50 W, and increasing the 
load every minute by 10 W during continuous ECG monitoring to maximum exercise. 
Blood pressure and 12-lead ECG registration will be monitored at rest, at maximum 
exercise, and every minute during the test. Automated calculation of ST-segment 
depression and slope is used, and data will be corrected for maximal systolic blood 
pressure heart rate product. 
Coronary angiography 
The coronary angiograms will be made at baseline and after 2 years of treatment with 
the same non-ionic iso-osmolar contrast agent, using the same cine-angiogram tech-
niques (Siemens Bicor and Digitron-3 quantitative measurement software package). No 
pre-angiographic vasodilatory agents will be given other than the ones needed to ame-
liorate catheter-induced vasospasm. The same sequence of projections will be used 
preferably at the same time of day. A centimeter grid is filmed to adjust for pincushion 
distortion and the same kind and diameter of catheters will be used and measured with a 
micrometer after the procedure to maximize quality control. Twelve to 15 coronary 
segments will be filmed in 2 or 3 projections. Computer-assisted quantitative analysis 
(CMS) of the paired angiograms will be performed blinded and at the angiography 
reference laboratory of the University Hospital of Leiden [59,60]. Minimal obstruction 
diameter will be assessed as a measure for localized atherosclerosis, whereas mean 
segment diameter will be used as measure for diffuse changes. Additionally, blinded 
qualitative analysis (global score) of pairs of angiograms will be performed by a panel 
of three independent cardiologists. Differences in determination of percent stenosis will 
be settled by revised general agreement of the whole panel. 
Videodensitometric assessment of coronary perfusion 
Coronary arteriography will be followed by coronary flow estimation after maximal 
vasodilation with intracoronary administration of papaverine using digital subtraction 
techniques (Siemens Digitron-3). Contrast is injected using a power injector. Image 
acquisition will be performed while holding the breath at maximal inspiration and using 
the principle of apparent cardiac arrest by achieving synchronization of the X-ray 
pulses with the paced heart beats as has been described previously [40,41]. At least 
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5 regions of interest (ROI) will be selected in which measurement of coronary flow 
should be performed. These ROI's are located adjacent to the three main coronary 
arteries and an area selected distal to severe stenosis and after bypass grafts. Gamma-
fitted time-density curves will be obtained by sampling the average pixel density within 
a ROI in the consecutive images and corrected by subtraction of the sampled average 
density in the corresponding background ROI. Data will be normalized for blood 
pressure values. 
Measurement of the intima-media thickness (IMT) of the carotid artery 
High resolution B-mode ultrasound examinations of the left and right carotid arteries 
are performed at baseline, and after 12 and 24 months of treatment, and are stored on 
videotape. An ACUSÓN 128XP duplex apparatus equipped with a 7.0-MHz L7384 
linear array/ 5.0-MHz pulsed Doppler transducer combination is used. Measurement of 
the IMT is based on the distance between ultrasonically defined interfaces of the lu-
men/intima and media/adventitia. From a fixed latero-lateral angle the near and far wall 
of the common carotid artery, bulbus and internal carotid artery will be scanned. The 
Table 2. Baseline characteristics (numbers or means±SD) 
Age (y) 
Weight (kg) 
BMI (kg.nr2) 
Blood pressure 
systolic (mmHg) 
diastolic (mmHg) 
Smoking 
Infarction 
CABG 
PTCA 
Hypertension 
Stroke 
Claudication 
LDL-apheresis 
(n=21) 
50.2±9.6 
81.5±9.7 
26.6±2.0 
129.3±17.3 
78.2±8.9 
3 
16 
10 
2 
2 
1 
3 
Medication-only 
(n=21) 
53.9±8.7 
80.8±8.6 
26.2±2.0 
126.3±18.1 
76.5±9.0 
4 
18 
10 
5 
5 
3 
5 
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Table 3. Baseline lipids and lipoproteins 
Tot.Cholesterol (mmol/L) 
Triglycerides (mmol/L) 
HDL-Cholesterol (mmol/L) 
LDL-Cholesterol (mmol/L) 
Apolipoprotein Al (g/L) 
Apolipoprotein В (g/L) 
Lipoprotein(a) (mg/dL) 
median 
LDL-i 
mean±SD 
9.72±1.84 
2.50±1.23 
0.95±0.19 
7.72±1.96 
1.43±0.30 
2.59±0.48 
57.0±63.4 
30.0 
ipheresis 
range 
7.9-14.3 
0.83-5.93 
0.60-1.45 
5.73-12.62 
0.97-2.18 
1.70-3.50 
2.9-254.1 
Medication-only 
mean±SD 
9.85±2.21 
2.65Ü.44 
0.93±0.21 
7.85±2.36 
1.46±0.38 
2.60±0.63 
38.4±39.4 
20.4 
range 
7.8-16.6 
0.66-5.29 
0.64-1.33 
5.44-14.55 
0.84-2.33 
1.40-4.20 
1.7-138.6 
dilation of the common carotid artery and the flow divider in the carotid artery are used 
as anatomical landmarks. The blinded off-line quantification of the IMT of the arterial 
segments is assessed by a semi-automated contour detection program and is performed 
at the vascular laboratory of Interuniversity Cardiology Institute of the Netherlands 
(Utrecht). 
Doppler spectrum analysis of the femoral artery and ankle/arm blood pressure ratio 
These will be performed after a 1-year interval in the vascular laboratory of the Univer-
sity of Nijmegen. Doppler signals are obtained with an 8-MHz bidirectional continuous 
wave Doppler apparatus (Medasonics Inc., Mountain View, CA). Reactive hyperaemia 
is induced by thigh cuff compression for 5 minutes at a pressure of at least 50 mmHg 
above the systolic arterial thigh pressure and Doppler spectra will be obtained approxi-
mately 15s after relief of the thigh compression. Doppler signals are processed by a 
real-time spectrum analyser (Radionics SA8000; Scarborough, Ontario, Canada) and 
subsequently fed into a Digital MNC 11/23 computer on the basis of electrocardio-
graphic triggering for off-line analysis. Maximum-frequency waveforms are calculated 
from the spectra by local convolution algorithm. To describe the shape of the wave-
forms, several parameters will be calculated [61]. Based on a combination of six of 
these Doppler parameters, the presence of haemodynamically significant aorto-iliac 
pathology can be assessed accurately [46]. The same Doppler probe is used to deter-
mine the ankle/arm pressure index. Haemodynamically significant vascular disease is 
defined as an ankle/arm pressure index at rest <0.90 and/or a decrease of the pressure 
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index during reactive hyperemia ¿0.20. 
Baseline characteristics 
In both treatment groups, 21 men were enrolled and some baseline characteristics are 
shown in Table 2. All patients had severe coronary atherosclerosis: a previous history 
of myocardial infarction was present in 16 vs 18 men in the apheresis and the medica-
tion group, respectively, and CABG had been performed in 10 men in both groups. In 
the apheresis group 17 of 21, and in the medication group 19 of 21 men, had 3-vessel 
CAD, whereas the other patients had 2-vessel disease. Haemodynamically significant 
lesions in the aorto-tibial tract were found in 4 and 5 men, and carotid artery segments 
with a mean IMT >1.0 mm were found in 29% and 22.8% in the apheresis and medica-
tion groups, respectively. Baseline cholesterol levels were very high, and predominant 
elevation of apoB-containing lipoproteins was found (Table 3). 
Conclusion 
LAARS will evaluate whether aggressive lipid lowering with LDL-apheresis in men 
with primary hypercholesterolaemia and extensive coronary artery disease will exert 
better retardation of the progression of atherosclerosis or even regression of coronary 
and peripheral atherosclerosis in comparison to conventional treatment. This study may 
help to answer the question whether extreme lipid lowering is indicated in this particu-
lar group of patients. 
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Submitted for publication as: 
The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation 
of mean lipoprotein levels. 
A.A. Kroon, M.A. van 't Hof, P.N.M. Demacker, A.F.H. Stalenhoef 
We studied the rebound of lipoproteins in 20 hypercholesterolemic men [mean total 
cholesterol (TC) levels 9.6±1.8 mmol/L] after LDL-apheresis (LA) to determine the 
rate of recovery, the change in cholesterol synthesis, and to find a uniform estimation 
for time-averaged levels. After 10-20 months on biweekly LA using dextran sulfate 
cellulose columns and concomitant simvastatin administration time-averaged levels 
(±SD) measured by integration of the area under the curve were as follows: TC 
4.4±1.0 mmol/L, LDL-cholesterol (LDL-C) 2.5±1.0 mmol/L, apolipoprotein В 
(apo B) 1.3±0.3 g/L, triglycerides (TG) 1.7±0.7 mmol/L, HDL-C 1.1 ±0.2 
mmol/L, and lipoprotein(a) [Lp(a)] 53.7±49.4 mg/dL. Mean acute reductions in TC, 
LDL-C, apo B, Lp(a), and TG were 61%, 77%, 75%, 76%, and 62%, respectively. 
HDL-C levels were not influenced. Median recovery half times for TC, LDL-C, apo 
B, and Lp(a) were 3.0, 4.0, 2.3, and 3.5 days, respectively. The rebound of Lp(a) 
was identical to LDL-C, in 12 and 13 days post-treatment, respectively, whereas apo 
В and TC returned to pretreatment levels in 7.5 and 10 days, respectively, due to the 
fast rebound of VLDL particles. Notwithstanding these differences, time-averaged 
levels (CAVG) could be estimated uniformly for the 4 latter parameters with the for­
mula: С
А О
=С
МШ
-І-0.73(С
МАХ
-С
МВ
,), where CM A X and CMIN are the immediate pre-
and post-treatment levels. During long-term treatment the whole-body cholesterol 
synthesis was increased as measured by the ratio lathosterol to cholesterol of 
3.60±1.45 μιηοΐ/mmol, whereas no further transient increase in the recovery period 
after LA was found. In conclusion, long-term LA and simvastatin therapy induced 
acute and chronic changes in lipids and lipoproteins showing the feasibility of bi­
weekly treatment. It was shown that time-averaged levels, as a measure for the 
effective plasma levels, can be accurately estimated from pre- and post-treatment 
levels only. 
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Introduction 
The performance of regular low density lipoprotein (LDL) apheresis permits the 
achievement of lower levels of LDL cholesterol which is usually not possible to attain 
with drug therapy alone [1,2]. Consequently, the application of LDL-apheresis may 
offer opportunities in the arrest of progression or regression of coronary and periph­
eral vascular disease in selected hypercholesterolemic patients [3-13]. Recently, the 
first two controlled LDL-apheresis regression studies were published, the FH Regres­
sion Study and the LDL-Apheresis Atherosclerosis Regression Study (LAARS) 
[12,13]. Both studies showed angiographical arrest of progression of coronary artery 
disease in severe hypercholesterolemic subjects concomitantly treated with an HMG-
CoA reductase inhibitor, whereas the latter also showed reduction of the extent of 
peripheral vascular disease [14]. 
Treatment using selective LDL-apheresis removes large amounts of apolipo-
protein В (apo B) containing lipoproteins from the body in a relatively short time, 
generally 2 - 4 h. Sawtooth-like alterations in lipoprotein levels are one of the most 
striking differences between patients undergoing repetitive LDL-apheresis and con­
ventional therapy [15]. The efficacy of the treatment depends on the pre- and post-
treatment lipid levels, and on the post-treatment return of lipids in plasma [16-20]. 
The combination therapy of LDL-apheresis and an HMG-CoA reductase inhibitor can 
be expected to decrease pretreatment LDL cholesterol to lower levels and slow down 
the post-apheresis rebound, which permits prolongation of the intervals between the 
apheresis procedures [17,20]. It has been shown that the increase of lipoprotein levels 
after the treatment can be explained by first order kinetics [16,21]. Therefore, it is 
accepted that time-averaged concentrations provide the best estimate of the phys­
iologically effective plasma levels during long-term treatment with LDL-apheresis. 
There is no universal agreement whether the cholesterol synthesis is increased 
after a single apheresis or during regular treatments. An increased rate of cholesterol 
biosynthesis without any change in apo В synthesis has been reported after plasma­
pheresis [22-24], whereas both a transient increase and no change in cholesterol 
synthesis have been shown after LDL-apheresis [19,20,25,26]. 
In this paper, we measured the rebound of lipids and lipoproteins in days fol­
lowing a treatment during long-term LDL-apheresis using dextran sulfate cellulose 
columns (DSC) [27,28]. Changes in the amounts of lipids and lipoproteins were 
measured, and the absolute and fractional recovery rates were calculated. Changes in 
cholesterol biosynthesis and in intestinal adsorption rate were quantitated indirectly 
by measurements of the sterol intermediate lathosterol and the plant sterol sitosterol 
in relation to serum cholesterol, respectively. The data were used for estimation of 
the mean effective lipid or lipoprotein concentrations with a formula during long-term 
biweekly treatment in LAARS [13]. 
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Materials and methods 
Subjects and treatment 
The present study was carried out in subjects randomized to treatment with LDL-
apheresis in the LDL-Apheresis Atherosclerosis Regression Study (LAARS) [13]. In 
this study the effect of 2 years of cholesterol lowering using biweekly LDL-apheresis 
plus simvastatin treatment was compared with the effect of conventional lipid lower­
ing with simvastin alone on coronary and peripheral vascular disease. All eligible 
LAARS participants were men with a primary hypercholesterolemia and extensive, 
angiographically assessed severe coronary artery disease. This study was approved by 
the ethical committee of the University Hospital of Nijmegen. Twenty-one subjects 
were enrolled for long-term LDL-apheresis of whom 20 men gave informed consent 
for the present study. All subjects, age 50 ± 9 years, range 30-66, were classified as 
heterozygous for familial hypercholesterolemia. Baseline lipids and lipoproteins 
before the start of the trial on a standard lipid lowering diet were as follows: total 
cholesterol 9.64±1.78 mmol/L, triglycerides 2.40±1.04 mmol/L, LDL cholesterol 
7.66±1.92 mmol/L, high density lipoprotein (HDL) cholesterol 0.96±0.18 mmol/L, 
lipoprotein(a) [Lp(a)] 59.7±64.3 mg/dL [median 34.7, range 3.1 - 236.3], and apo В 
2.55 ±0.43 g/L. 
Concomitant treatment with the HMG-CoA reductase inhibitor simvastatin 
(40 mg/day) was started at the beginning of the study. LDL-apheresis was performed 
fortnightly with an automated system equipped with 2 small-sized dextran sulfate 
cellulose columns (Liposorber·) in combination with a membrane type plasma sepa­
rator (MA-01 unit, Kanegafuchi Chemical Industry Co. Ltd., Osaka, Japan). During 
this extracorporeal procedure blood was anticoagulated with heparin at a rate of 
2,000 U/h. A volume of 5000 mL (approximately 1.5 plasma volumes) was treated 
per session, which lasted 3 to 4 h at a blood pump rate ranging between 80 and 120 
mL/min. The present experiments were performed for every subject on one occasion, 
10 to 20 months after the start of the first apheresis. 
Rebound curves 
In order to follow the return of the various lipids and (apo)lipoproteins to their 
pretreatment values blood samples were taken immediately before and immediately 
after apheresis, and at 24 h intervals subsequent to the apheresis for a period of seven 
days, and on the 10th and 14th day post-apheresis. For construction of the rebound 
curve additional data of immediate pre- and post-treatment levels from 4 forgoing 
apheresis procedures were used to reduce the individual variability. The coefficient of 
variation of these pre- and post-treatment levels was within total analytical and bio­
logical variance. 
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Analytical procedures 
All blood samples, except those taken immediately after apheresis, were obtained 
between 8:00 and 9:00 h by venapuncture after an overnight fast. The post-apheresis 
samples were drawn between 13:00 and 14:00 h. For the indirect assessment of 
whole body cholesterol biosynthesis in vivo we used the quantification in serum of 
the cholesterol intermediate lathosterol, and more specifically the lathosterol to 
cholesterol ratio [29-31]. Serum concentrations of lathosterol are directly associated 
with hepatic HMG-CoA reductase activity [32]. Serum lathosterol concentration and 
the lathosterol to cholesterol ratio are independent of the composition of diet [30], but 
are increased during treatment with resins [33] and decreased during therapy with 
HMG-CoA reductase inhibitors [30,34] reflecting corresponding changes in choles-
terol biosynthesis in the liver. Plasma concentrations of the plant sterol ß-sitosterol 
were also measured. Sitosterol levels and especially the sitosterol to cholesterol ratio 
reflect the balance between sterol absorption and biliary excretion rate, and are closely 
related to the fractional absorption of dietary cholesterol [35,36]. Plasma lathosterol and 
sitosterol levels were measured by high-performance liquid chromatography (HPLC 
Spectra Physics model 8800, Breda, The Netherlands), essentially as reported before, 
and shown in μπιοΙ/L and also as μηιοΐ/mmol cholesterol to correct for the effects of 
apheresis in removing lipoproteins [30]. Plasma cholesterol and triglycerides were 
determined with commercially available enzymatic methods (Boehringer Mannheim, 
FRG, Nos. 237574, and Sera-PAK, Miles, Italy, no. 6639, respectively). To determine 
plasma HDL cholesterol the polyethylene glycol 6000 precipitation method was used 
[37]. LDL cholesterol was calculated by the Friedewald formula. Samples for apo В 
and Lp(a) were initially stored at -80°C, and determined at the end of the study. Apo В 
was quantified by immunonephelometry [38] and recalculated on the basis of data from 
exchange of sera with the North West Lipid Research Clinic (Seattle, USA). Lp(a) was 
be measured by a specific radioimmuno-assay [apolipoprotein(a) RIA 100, Pharmacia 
Diagnostics AB, Uppsala, Sweden]. 
Statistical procedures 
Assuming a one-compartment model and semi-steady state conditions, the rate of return 
to pretreatment cholesterol concentration can be predicted from the following equation: 
Ст
=
СмАх-(СмАх-См^)е"кт. where Τ is the time in days after the treatment, and Смдх and 
CM1N represent the levels immediately pre- and post-apheresis [16]. The first-order 
turnover constant к or the fractional catabolic rate (FCR) can be estimated by curve-
fitting using nonlinear regression (first order reappearance curve), i.e. a least squares 
regression analysis. The time in days to regain 50% and 90% of the eliminated amount 
was derived from k, since T50%=0.69/k and T90%=2.30/k. When in this first-order 
model the lipoprotein pool is acutely depleted, the subsequent asymptotic recovery is 
characterized by a constant absolute inflow and a constant fractional outflow of lipo-
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Table 1. Change 
С-млх 
CMIN 
% change 
C A V 0 (AUC) 
CAvo (formula) 
in plasma lipids and 
TC 
(mmol/I) 
5.36±1.22 
2.07 ±0.50 
-61 ± 5 * 
4.36±0.95 
4.44±1.16 
lipoproteins 
TG 
(mmol/l) 
1.76±0.77 
0.46 ±0.20 
-62±9%* 
1.69 ±0.73 
-
LDL-C 
(mmol/l) 
3.48±1.20 
0.79±0.44 
-77±6%* 
2.47 ±0.97 
2.57±1.08 
HDL-C 
(mmol/l) 
1.07±0.21 
1.06±0.19 
-2 ±7 
1.07 ±0.20 
-
Lp(a) 
(mg/dl) 
60.6±67.5 
14.2±14.6 
-76±13%* 
53.7±49.4 
57.9±57.2 
apo В 
(g/L) 
1.53 ±0.37 
0.39±0.13 
-75±6%* 
1.28±0.27 
1.24±0.35 
о-
о 
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Data represent means±SD (n=20). TC, total cholesterol; TG, triglycerides; L(H)DL-C, low (high) density lipoprotein cholesterol; Lp(a), 
lipoprotein^); apo B, apolipoprotein B; C^ and CMN, levels immediately before and after 5 consecutive aphérèses; CAVC, time-averaged 
levels, as measured by integration of the area under the rebound curve (AUC) or estimated by a formula (see text); %change versus C^« : 
*P<0.001 (t-test or Mann-Whitney U-test were appropriate) 
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proteins [16,22,23,26]. The absolute recovery rate was calculated by multiplying the 
change in pool size with k, and expressed relatively to body weight (mg/kg/day). For 
estimation of the size of the removed pools, plasma volumes were calculated with the 
formula: VPLASMA= (1-hematocrit [l/l]).weight[kg]/13. 
Time-averaged concentrations (CAVG) were measured in each patient by integra­
tion of the area under the rebound curve. Since CAVG is determined under first-order 
conditions by Смдх and CMIN and a constant α in the formula CAVG= aCMAX+(l-o)CMIN, 
we were able to calculate α for all procedures from a=(Cavg-Cmin)/(Cmax-Cmin) [39]. 
To investigate whether time-averaged levels of total cholesterol, LDL cholesterol, 
Lp(a), and apo В could be estimated correctly by using this simple formula, we used a 
median α for all four parameters. Time-averaged levels calculated with this formula 
were then compared with those measured by integration under the curve. 
Analyses were performed with procedures available in the software package of 
SPSS (SPSS Inc., Chicago, IL.). Multivariate analysis of variance (ANOVA), followed 
by i-tests were used for normally distributed data, whereas Wilcoxon's signed ranks 
tests were used for differences in means of not normally distributed data. For measure­
ments of agreement the Pearson product-moment correlation coefficient was used. A 
two-sided p-value of less than 0.05 was considered to be significant. Results are ex­
pressed as means ± SD, unless otherwise indicated. 
Results 
Acute reductions in plasma lipids and lipoproteins 
During biweekly treatment with LDL-apheresis and simvastatin lipid and lipoprotein 
concentrations were reduced to the pretreatment levels (CMAX), as shown in Table 1. 
LDL-apheresis acutely reduced plasma total cholesterol and triglycerides to the same 
extent, 61% and 62%, respectively, whereas LDL cholesterol, apo B, and Lp(a) were 
lowered further and also to the same extent by an average of 77%, 75%, and 76%, 
respectively. HDL cholesterol levels were not influenced by LDL-apheresis. Immediate 
post-treatment levels (CMIN) of all apo B-containing lipoproteins were below 10% limit 
values of a normal population, as shown in Table 1. The mean removed amounts in 
grams by a single apheresis are shown in Table 2. A good correlation was found be­
tween the removed amounts of lipids and lipoproteins and the initial amount in total 
plasma volume, with r ranging from 0.96 to 0.99 (PO.OOl) for total cholesterol, tri­
glycerides, LDL cholesterol, apo B, and Lp(a). This is shown exemplarily for LDL 
cholesterol in Figure 1, based on 5 consecutive procedures in all 20 patients. Generally, 
this indicates that the higher the plasma concentration of LDL cholesterol, the higher is 
the removed mass, given a constant treated plasma volume of 5000 mL. 
57 
Rebound after LDL-apheresis 
Table 2. Kinetics of recovery after a single LDL-apheresis during treatment with simvastatin 
removed pool (g) 
к (pools/day) 
T50% (days) 
T90% (days) 
Abs. recovery rate 
(mg/kg/day) 
TC 
4.51±1.72 
(4.03) 
0.24±0.08 
(0.23) 
3.2±1.0 
(3.0) 
10.5±3.5 
(10.0) 
12.9±4.5 
(12.7) 
LDL-C 
3.54 ±1.62 
(3.03) 
0.19±0.08 
(0.18) 
4.3±2.2 
(4.0) 
14.4±7.4 
(13.2) 
8.2±4.7 
(7.4) 
Lp(a) 
2.04±2.18 
(1.53) 
0.24±0.18 
(0.20) 
3.9±1.9 
(3.5) 
12.9±6.3 
(11.8) 
4.7±4.9 
(3.5) 
apoB 
4.20±1.35 
(3.95) 
0.32±0.17 
(0.31) 
2.5±0.9 
(2.3) 
8.4±3.1 
(7.5) 
16.4±9.9 
(14.0) 
Data represent mean±SD and median levels between brackets (n=20). TC, total cholesterol; 
LDL-C, low density lipoprotein cholesterol; Lp(a), lipoprotein(a); apo B, apolipoprotein B; 
к, first-order turnover constant; Τ50% and T90%, time for resynthesis of 50% and 90% of the 
eliminated concentration; abs. recovery rate, absolute recovery rate 
00 
Q 
I 
Circulating LDL (g) 
Fig. 1. Low density lipoprotein (LDL) cholesterol removed (g) by LDL-apheresis using 
dextran-sulfate cellulose columns in relation to the circulating amounts (g) in 5 consecutive 
procedures of 20 patients 
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Description of the rebound curves 
The recovery after LDL-apheresis of the various lipoproteins was different. Triglycer­
ides recovered rapidly, reaching 83% of the pretreatment levels within 1 day after 
treatment. Therefore, time-averaged levels of triglycerides were not significantly 
different when compared to pretreatment concentrations, 1.69±0.73 versus 1.76±0.77 
mmol/L, respectively (P=0.21). The recovery of the other lipid and lipoproteins was 
much slower. The time for recovery of 50% of the removed amount (T50%) was 
between 2-4 days, followed by a successive slower rise indicated by the time for recov­
ery of 90% of the eliminated amount (T90%) (Table 2). The median values for the first-
order turnover constant к of total cholesterol, LDL cholesterol, Lp(a), and apo В were 
0.23, 0.18, 0.20, and 0.31, respectively, showing the fastest recovery of apo В and an 
intermediate position for total cholesterol. The rebound curves of Lp(a) and LDL 
cholesterol, when expressed as a proportion of the removed amount of lipoprotein, were 
not significantly different (Fig. 2). The absolute recovery rate (Table 2) was lowest for 
Lp(a), subsequently followed by LDL cholesterol (compared with Lp(a): P=0.03), total 
cholesterol (compared with LDL: P=0.006), and apo В (compared with total choles­
terol: P=0.0$). Pearson's correlation coefficients between the removed amount and the 
absolute recovery rate were as follows: total cholesterol r=0.45 (P=0.04), LDL choles­
terol r=0.64 (P=0.002), Lp(a) r=0.74 (P=0.00l), and apo В r=0.17 (P=0.48). This 
generally indicated a higher absolute recovery rate of LDL cholesterol and Lp(a) in 
patients with high pretreatment levels. 
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Fig. 2. Recovery of apolipoprotein В (apo B, diamonds), low density lipoprotein cholesterol 
(LDL, triangles) and lipoprotein(a) (Lp(a), squares) in days after LDL-apheresis expressed as 
ratio of the removed amount of lipoproteins (n=20) 
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Table 3. Mean plasma total lathosterol and sitosterol levels immediately before 
and after LDL apheresis during treatment with simvastatin 
Before 
After 
%change 
Lathosterol 
(μπιοΙ/L) 
18.03±7.13 
6.40±3.42 
-67±14* 
Latho/Chol 
(μπιοΐ/mmol) 
3.60±1.45 
3.41Ü.90 
-10±23 
Sitosterol 
(цтоІ/L) 
15.73±7.66 
6.60±3.01 
-57±9* 
Sito/Chol 
(цтоі/ттоі) 
3.03Ü.08 
3.34Ü.13 
+14±26 
Data represent means±SD of 2 procedures in 12 patients. Latho/Chol, lathosterol to 
cholesterol ratio; Sito/Chol, sitosterol to cholesterol ratio. Normal values in a sex-, 
age-, and cholesterol-matched population: lathosterol 7.43±2.84 μmol/L, sitosterol 
6.78±2.88 pmol/L (n=158) [31]. Differences: *P<0.001 (t-test) 
Time-averaged concentrations 
Time-averaged ( C A V G ) lipid and lipoprotein levels, calculated by integrating beneath the 
rebound curve, are shown in Table 1. These concentrations could be uniformly esti­
mated by the formula mentioned in the method section. Mean levels of α for total 
cholesterol, LDL cholesterol, apo B, and Lp(a) were 0.72±0.09, 0.70±0.09, 0.78±0.10, 
and 0.68±0.11, respectively. The application of the overall median a=0.73 showed very 
good correlations between both methods of calculation of C A V G for all four parameters 
with correlation coefficients r ranging from 0.96 to 0.99 (.PO.001). 
Measurements of plasma lathosterol and sitosterol levels 
Pre- and post-treatment lathosterol and sitosterol concentrations, only measured in 
12 patients, are shown in Table 3. Pretreatment levels and ratios to cholesterol were 
high, when compared to normal ranges in men with the same age and cholesterol levels 
[31 ], indicating an overall increased whole-body cholesterol synthesis in these patients 
on long-term apheresis and a cholesterol synthesis inhibitor. After a single apheresis a 
significant reduction of 67% in lathosterol and 57% in sitosterol levels were found. 
However, when expressed relatively to cholesterol no significant changes in plasma 
total lathosterol and sitosterol levels were observed immediately after apheresis. More­
over, multivariate ANOVA of the recovery curves in days after apheresis (data not 
shown) of both lathosterol to cholesterol ratio and sitosterol to cholesterol ratio showed 
no statistically significant changes compared to pretreatment levels, P=QA4 and 
P=0.37, respectively, indicating no further increase in cholesterol synthesis nor in 
cholesterol absorption rate in the days post-apheresis. 
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Discussion 
The aim of the present study was to examine acute changes induced by a single 
apheresis procedure during chronic treatment. It was demonstrated that LDL-apheresis 
induced substantial reductions in plasma lipids and lipoproteins, more than has been 
shown by others using DSC columns, immunoadsorption, or HELP (Heparin Extracor­
poreal LDL Precipitation) [8-12]. Dependent on the initial levels, apheresis selectively 
removed large amounts of apo B-containing lipoproteins from the body, including 
VLDL, roughly 5 to 6% of the total exchangeable cholesterol body stores [40]. The 
post-treatment rebound of serum triglycerides was very fast, reaching pretreatment 
values within 1 to 2 days, whereas the recoveries of apo B, total cholesterol, LDL 
cholesterol, and Lp(a) during concomitant therapy with simvastatin ranged between 
8 and 13 days, and were not associated with a post-treatment increase in whole-body 
cholesterol synthesis or intestinal cholesterol absorption. 
Long-term turnover studies using radio-labelled cholesterol have suggested the 
existence of three body pools of cholesterol [40]. After depletion of the rapid exchange­
able pool, represented by e.g. plasma lipoproteins, erythrocytes, liver, and intestines, 
recuperation of this pool is mediated by input via an intermediate exchangeable pool 
(e.g. skin and adipose tissues) and a slowly exchangeable pool (e.g. skeletal muscles 
and arterial wall). In addition, cholesterol homeostasis will also be corrected by in­
creased cholesterol synthesis and intestinal absorption. Using stable isotope methodol­
ogy Arends et al [26] have shown no increase in the absolute hepatic VLDL apo В 
production as well as LDL apo В production in normal volunteers after a single LDL-
apheresis. Among others [24], these latter authors plausibly showed a constant absolute 
apo В synthesis versus a constant fractional catabolic rate independent of the change in 
pool size post-apheresis, which concords with a simple one-compartment model as 
assumed by Apstein et al [16]. Analyses of such models reduces complexity, but have 
also been shown to yield similar results as multi-compartment models [41]. Moreover, 
values for к calculated as described in the method section using a simple nonlinear 
model of asymptotic regression, have been shown to be comparable to those measured 
in steady state conditions during turnover studies with radio-labelled isotopes [16,42]. 
Comparison of the absolute recovery rates and the recovery half-times (T50%) 
clearly showed the highest rebound for apo В and total cholesterol. This must be ex­
plained by the very fast recovery of triglycerides, in particular VLDL particles. It has 
been reported that the absolute production rate of VLDL apo В is twice that of LDL 
apo В and returns to baseline 16 h after apheresis [26]. The major apolipoprotein of 
LDL, apo B-100, is predominantly synthesized in the liver and enters the circulation as 
a component of VLDL [43,44]. Conversion of VLDL to LDL and thus transfer of apo В 
to LDL takes place through lipolysis. Since we did not observe a post-treatment in­
crease in intestinal absorption, i.e. sitosterol to cholesterol ratio, the fast increase in 
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triglycerides after apheresis reflects de novo VLDL synthesis. This explains that T50%-
values for apo В and total cholesterol are lower than for LDL, because they also reflect 
the rapid increase in VLDL particles, which are not present in the LDL fraction. 
We did not observe a different rebound between LDL cholesterol and Lp(a), as 
has been shown by others [12,47]. Median values for constant к of LDL cholesterol in 
our study were lower than what has been shown by others [45-47] ranging between 
0.22 and 0.23, which is probably associated with the more effective inhibition of HMG-
CoA reductase using simvastatin [17,47]. As indicated by median k-value of 0.14 for 
Lp(a), Armstrong et al [45] observed a slower rebound of Lp(a) in comparison to LDL, 
whereas Koizumi et al [47] found a faster recovery for Lp(a). However, the recovery 
curves of the latter author were only based on 3 time points. Taking into account the 
skewness of the data, the more appropriate median figure for к of Lp(a) in this latter 
study of 0.19 indicates rather a slower rebound when compared to the median for LDL 
of 0.22. Therefore, that there is no reason to believe that the rebound of Lp(a) is faster 
than that of LDL cholesterol. 
Body stores would be quickly depleted if not replaced by absorption of dietary 
cholesterol or newly synthesized cholesterol. Parker [19] and Pfohl et al [20] have 
shown evidence for transiently increased endogenous cholesterol synthesis after LDL-
apheresis. In agreement with Gylling et al [25], however, we did not find an increase in 
cholesterol synthesis nor in intestinal absorption. These different observations may be 
explained by the fact that we measured the rebound during ongoing long-term biweekly 
treatments, whereas several other investigators have analyzed the recovery of lipids and 
lipoproteins after a single procedure [19,26,45,47]. Indeed, we observed high pretreat­
ment ratios for plasma lathosterol and sitosterol relative to cholesterol, indicating an 
upregulated cholesterol synthesis and intestinal absorption before the start of the analy­
sis of the rebound. Since it has been shown that long-term therapy with HMG-CoA 
reductase inhibitors induced a reduction or no change in the rate of whole-body choles­
terol synthesis [48,49] the lack of a further transient post-treatment increase in choles­
terol synthesis post-apheresis is reasonably explained by the yet increased rate of 
synthesis, due to the many forgoing procedures. However, Pfohl et al [20] also studied 
their patients under long-term LDL-apheresis. Their treatment was not as effective as 
ours, since pretreatment total cholesterol and LDL cholesterol after 12 months of 
apheresis were still 7.4±0.3 and 5.5±0.3 mmol/L, respectively. Besides, it was accom­
panied by a gradual, although not significant, increase in lathosterol to cholesterol ratio 
and mevalonic acid, and changes in levels of these cholesterol precursors were nega­
tively correlated with the post-apheresis LDL cholesterol level. So, more aggressive 
lipid lowering in our study may have induced a yet increased pretreatment cholesterol 
synthesis, preventing further transient post-treatment increments. 
The continuous rise and fall of plasma lipoproteins necessitates the estimation of 
the time-averaged levels, since the mean of pre- and post-treatment concentrations 
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overestimates effective plasma levels [12]. We showed that the estimation of time-
averaged levels of total cholesterol, LDL cholesterol, apo B, and Lp(a) could be accu­
rately performed by a simple uniform formula using only pre- and post-treatment 
levels, CAVG^MIN+O-^CCMAX-CMIN), notwithstanding the differences in post-treatment 
rebound. Theoretically, this formula is not specific for the conditions we used during 
the study, i.e. biweekly procedures and a treated plasma volume of 5000 mL. This 
should, however, be evaluated first before this formula is used under different condi­
tions. 
In conclusion, our study showed that chronic, aggressive lipid lowering with 
LDL-apheresis stimulated cholesterol biosynthesis, which was not prevented by con­
comitant treatment with simvastatin. Biweekly procedures were not followed by a 
transient further increase in cholesterol absorption or whole-body synthesis. The fast 
rebound of the VLDL pool determined a quicker recovery of total cholesterol and apo 
B, whereas the return to pretreatment levels of Lp(a) and LDL cholesterol in 12 and 
13 days, respectively, showed that biweekly apheresis procedures, treating 5000 mL of 
plasma, is an acceptable strategy. 
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A.A. Kroon, P.N.M. Demacker, A.F.H. Stalenhoef 
The changes in low density lipoprotein (LDL) composition and oxidizability after 
LDL-apheresis (LA) using dextran sulfate cellulose columns were evaluated in 
12 hypercholesterolemic men [mean (±SD) total cholesterol (TC) 9.7±1.8 mmol/L]. 
After 10-20 months on biweekly LA and 40 mg per day simvastatin immediate pre-
apheresis levels of TC, LDL-cholesterol, and apolipoprotein В were decreased to 
5.3±1.3 mmol/L, 3.3±1.2 mmol/L, and 1.6±0.4 g/L, respectively, whereas apheresis 
induced mean acute reductions of 61%, 78%, and 76%, respectively. Measurements of 
copper-induced LDL-oxidizability in vitro showed an increased resistance against 
oxidation after LA until day 3 post-treatment: lag time (min) [day 0 (before LA) vs 
day 1 (post-LA)] 112±27 vs 130±26 (/·=0.001), maximal rate of diene production 
(nmol/min/mg LDL) 11.1±2.7 vs 9.1±2.1 (/^O.OOl), and time to maximal diene pro­
duction (min) 186±39 vs 209±35 (P=0.001). Analysis of the chemical composition of 
LDL revealed a 25% (P<0.00\) reduced content of cholesteryl esters and a decrease of 
the cholesterol to protein ratio of 1.20±0.25 to 0.70±0.22 (P<0.001) through the 3rd 
day post-LA. Linoleic acid and arachidonic acid content of LDL decreased 11 and 
18%, respectively, at the expense of palmitic acid. Vitamin E levels (mg/L) were 
significantly lowered due to reduction of the lipoprotein pool by apheresis, however, 
vitamin E content of LDL did not change in the days after apheresis when expressed 
per g protein or per цтоі linoleic acid. The changes in fatty acid pattern were strongly 
associated with changes in LDL-oxidizability indices (PsO.01). Thus, LA effectively 
decreased LDL pool size, inducing the presence of less buoyant lipoproteins, which 
were less susceptible to in vitro oxidation. This was not explained by changes in 
vitamin E levels, but by short-term changes in the fatty acids composition. 
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Introduction 
Progression of coronary and peripheral atherosclerosis can be retarded or even re­
gressed by effective cholesterol lowering [1,2]. Continuous LDL-apheresis with dextran 
sulfate cellulose as adsorbent selectively removes apolipoprotein (apo) В containing 
lipoproteins from the plasma [3]. This procedure has gained interest in the treatment of 
hypercholesterolemic patients, especially those refractory to drug treatment and with 
extensive coronary artery disease [4-6]. The efficacy of this treatment depends on the 
pre- and post-treatment lipid levels, and on the post-treatment return of lipids in plasma 
[7-10]. 
Evidence exists to suggest that oxidative modification of low density lipoproteins 
(LDL) plays a key event in the development of atherosclerosis. It has been shown that 
LDL must undergo oxidative modification before it can be taken up by macrophages 
[11-13]. Oxidative modification of LDL converts it to a form recognized by the macro­
phage scavenger receptor [14], leading to its unlimited uptake by cells. The presence of 
oxidized LDL and lipid peroxides in areas of atherosclerotic plaques and the observa­
tions that antioxidant treatment with probucol and vitamin E slows the progression of 
atherosclerosis in the animal model strongly support the role of LDL modification in 
atherogenesis [15-19]. However, in the animal model a decrease in oxidative suscepti­
bility alone is not sufficient to attenuate atherogenesis when cholesterol levels remain 
markedly elevated [20,21]. Apart from the antioxidant content of LDL, susceptibility of 
LDL to oxidation is determined by the chemical composition and fatty acid content of 
LDL [22-27]. Changes in the relative cholesterol and protein content may lead to con­
formational changes in the core of the particle, possibly resulting in a different expo­
sure of fatty acids to oxygen radicals and a decreased rate of lipid peroxidation [28]. 
Data on compositional changes of lipoprotein particles after apheresis are scarce 
[29-31]. It has been reported that particles of the high density lipoprotein (HDL)3 
subfraction become enlarged and enriched with free cholesterol and phospholipids, 
whereas the composition of the HDL2 is only slightly modified [30]. Jadhav and 
Thompson reported the normalization of the cholesterol to phospholipid ratio in famil­
ial hypercholesterolemic patients within 1 day after plasma exchange, reversing to the 
pretreatment state in 2 to 3 weeks [29]. The lipid composition of the LDL fraction after 
apheresis has been reported only once [31 ]; the authors of this study showed that 
immediately post-apheresis LDL particles had more surface than core constituents and 
were also structurally different in comparison to pretreatment. 
Since LDL-apheresis induces major changes in the cholesterol pool, which may 
affect the conformation of LDL and consequently influence LDL-oxidizability, we 
analyzed in the present study the acute changes in in-vitro oxidizability of LDL in days 
after LDL-apheresis in relation to its compositional changes. This opportunity was 
offered by a controlled study in our center which investigated the effect of more aggres-
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sive cholesterol lowering on atherosclerosis using long-term treatment with LDL-
apheresis [6]. 
Materials and methods 
Subjects and treatment 
The present study was carried out in subjects randomized to treatment with LDL-
apheresis in the LDL-Apheresis Atherosclerosis Regression Study (LAARS) [6]. In this 
study the effect of 2 years of more aggressive cholesterol lowering using biweekly 
LDL-apheresis plus simvastatin treatment was compared with the effect of conven­
tional lipid lowering with simvastatin alone on coronary and peripheral vascular dis­
ease. All eligible LAARS participants were men with a primary hypercholesterolemia 
and extensive, angiographically assessed coronary artery disease. Twenty-one subjects 
were enrolled for long-term LDL-apheresis of whom 12 (age 50±10, range 31-64 years) 
gave informed consent for the present study. Baseline lipids and lipoproteins (CBAS) on 
a standard lipid lowering diet are given in Table 1, showing a predominant elevation of 
LDL cholesterol and apo В according to the inclusion criteria of the study. Lipopro­
tein^) [Lp(a)] levels showed a skewed distribution (median 30.0, range 2.9 to 254.1 
mg/dL). During the study all subjects continued their lipid lowering diet and were 
treated with the HMG-CoA reductase inhibitor simvastatin (40 mg/day). LDL-apheresis 
was performed fortnightly with an automated system equipped with 2 small-sized 
dextran sulfate cellulose columns (Liposorber®) in combination with a membrane type 
plasma separator (MA-01 unit, Kanegafuchi Chemical Industry Co. Ltd., Osaka, Ja­
pan). For this extracorporeal procedure blood was anticoagulated with heparin at a 
continuous flow of 2,000 U/h. A volume of 5000 mL (approximately 1.5 plasma vol­
umes) was treated per session. All subject were also on concomitant treatment with 
anti-anginal drugs and acetylsalicylic acid in most cases. 
During the study a rebound curve was constructed for every subject on one occa­
sion in a semi-steady state phase, 10 to 20 months after the start of the study. Lipids and 
lipoproteins, oxidizability, chemical composition, fatty acid composition, and vitamin E 
content of LDL were determined immediately before and after apheresis, and on days 1, 
3, 7, and 10 after apheresis. 
Plasma samples 
Blood samples were obtained by venapuncture after an overnight fast and collected into 
evacuated EDTA-containing (1 g/L) tubes. After centrifugation at room temperature 
(10 minutes at 2200g), 5 mL plasma samples were collected in polypropylene vials to 
which 50 μί- 600 g/L saccharose was added as cryopreservant to prevent LDL aggrega­
tion. The vials were stored at -80°C until use. 
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Lipoprotein isolation 
Very low density lipoproteins (VLDLs) plus intermediate density lipoproteins (IDLs) 
(¿< 1.019 g/mL) and LDLs (l.0l9<d< 1.063 g/mL) were isolated by sequential ultracen-
trifugation, essentially as described by Havel et al [32]. LDL was dialyzed in the dark 
for 24 hours at 4°C against 3 L phosphate-buffered saline containing 10 μηιοΙ/L EDTA. 
The buffer was made oxygen-free by vacuum degassing followed by purging with 
nitrogen. The LDL containing solution was filtered through a 0.45 μτη filter. 
LDL oxidation 
The in vitro oxidation of LDL was performed as described previously [25]. In short, 
10 μιηοΙ/L EDTA-containing dialyzed LDL (adjusted to 0.5 mg LDL protein/mL) was 
diluted directly before the start of the oxidation with EDTA-free phosphate buffer to a 
final concentration of 0.05 mg/mL. This reduces the final EDTA concentration in the 
cuvette to 1 μιτιοΙ/L. Oxidation was initiated by addition of a freshly prepared 
CuCl2.2H20 solution (final concentration 15 μιτιοΙ/L). The kinetics of LDL oxidation 
were determined by measuring the formation of conjugated dienes by monitoring the 
change in the 234 nm absorbance at 30°C on a Perkin-Elmer Lambda 5 UV spectropho­
tometer equipped wit a six-position automatic sample changer, allowing for the deter­
mination of up to 6 samples at the same time. Absorbance was recorded every 3 min­
utes for at least 5 hours. All measurements were performed in duplicate. 
The kinetics of the absorbance profile of each individual LDL preparation was 
described by the following indices: the initial 234 nm absorbance (diene0, expressed as 
nmol/mg LDL protein); the lag time, defined as the interval between the intercept of the 
linear least-square slope of the curve with the 'initial absorbance axis', expressed in 
minutes; the maximal rate of oxidation (rate), calculated from the slope of the 
absorbance curve during the propagation phase, expressed as nmol/min/mg LDL 
protein; the maximal amount of dienes formed (diene^,^); and t^j^, the time needed to 
reach maximal absorbance, expressed in minutes. The amount of dienes produced was 
calculated by subtraction of diene0 from dienen^*. 
Other methods 
Plasma total cholesterol, free (unesterified) cholesterol, phospholipids, and triglycerides 
in LDL samples were determined with commercially available enzymatic methods 
(Boehringer Mannheim, FRG, Nos. 237574, 310328, and 691844; and Sera-PAK, 
Miles, Italy, no. 6639, respectively). LDL protein was measured by the method of 
Lowry et al [33]. Plasma HDL cholesterol was determined using the polyethylene 
glycol 6000 precipitation method [34]. LDL cholesterol was calculated by subtraction. 
Apo В was quantified by immunonephelometry [35] and recalculated on the basis of 
data from exchange of sera with the North West Lipid Research Clinic (Seattle, USA). 
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Table 1. Change in plasma lipids and lipoproteins 
TC 
(mmol/1) 
TG 
(mmol/1) 
LDL-C 
(mmol/1) 
HDL-C 
(mmol/1) 
Lp(a) 
(mg/dl) 
apoB 
(g/L) 
C B A S 9.72±1.84 2.32±1.03 7.78±1.86 0.93±0.18 57.0±63.9 2.59±0.47 
CMAX 5.28±1.30 1.75±0.88 3.25±1.22 1.08±0.23 60.8±68.0 1.58±0.40 
CMIN 2.06±0.51 0.51±0.28 0.73±0.43 1.06±0.22 13.8±14.4 0.39±0.15 
change -61±6%* -68±15%* -78±6%* -2±7% -72±12%* -76±12%* 
C A V G 4.17±0.91 1.67±0.71 2.28±0.72 1.08±0.20 45.4±52.3 1.20±0.23 
Data represent means±SD of 12 patients. TC, total cholesterol; TG, triglycerides; 
L(H)DL-C, low (high) density lipoprotein cholesterol; Lp(a), lipoprotein^); apo B, apoli-
poprotein B; C^j, baseline concentrations; Сщх and CMIN, levels immediately before and 
after apheresis; time-averaged concentrations (CAVG) were calculated by integral calculation 
of the area under the rebound-curve. Changes versus Сщх (absolute and proportional): 
*P< 0.001 (t-test or Mann-Whitney U-test were appropriate) 
mmol/L or g/L 
3 -
2-
1-
mg/dL 
70 
60 
50 
40 
30 
-20 
10 
time (days) 
Fig. 1. Recovery of plasma total cholesterol (TC, circles), lipoprotein^) (Lp(a), squares), 
LDL cholesterol (LDL-C, triangles), and apolipoprotein В (ApoB, diamonds) in days after 
LDL-apheresis performed at biweekly intervals. B, immediately before apheresis; A, immedia­
tely after apheresis 
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Lp(a) was be measured by a specific radioimmunoassay [apolipoprotein(a) RIA 100, 
Pharmacia Diagnostics AB, Uppsala, Sweden]. Vitamin E (α-tocopherol) concentra­
tions in LDL were measured by high-performance liquid chromatography (HPLC 
Spectra Physics model 8800, Breda, The Netherlands) [24]. Fatty acid measurements in 
LDL were performed by gas chromatography (Varían 3400 GC, Houten, The Nether-
lands) [26]. 
Statistical analysis 
Analyses were performed with procedures available in SPSS (SPSS Inc., Chicago, IL.). 
Multivariate ANOVA (with correction for repeated measures) followed by Mests were 
used for normally distributed data, whereas Friedman's ANOVA (with correction for 
multiple testing) followed by Wilcoxon's signed rank tests were used for differences in 
means of not normally distributed data. For measurements of agreement the Pearson 
product-moment correlation coefficient was used. Stepwise least-squares multivariate 
regression analysis was performed using a maximal p-value in the F-test of 0.05 before 
a variable could be added and a minimal tolerance (collinearity) of 0.01. A two-sided 
P-value of less than 0.05 was considered to be significant. Results are expressed as 
means ± SD, unless otherwise indicated. 
Results 
Plasma lipids and lipoproteins 
Due to ongoing treatment with LDL-apheresis and simvastatin baseline lipid and 
lipoprotein levels were reduced to the pretreatment levels (CMAX) as shown in Table 1. 
Mean acute reduction of total cholesterol, LDL cholesterol, apo B, Lp(a), and triglycer-
ides were 61, 78%, 76%, 72%, and 68%, respectively (PO.OOl). HDL cholesterol 
levels were not influenced by the treatment. After apheresis, LDL carried less choles-
terol, as indicated by the LDL cholesterol to apo В ratio, changing from 0.72±0.16 to 
0.63±0.15 (P=0.04) immediately post-treatment and to 0.44±0.15 (PO.001) on day 1 
(Table 2). The rebound after LDL-apheresis of the various lipoproteins was different. 
Triglycerides recovered rapidly, reaching 83% of the pretreatment level within 1 day 
after treatment (data not shown). The rebound of total cholesterol, LDL cholesterol, apo 
B, and Lp(a) was much slower: 50% recovery within 2-4 days, followed by a succes­
sive slower rise (Fig.l). The ratio LDL cholesterol to apo В gradually increased and 
was comparable to the pretreatment value at day 7 (Table 2). 
In vitro susceptibility of LDL to oxidative modification 
For each subject, LDL was isolated immediately before and after apheresis, and on days 
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Table 2. Change in chemical composition in percentage of dry mass of low density lipoprotein 
(LDL) particles (1.019 < d < 1.063 g/mL) and LDL cholesterol to apolipoprotein В ratio 
presented in days after LDL-apheresis 
%FC 
%CE 
%TG 
%PL 
%Prot 
C/Prot 
LDL-C 
/apoB 
day 0-Bt 
8.3±1.0 
39.2±3.2 
4.9±1.2 
19.7±2.0 
27.2±4.1 
1.2±0.3 
0.72±0.16 
day 0-Af 
8.1±0.7 
31.1±5.71 
7.9±2.1t 
14.1±5.5# 
38.8±7.81 
0.7±0.2K 
0.63 ±0.15* 
day 1 
7.4±1.5* 
29.5±3.45 
7.6±2.H 
18.5±2.6 
37.1 ±6.51 
0.7±0.2i 
0.44±0.151 
day 3 
8.2±0.8 
37.9±1.9* 
6.0±1.1# 
19.3±2.3 
28.6±2.9 
1.1±0.1* 
0.61±0.16\ 
day 7 
8.2±0.7 
40.1 ±2.5 
5.2±1.1 
19.5 ±1.3 
27.0±3.2 
1.2±0.2 
0.68±0.15 
day 10 
8.3±0.8 
40.8±2.0 
4.9±1.0 
19.5±1.7 
26.6±2.5 
1.2±0.2 
0.72±0.17 
Data represent means (±SD); t. day 0 immediately before (B) and after (A) LDL-apheresis; 
FC, free cholesterol; CE, cholesteryl ester; TG, triglyceride; PL, phospholipid; Prot, protein; 
C/Prot, cholesterol (FC + cholesterol moiety of CE [~ 0.59 χ weight of CE]) to protein ratio; 
LDL-C/apoB, LDL cholesterol to apolipoprotein В ratio. Differences versus before apheresis 
*0.01<P<0.05; #0.001 <P<0.01; \p<0.001 (multivariate ANOVA, followed by paired 
t-test) 
Absorbance (234 nm) 
1.20 
0.90 
0.60 
0.30 
0.00 
1:00 1:30 2:00 2:30 3:00 
time (hours) 
3:30 4:00 
Fig. 2. Example of curve plot depicting the kinetics of LDL-oxidation in one subject 
immediately before (day 0-B), immediately after (day 0-A), and 1, 3, and 10 days after 
LDL-apheresis 
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Table 3. Change in characteristics of the absorbance curves at 234 nm determined by 
measuring the formation of conjugated dienes after copper-induced oxidation of low density 
lipoproteins (LDL) in days after LDL-apheresis 
day O-Bt day O-Af day 1 day 3 day 10 
lag time (min) 112.3±27.2 132.2±32.1# 130.2±26.4# 116.4±30.2 106.5±26.1 
rate (nmol/min/ 11.1±2.7 9.9±4.1 9.1±2.1# 10.9±2.4 11.5±2.2 
mg LDL) 
dienes prodi 558.2±70.7 497.8±99.6* 500.2±78.9* 555.8±86.5 557.0±48.4 
(nmol/mg LDL) 
t M A X (min) 185.7±38.8 216.2±47.7# 209.4±34.7# 190.9±41.0 177.6±34.5 
Data represent means (±SD) from duplicate measurements in each patient; t. day 0 imme­
diately before (В) and after (A) LDL-apheresis; φ, dienes prod, аіепещх minus dieneo, for 
definitions see 'Materials and Methods' section. Differences versus before apheresis: 
*0.01<P<0.05; #0. OOK Ρ < 0.01 (multivariate ANOVA, followed by paired t-test) 
1, 3 and 10 post-apheresis. An example of the continuously monitored formation of 
conjugated dienes, as a measure of Cu2+-induced LDL-oxidation, is shown in Figure 2. 
The means of the characteristics of the absorbance curves, depicting changes in LDL-
oxidizability are shown in Table 3. LDL appeared less susceptible to in vitro oxidation 
immediately after apheresis and on day 1 post-treatment: all indices for LDL-
oxidizability were significantly different from pretreatment. At 3 days post-treatment 
the indices were again comparable to pre-apheresis and remained unchanged on day 10. 
Changes in composition of lipoproteins 
The chemical composition in percentage of dry mass was determined immediately 
before and immediately after apheresis, and on days 1, 3, 7, and 10 post-treatment. 
Until and including the third day a significant reduction in cholesterol content (predom­
inantly cholesteryl ester) of LDL particles was observed, associated with a relative 
enrichment in triglycerides and proteins (Table 2). As a consequence, the ratio cholest­
erol to protein was significantly reduced through the third day post-apheresis, indicat­
ing smaller, less buoyant lipoprotein particles. VLDL and IDL particles showed compa­
rable changes as LDLs, which lasted until the first day post-treatment (data not shown). 
The fatty acid composition expressed in proportions of total LDL fatty acid 
content was measured immediately before and immediately after apheresis, and on days 
1,3, and 10 post-apheresis. In general, the fatty acid composition of each isolated LDL 
showed a decreased amount of unsaturated fatty acids and an increasing percentage of 
saturated fatty acids (Table 4). The arachidonic acid (20:4) and linoleic acid (18:2) 
content showed a significant decrease through the first day after apheresis at the ex-
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Table 4. Change in fatty acid composition in percentage of low density lipoprotein (LDL) 
total fatty acid profile in days after LDL-apheresis 
day O-Bt day O-At day 1 day 3 day 10 
Arachidonic acid 9.5±3.8 8.8±3.5 7.8±2.2# 9.5±3.2 9.8±3.8 
(20:4) 
Linoleicacid 40.3±4.0 38.7±6.0 35.9±5.3# 40.1±4.4 41.5±5.3 
(18:2) 
Oleic acid (18:1) 19.7±2.3 18.7±3.6 20.6±4.3 20.2±2.4 19.1 ±3.3 
Stearic acid 8.6±1.2 9.8±1.5* 9.2±2.1 8.0±1.2 8.4±1.2 
(18:0) 
Palmitic acid 22.0±5.4 24.0±5.0 26.4±3.6* 22.2±4.0 21.2±4.5 
(16:0) 
Data represent means (±SD) in percentages of LDL total fatty acid profile; t. day 0 imme-
diately before (B) and after (A) apheresis. Differences versus pretreatment levels: 
*0.01<P<0.05; #0.001<P<0.01 (Friedman's ANOVA, followed by Wilcoxon's signed 
rank test) 
pense of an increase in palmitic acid (16:0) and stearic acid (18:0). No significant 
changes were observed in the oleic acid (18:1) content. 
The absolute vitamin E levels decreased significantly after LDL-apheresis, com-
parable to the reduction in lipoprotein concentrations. However, when expressed in 
milligrams per gram of LDL protein or per micromol of linoleic acid no significant 
reductions in vitamin E levels were observed compared to pretreament levels (Table 5). 
Correlations 
No correlations were observed between vitamin E, expressed per gram of LDL protein, 
and any of the lipids and lipoproteins. Difference between pretreatment and immediate 
post-treatment levels of vitamin E, expressed in mg/L, showed significant correlations 
with changes in total cholesterol, triglycerides, LDL cholesterol, and apo B, indicating 
a relation with the reduced number of circulating lipoprotein particles. Using stepwise 
multivariate regression absolute vitamin E levels were only explained by absolute 
changes in total cholesterol concentration (variance R^O.42, P=0.02). Stepwise addi-
tion of other variables did not further improve the explained variance significantly. 
No significant correlations were found between the change in any of the 
oxidizability parameters and change in lipids, lipoproteins, vitamin E, or the chemical 
composition of LDL or VLDL. Good correlations were observed between the change in 
all oxidizability indices and the change from pretreatment to the first day post-apheresis 
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Table 5. Vitamin E content of low density lipoproteins (LDLs) in days after LDL-apheresis 
day O-Bt day O-At day 1 day 3 day 10 
Vitamin E 11.3±2.0 4.6±0.9l 7.0±1.21 8.9±1.5# 10.3±1.4 
(mg/L) 
Vitamin Εφ 4.4±1.5 3.8±2.1 4.3±2.0 5.1±1.1§ 4.9±1.3§ 
(mg/g protein) 
Vitamin E 6.99±1.45 6.11±1.87 6.93±1.52 6.99±0.97 7.37±1.98 
(mg//tmol linoleic acid) 
Data represent means (±SD); t. day 0, immediately before (B) and after (A) apheresis; 
І, normal range for healthy volunteers: 4.63±1.38 mg/g LDL protein (n=28). Differences 
versus pretreatment levels: #0.001 <P<0.01; V<0.001; differences versus post-treatment 
levels: §0. OK Ρ< 0.05 (multivariate ANOVA, followed by paired t-test) 
in palmitic and arachidonic acid content (data not shown). By multiple regression the 
change in lag time was explained by the change in arachidonic acid and linoleic acid 
(total variance R^O.71, /М).004), change in the maximal rate of oxidation was ex­
plained by the change in palmitic acid (variance R M J . 4 9 , P=0.01), and change in time 
to maximal absorbance by the change in arachidonic acid and linoleic acid (total vari­
ance R^O.66, /MJ.008); stepwise addition of other variables did not further improve 
the explained variance significantly. 
Discussion 
In the present study we were able to investigate patients with a primary 
hypercholesterolemia, who were on long-term LDL-apheresis and were treated con­
comitantly with the HMG-CoA reductase inhibitor simvastatin. The intermittent nature 
of LDL-apheresis, which results in plasma concentrations above the time-averaged 
levels for approximately 9 out of 14 days between consecutive fortnightly procedures, 
has been used as a less favourable aspect of this procedure [5]. In the present study we 
observed quantitative changes in lipids and lipoproteins which were in accordance with 
previous data [3-5]. Characteristically, triglycerides returned quickly to the pretreat­
ment levels, within 1 to 2 days, due to fast increase in VLDL synthesis, whereas LDL 
cholesterol showed a much slower rebound [10]. As a consequence of the apheresis-
induced marked reductions in pool size, vitamin E levels were reduced considerably. 
Nevertheless, short-term favourable effects on LDL-oxidizability were observed in the 
days post-apheresis, which were explained by significant compositional changes of 
VLDL and LDL, i.e. reductions of the unsaturated fatty acid content of LDL. 
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A potential shortcoming of this study may be the concomitant use of simvastatin. 
This HMG-CoA reductase inhibitor was administered to reduce the post-treatment 
rebound and to prolong the interval between apheresis procedures [8-10]. It has been 
shown that statins selectively reduce the concentration of cholesteryl-ester-enriched apo 
B-containing lipoproteins and consequently decrease LDL-oxidizability [36-38]. Since 
simvastatin was administered for a longer period before the start of this study and was 
not discontinued, the observed changes in this study will be evoked by apheresis. 
This study did not investigate the long-term effects of LDL-apheresis on 
oxidizability. The main issue studied here were the changes between two procedures. 
We found that the acute reduction in cholesterol pool size was accompanied by qualita-
tive changes is the LDL particle, rendering it less susceptible to in vitro oxidative 
modification. The oxidizability indices showed a longer lag time, indicating more 
resistance against oxidative damage, and both the rate of oxidation and the amount of 
dienes formed were significantly lower post-apheresis, as measures of the extent of 
oxidative modification. Vitamin E, quantitatively the most important lipophilic antioxi-
dant in LDL [22], did not change significantly when expressed per LDL particle or per 
micromol of linoleic acid. Indeed, a relation between the vitamin E content and resis-
tance against oxidation of LDL has not been demonstrated, unless vitamin E was 
supplemented [25,39,40]. 
Moreover, the time span along which changes reversed was rather short, and so 
the biological consequences of this period of reduced susceptibility to oxidation re-
mains uncertain. Therefore, the observation that there was no increase or overshoot in 
oxidizability after an initial period with less susceptibility may be of more importance. 
In trying to explain the reduced oxidizability we considered the physicochemical 
properties of LDL. On the average, the LDL mass comprises approximately 40% 
cholesteryl esters, 25% proteins, 20% phospholipids, 10% unesterified cholesterol, and 
5% triglycerides [41]. We observed a reduction of the cholesteryl ester content of LDL, 
yielding less substrate per particle available for oxidation, which was in line with the 
reduced ratio cholesterol to protein (Table 2) [36]. The fatty acid composition is an-
other important determinant of LDL-oxidizability [22,25,26]. The rate and extent of 
diene formation are governed mainly by the amount of polyunsaturated fatty acids 
available for oxidation. The more unsaturated the fatty acids, the more susceptible they 
are to oxidation [42,43]. The main polyunsaturated fatty acid in LDL was linoleic acid 
(Table 4). The relative amount of arachidonic acid and linoleic acid were reduced by 18 
and 11%, respectively, explaining the decreased susceptibility to oxidation by multiple 
regression [26]. 
Reportedly, a reduced susceptibility to oxidative modification can also be found in 
structural changes in the surface lipid monolayer of the lipoprotein particles by differ-
ences in physical state of the LDL particle core [28,44,45]. By analysis of subclasses of 
LDL, it has been shown that mean particle diameter, molecular weight, and lipid to 
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protein ratio decrease progressively with increasing density of the particles [46]. In 
various reports, these small and dense LDLs have been associated with clinical and 
angiographic indices of coronary artery disease, related to their enrichment with 
cholesteryl esters and an increased content of cholesteryl oleate compared to cholesteryl 
linolate [38,44,45,47]. In addition, these small, dense LDL sub fractions are more 
susceptible to Cu2+-induced oxidative modification [45], as has been reported first by 
our lab [24]. In the present study, lipoprotein particles were also smaller and more 
dense after apheresis, indicated by the decreased cholesterol to protein ratio. However, 
they contained less cholesteryl ester and relatively more surface lipid components, so 
they had a more or less "loose fitting" surface layer (Table 2). This observation con­
cords with the observed change in immunoreactivity against different apo В epitopes of 
post-apheresis LDL, as has been shown by Gandjini et al [31]. These and other authors 
argued that newly formed LDL, either derived from VLDL or directly secreted by the 
liver, are responsible for the compositional changes found after LDL-apheresis [29,31]. 
The latter authors also showed that post-apheresis LDL did not originate from selective 
binding of various LDL subfractions to dextran sulfate cellulose beads, by showing 
equal affinity of per- and post-apheresis LDL for the Liposorber® columns. Our data fit 
rather well with the assumption of the presence of newly formed post-apheresis LDL. 
Moreover, it also explains the reduced susceptibility to Cu2+-induced oxidizability in 
newly formed LDL in comparison to structurally and compositionally different mature 
LDL. 
The present study showed features that are not unique for LDL-apheresis and can 
be explained on the basis of differences in chemical composition and fatty acid content 
and differences in structure of the LDL particle [45,48]. It has been shown that treat­
ment with various lipid lowering agents not only results in a decrease in the number of 
circulating atherogenic lipoprotein particles but also affects the composition and 
oxidizability of LDL [36,38,45,49]. In conclusion, our data clearly indicated that 
apheresis-induced fluctuations in LDL cholesterol and vitamin E levels did not influ­
ence oxidizability in a negative sense, even on the days LDL cholesterol level was 
above the time-averaged concentration. In contrast, short-term, decreased susceptibility 
to in vitro Cu2+-induced LDL-oxidation was observed caused by changes in fatty acid 
composition in less buoyant LDL particles. 
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Background. Intensive lipid lowering may retard the progression of coronary athero-
sclerosis. Low density lipoprotein (LDL) apheresis has the potential to decrease LDL 
cholesterol to very low levels. To assess the effect of more aggressive lipid lowering 
with LDL-apheresis, we set up a randomized study in men with hypercholesterolemia 
and severe coronary atherosclerosis. 
Methods and Results. For two years 42 men were treated with either biweekly LDL-
apheresis plus medication or medication alone. In both groups a dose of simvastatin of 
40 mg per day was administered. Baseline (mean ± SD) LDL cholesterol was 7.8±1.9 
mmol.L'1 and 7.9±2.3 mmol.L'1 in the apheresis and medication group, respectively. 
The mean reduction in LDL cholesterol was 63% (to 3.0 mmol.L"1) and 47% (to 4.1 
mmol.L"1), respectively. Primary quantitative coronary angiographic endpoints were 
changes in average Mean Segment Diameter (MSD) and Minimal Obstruction Diame-
ter (MOD). No differences between the apheresis vs medication group were found in 
MSD (-0.0Ü0.16 mm vs 0.03±0.16 mm, respectively) or in MOD (-0.01±0.13 mm vs 
0.01 ±0.11 mm, respectively), expressed as means per patient. On the basis of coronary 
segment, mean percent stenosis of all lesions showed a tendency to decrease; only in 
the apheresis group more minor lesions disappeared in comparison to the medication 
group. On bicycle exercise tests the time to 0.1 mV ST-segment depression increased 
significantly by 39% and the maximum level of ST-depression decreased significantly 
by 0.07 mV in the apheresis group versus no changes in the medication group. 
Conclusions. Two years of lipid lowering both with medication alone or LDL-
apheresis with medication showed angiographic arrest of the progression of coronary 
artery disease. However, more aggressive treatment induced functional improvement, 
which may precede anatomic changes. 
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Introduction 
The relation between total cholesterol and low density lipoprotein (LDL) cholesterol 
levels and the incidence of coronary artery disease (CAD) is well established [1,2]. 
Primary and secondary prevention trials, predominantly conducted in men with 
hypercholesterolemia, have shown that lipid lowering regimens result in less progres-
sion of angiographic lesions [3]. Regression of coronary atherosclerosis is demonstrated 
to a limited extent in some patients in most of these trials [4-12]. The common denomi-
nator of these trials is reduction of LDL cholesterol [13]. Until today intensive lipid 
lowering in men with established CAD using HMG-CoA reductase inhibitors is the 
most effective means in terms of slowing or arrest of progression of coronary athero-
sclerosis [14,15] and consequently reducing the number of clinical events [16]. 
Continuous LDL-apheresis, using dextran sulfate cellulose columns, selectively 
removes apolipoprotein B-containing lipoproteins from plasma [17,18]. The perfor-
mance of regular apheresis permits the achievement of lower levels of LDL cholesterol 
which is not usually possible to attain with drug therapy alone. The application of this 
method may offer opportunities in the prevention of progression, or even inducing 
regression of coronary atherosclerosis in selected patients with a primary 
hyperlipidemia and established CAD [19-22]. 
The quantitative computerized analysis of the extent of atherosclerosis on coro-
nary angiograms (QCA) has been developed and extensively evaluated for 
angiographic trials [23-25]. Despite certain limitations, QCA is one of the most precise 
procedures available for assessing progression or regression of CAD [26]. Given the 
relatively small changes in the severity of lesions demonstrated in angiographic trials 
and the unclear clinical benefits of such changes, the addition of measurements to 
predict the functional significance of changes in coronary stenosis seems important 
[27]. 
The LDL-Apheresis Atherosclerosis Regression Study (LAARS) was designed as 
a prospective, open, randomized, single-centre study in men with primary 
hypercholesterolemia and extensive coronary artery disease. The objective was to 
determine whether more aggressive LDL cholesterol lowering, with biweekly LDL-
apheresis plus the HMG-CoA reductase inhibitor simvastatin, exerts better an anti-
atherosclerotic effect than lipid lowering to more conventional cholesterol levels with 
simvastatin alone. In this article the results of sequential exercise tolerance tests and 
quantitative computer-assisted analysis of coronary angiograms during 2 years of 
treatment are described and related to the lipid and lipoproteins levels. The results of 
functional measurements of coronary blood flow by means of videodensitometry will 
be presented separately. 
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Patients and Methods 
Subjects and treatment 
From January 1990 until May 1992, men aged between 30 and 67 years, who under­
went diagnostic coronary angiography for angina pectoris were screened for eligibility. 
Included were patients with a mean of two successive serum total cholesterol determi­
nations above 8.0 mmoLL'1 or LDL cholesterol above 5.8 mmol.L"1, and a mean of two 
successive fasting serum triglycerides measurements below 5.0 mmol.L'1 on a standard 
lipid lowering diet without other lipid lowering treatments, and extensive coronary 
atherosclerosis as shown by visual assessment of their coronary angiogram. Excluded 
were patients with a ventricular ejection fraction <0.35, acute myocardial infarction or 
percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass 
grafting (CABG) within the previous 3 months, impaired hepatic (>30% above normal 
range) or renal function (plasma creatine к 150 μπιοΐ.ί"1), hypertension (diastolic blood 
pressure ¿100 mmHg), diabetes mellitus, severe obesity (BMI ¿30 kg.m"2), homozy-
gous familial hypercholesterolemia, any secondary hyperlipidemia, and heavy smokers 
(>10 cigarettes per day). Patients with a history of PTCA and CABG were included 
because these modalities have become an integral part in the treatment of patients with 
CAD. Excluding these patients would have introduced a selection bias. Both patients 
with and without PTCA or CABG had severe coronary atherosclerosis till the same 
degree (Table 1). 
At least 2 months prior to the start of the study all lipid lowering drugs were 
stopped. Only a cholesterol lowering diet equivalent to the American Heart Association 
step I diet was continued or prescribed and the patients were instructed by a dietician. 
During this 2-months run-in period an exercise test and coronary angiography were 
performed. Written informed consent according to the Declaration of Helsinki was 
obtained. Those patients who met all in- and exclusion criteria were allocated at ran-
dom to either biweekly LDL-apheresis plus simvastatin (40 mg/day), a potent HMG-
CoA reductase inhibitor [28,29], or simvastatin treatment (40 mg/day) alone. Random-
ization was stratified for the level of serum total cholesterol and lipoprotein(a) [Lp(a)], 
age, and CABG status. 
LDL-apheresis was performed with an automated system with two small-sized 
dextran sulfate cellulose columns (MA-01 unit, Kanegafuchi Chemical Industry Co. 
Ltd., Osaka, Japan). In this system the plasma is separated by a polysulfone membrane 
separator, and apolipoprotein B-containing particles are adsorbed in one of two col-
umns containing cellulose-bound dextran sulfate used in rotation in a veno-venous 
extracorporeal circuit. A volume of 5000 mL (approximately 1.5 plasma volume) was 
treated per session. The combination therapy of LDL-apheresis and simvastatin can be 
expected to slow down the post-apheresis rebound in serum cholesterol, which permits 
prolongation of the intervals between the apheresis procedures [30,31 ]. Patients allo-
86 
oooooo 
cated to lipid lowering with drugs attended the outpatients clinic each month; those on 
LDL-apheresis were seen fortnightly. In both groups a resin in the highest tolerable 
doses was added to the treatment if (pre-apheresis) serum cholesterol levels in 2 con­
secutive months remained above 8.0 mmol.L', since it was considered not appropriate 
to continue single drug treatment above this level. At each visit, the patients were 
subjected to a brief physical examination, and additional dietary instruction was re­
peated frequently. Antianginal medication was continued at the same doses during the 
study. If adaptation was necessary during the study, the original prescription, if possi­
ble, was restored before the follow-up heart catheterization. 
Lipids, lipoproteins and laboratory safety measures 
In both groups lipids, lipoproteins, blood chemistry, hemograms, and routine urinalysis 
were performed monthly. Apolipoprotein (apo) Al, apo B, and Lp(a) were measured 
bimonthly. In the apheresis group lipids and lipoproteins and some extra laboratory 
safety parameters (hemogram, calcium, and total protein level) were measured before 
and immediately after each LDL-apheresis. Serum total cholesterol and fasting triglyc­
erides were determined enzymatically (CHOD-PAP, no. 237574, Boehringer 
Mannheim GmbH, FRG and Sera-PAK, no. 6639, Miles, Italy, respectively). High 
density lipoprotein (HDL) cholesterol was determined using the polyethylene glycol 
6000 precipitation method [32]. LDL cholesterol was calculated by subtraction. Sam­
ples for apo Al, apo B, and Lp(a) were stored at -80°C, and determined at the end of 
the study. Apo Al and apo В were quantified in serum by immunonephelometry [33]. 
Lp(a) was measured by a specific radioimmunoassay (apolipoprotein(a) RIA 100, 
Pharmacia Diagnostics AB, Uppsala, Sweden). Hyperhomocysteinemia was excluded 
by measuring fasting homocysteine levels [34]. Fibrinogen levels did not differ be­
tween both groups. Apheresis produced an acute 35% reduction of fibrinogen, returning 
to pretreatment levels between 2 and 7 days (n=l 1, data not shown). 
The selective removal of apo B-containing lipoproteins with LDL apheresis 
causes sawtooth-like alterations in lipoprotein concentrations [35]. The increase of 
lipoprotein levels after the treatment can be explained by first-order kinetics [36-38]. 
Therefore, time-averaged concentrations (C A V G) or interval means of total cholesterol, 
LDL cholesterol, apo B, and Lp(a) were calculated by applying a formula derived from 
the rebound curves which were constructed for each patient at one occasion: 
CAVG
=CMIN+0-73(CM A X-CM 1 N), where CMA* is the pretreatment level and CMIN the levels 
immediately after apheresis [39]. For serum triglycerides and HDL cholesterol only 
pretreatment levels were used in the analysis because triglycerides reach pretreatment 
levels within 1 to 2 days after apheresis and HDL cholesterol is not influenced by LDL-
apheresis. 
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Exercise tests 
Bicycle exercise tests were done at baseline, after 12 months, and after 24 months of 
the start of the study. The assessments at the end of the study were done 3 to 4 weeks 
after the last apheresis. An electronic braked ergometer (Marquette Case 15, Marquette 
Electronics Inc., Milwaukee, USA) was used, starting at a load of 50 W and raising it 
every minute by 10 Watt during continuous ECG monitoring to maximum exercise 
limited by chest discomfort or usual criteria for stopping the test. Blood pressure and 
12-lead ECG registration were monitored at rest, at maximum exercise, and every 
minute during the test. Automated calculation of ST-segment depression was performed 
at a point located 80 msec beyond the J-point. Data were corrected for systolic blood 
pressure-heart rate product at maximal load. An additional exercise thallium scintigra-
phy was performed when the bicycle exercise test was not conclusive due to a maxi-
mum heart frequency ¿85% of the predicted value corrected for age and body mass, 
and/or the predicted load ¿80% without ST-segment changes. 
Coronary angiography 
The coronary angiograms were obtained at baseline and after 2 years of treatment, 
4 weeks after the last apheresis, using the same protocol as has been described for the 
Regression Growth Evaluation Statin Study (REGRESS) [12]. During both procedures 
the same non-ionic iso-osmolar contrast agent [Iohexol 350 (Nycomed AS, Oslo, 
Norway)] and the same cineangiographic techniques were used, according to standard 
requirements for quantitative analysis [25]. A centimeter grid was filmed to adjust for 
pincushion distortion. The same type and diameter of catheters were used in both 
procedures and used as a scaling device in QCA analysis. The protocol required admin-
istration of 5 to 10 mg of isosorbidedinitrate sublingually 5 minutes prior to the first 
intracoronary injection of contrast, which was repeated during the procedure if neces-
sary. Twelve to 15 coronary segments were filmed in 2 projections [40]. Preferably, 
end-diastolic frames were selected for blinded computer-assisted quantitative analysis 
of paired angiograms, which was performed at the Heart Core Angiographic Reference 
Laboratory at the University Hospital of Leiden using the Cardiovascular Measurement 
System (CMS-Medis Medical Imaging Systems, Nuenen, the Netherlands [CMS-
version 2.3D]) [41]. This system uses a high-quality cine-video converter (CAP 35E) 
that allows a selected cine frame to be projected onto a digital camera through a zoom 
lens (magnification 2.3x). The video signal of the magnified region was digitized at a 
matrix size of 512x512x8 bits. For calibration, the boundaries of a nontapering part of 
the catheter were determined automatically over a length of approximately 2 cm. To 
assess the contours of the vessel, the beginning and the end of the specific coronary 
segment had to be indicated, after which a pathline was computed connecting these two 
points. The contours of the vessel were then computed in multiple iterations by the 
minimal cost contour detection technique. The edge strength of a point was based on 
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the weighted sum of the first and second derivative functions; this edge strength was 
corrected for the limited resolution of the entire imaging chain, a procedure that is 
particularly important for the accurate measurement of small vessels. A diameter 
function was determined in absolute terms (in mm) by computing the shortest distances 
between the left and right contours along the vessel centerline. The reference diameter 
was defined as previously described [42]. Primarily, minimal obstruction diameter 
(MOD), as a measure for localized atherosclerosis, and the mean segment diameter 
(MSD), as a measure for diffuse changes, were assessed. Only segments without over-
lap and minimal foreshortening were analyzed, including bypass segments. PTCA 
segments from procedures after the randomization and segments distal to an occlusion 
were excluded from analysis. Patients were categorized with regard to MOD and 
clinical events as regressors, stable patients, and progressors, according to the RE-
GRESS protocol [12]. Patients with at least one lesion worsening by ¿0.4 mm or 
development of a lesion which reduced the lumen diameter by ¿0.4 mm were defined 
as progressors. Regressors were patients with at least one lesion improving ¿0.4 mm 
and no lesions worsening ¿0.4 mm. Stable patients had no lesions worsening or im-
proving by ¿0.4 mm. Patients with regressing and progressing lesions were considered 
to be progressors because simultaneous progression and regression reflect an unstable 
process in coronary atherosclerosis [10]. If a patient had suffered from a myocardial 
infarction or unstable angina, he was considered to be a progressor irrespective of 
angiographic outcome. Additionally, the percentage of stenoses in each segment was 
calculated as the mean of the percent stenosis in 2 projections, assuring for comparabil-
ity of the segments by available angiographic landmarks, in the baseline and in the 
follow-up angiograms. Only segments with a mean percentage of stenosis ¿20% at 
either baseline or follow-up were analyzed. If only one projection was available of a 
stenosis ¿20%, this figure was used as the mean percent stenosis in that particular 
angiogram. New lesions were defined as <20% at baseline and ¿20% at follow-up. 
Statistical analysis 
The sample size was limited for logistic reasons to approximately 40 patients. At the 
start of the study the observed SD for mean progression in coronary segments from 
previous trials was 0.23 to 0.32 mm (0.32 mm with baseline total cholesterol 
>6.0 mmol.L"'). Considering the expected changes in cholesterol levels a minimal 
sample size of 19 patients in each group was calculated (SD=0.25 mm, expected differ-
ence=0.20 mm) [25]. 
Analyses were done with procedures available in the statistical package for social 
sciences (SPSS Inc., Chicago, IL.), using Student's Mest and multivariate ANOVA 
(with correction for repeated measures or covariates) for normally distributed data, or 
Mann-Whitney U-test for differences in means of not normally distributed data. Differ-
ences in proportions were analyzed with the (Yates') corrected chi2-test, and analyses 
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for trends in proportions were performed with the extended Mantel-Haenszel chi2-test. 
A two-sided Fisher's exact test was used when the total number of cases was less 
than 15. For measures of agreement the Pearson product-moment correlation coefficient 
was used. Analyses were based on randomization assignment, except for one patient in 
the apheresis group, who died within 3 months from the start of the study. A two-sided 
P-value of less than 0.05 was considered significant. Results are expressed as means 
± SD, unless otherwise indicated. 
Table 1. Baseline characteristics (numbers (percentages) or means ± SD) 
Age [years] 
Weight [kg] 
BMI [kg.m2] 
Blood pressure [mmHg] 
systolic 
diastolic 
Current smoking 
Vascular disease 
Infarction 
CABG 
PTCA 
Hypertension 
Stroke 
Claudication 
Drug treatment 
ß-Blocker 
Ca-channel blockers 
Long acting nitrates 
Anticoagulants 
Platelet aggregation inhibitors 
Apheresis 
(n=21) 
50.2±9.6 
81.5±9.7 
26.6±2.0 
129.3±17.3 
78.2±8.9 
3 (14.3) 
16 (76.2) 
10(47.6) 
2(9.5) 
2(9.5) 
1 (4.8) 
3 (14.3) 
10(47.6) 
4(19.0) 
4 (19.0) 
3 (14.3) 
4 (19.0) 
Medication only 
(n=21) 
53.9±8.7 
80.8±8.6 
26.2±2.0 
126.3±18.1 
76.5±9.0 
4(19.0) 
18(85.7) 
10 (47.6) 
5 (23.8) 
5 (23.8) 
3 (14.3) 
5 (23.8) 
14 (66.7) 
7 (33.3) 
4 (19.0) 
6 (28.6) 
8(38.1) 
P* 
0.43 
0.88 
0.64 
0.56 
0.63 
1.00 
0.69 
0.75 
0.41 
0.41 
0.60 
0.69 
0.35 
0.48 
0.69 
0.45 
0.31 
*t-test or chi2-test where appropriate. BMI, body mass index; CABG, coronary 
artery bypass graft; PTCA, percutaneous transluminal coronary angioplasty 
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Results 
Baseline characteristics 
In both treatment groups 21 men were enrolled of whom baseline characteristics are 
shown in Table 1. In both groups, 16 patients were heterozygous for familial 
hypercholesterolemia (76% of the study population). Risk factors for atherosclerosis 
were equally distributed. All patients had severe coronary atherosclerosis. A previous 
history of myocardial infarction was present in 16 versus 18 men in the apheresis and 
the medication group, respectively, and CABG had been performed in 10 men in both 
groups. By the criterion of a stenosis of *50% being considered significant, 17 of 
21 men in the apheresis group, and 19 of 21 men in the medication group had 3-vessel 
disease of the coronary arteries, and the other patients had 2-vessel disease. Drug 
treatment at randomization showed a higher but not statistically significant number of 
patients in the medication group using anticoagulants or platelet aggregation inhibitors 
(Table 1 ). At the time the study started anticoagulants or platelet inhibitors were less 
used. Baseline cholesterol levels were high, and predominant elevation of apo B-con-
taining lipoproteins was found in agreement with the inclusion criteria (Table 2). Lp(a) 
levels showed a skewed distribution with median baseline levels of 28.8 and 
19.8 mg.dL'1 in the apheresis and medication group, respectively. The treatment groups 
were well balanced and no significant differences were found with respect to baseline 
characteristics and baseline lipid and lipoprotein concentrations. 
Clinical events and patient evaluation 
Three patients in the apheresis group and 5 in the medication group had to be hospital-
ized for unstable angina (Table 3). One of these patients in the apheresis group was lost 
to follow-up, due to death immediately after coronary surgery within 3 months after the 
start of the study. From the other two patients in the apheresis group with unstable 
angina one had to undergo CABG at 9 months after the start of the study and continued 
only treatment with simvastatin after this procedure; the other one had to undergo a 
PTCA procedure at 12 months and continued treatment with LDL-apheresis afterwards. 
Four men in the apheresis group had a myocardial infarction, all within 6 months (range 
2-6) after the start of the study. In all these patients LDL-apheresis and simvastatin 
treatment were continued. Unstable angina in the medication group was observed 
5-24 months after the start of the study, causing hospitalization and adjustment of anti-
anginal drugs, and 2 interventions (PTCA and CABG) at the end of the study. A total of 
7 cardiac events (unstable angina and infarction) in 7 different patients in the apheresis 
group versus 5 events in 5 different patients in the medication group was observed 
(P=0.73). Most events took place in the first year of treatment with a median of 
5 versus 5.5 months after the start of the study in the apheresis and medication group, 
respectively. There were no significant differences between both groups (Table 3). 
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Table 2. Changes in lipids and lipoproteins: 
Tot chol 
Triglyc 
LDL chol 
HDL chol 
Lp(a) 
Apo Al 
ApoB 
basal 
9.72±1.84 
2.32±1.03 
7.78Ü.86 
0.93±0.18 
57.0±63.9 
1.43±0.29 
2.59±0.47 
before 
5.60Ы.26 
1.83±0.76 
3.72±1.26 
1.09±0.20 
59.1±68.8 
1.34±0.17 
1.65±0.43 
baseline and treatment levels (ι 
Apheresis (n= 
after 
2.06±0.46 
0.48±0.28 
0.82±0.41 
1.08±0.20 
13.8±15.3 
1.08±0.13 
0.45±0.16 
=21) 
interval 
mean 
4.63±1.18 
1.83±0.76 
2.95±1.13 
1.09±0.20 
44.5±54.3 
1.34±0.17 
1.32±0.35 
neans ± SD) 
% change 
-52.9±6.6 
-17.4±24.4 
-62.9±8.3 
+17.7±13.6 
-18.6±18.0 
-5.3Ü3.0 
-49.0±7.6 
Me 
basal 
9.85±2.17 
2.64Ü.33 
7.85±2.34 
0.92±0.19 
38.4±39.7 
1.46±0.38 
2.60±0.61 
dication only (n: 
mean 
5.95±1.60 
1.84±0.89 
4.13±1.58 
1.05±0.22 
44.5±45.7 
1.33±0.21 
1.74±0.47 
=21) 
% change 
-39.5±7.7 
-26.5±20.3 
-47.4±8.1 
+13.7Ü0.9 
+14.9±16.3 
-5.4±16.8 
-31.0±17.0 
Diff 
Ρ 
0.005 
0.38 
0.01 
0.23 
0.02 
0.89 
0.003 
τ;· 
δ 
О 
3 3 
4 
о 
й-
ι 
Cholesterol and Triclycerides levels in mmol.L', Lp(a) in mg.dL' and Apo Al and В in g.L'. Apheresis group: 52 measurements per patient. 
Medication group: 26 measurements per patient. Before, pre-treatment levels (Сщ^; after, post-treatment levels (C^; interval mean, time-
averaged levels (С
АУа
), calculated as follows: CAVG= Смы+О-ІЦСшх-См^ (see text); % change, difference between basal and mean levels; P, 
P-values of differences between interval mean in the apheresis group and mean levels in the medication group (t-test or Mann-Whitney U-test 
where appropriate). To convert values for total cholesterol to mg/dL, multiply by 38.67, and to convert values for triglycerides to mg/dL, 
multiply by 88.57 
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Lipid and lipoprotein profiles 
Three patients in the apheresis group and 4 in the medication group received additional 
resin treatment, 8-24 g cholestyramine per day. LDL-apheresis caused an acute reduc­
tion of 62%, 78%, 71%, and 72% of the mean concentrations of total cholesterol, LDL 
cholesterol, Lp(a) and apo B, respectively (Table 2). HDL cholesterol levels were not 
influenced by this procedure, and apo Al levels were acutely decreased on the average 
by 20%. Pretreatment levels of total cholesterol, triglycerides, LDL cholesterol, HDL 
cholesterol, apo Al, and apo В in the apheresis group were not significantly different in 
comparison to mean levels in the medication group. Pretreatment levels of Lp(a) in the 
apheresis group did not change compared with basal concentrations, whereas an in­
crease of 15% (P=0.03) in the medication group was found. Differences in treatment 
effects were established by comparison of interval mean concentrations in the apheresis 
group and mean concentrations in the medication group. During the entire course of the 
study a constant reduction of 63% of LDL cholesterol was found in the apheresis group 
to an interval mean level of 2.95Ü.13 mmol.L"'. Total cholesterol, LDL cholesterol, 
and apo В showed the same course and were significantly lower in comparison to the 
medication group (Table 2). HDL cholesterol levels at baseline and during the study 
were comparable in both groups; an increase of 14-18% was observed while on treat­
ment with simvastatin (Table 2). Although significantly reduced, the mean serum 
triglyceride levels showed no differences between the groups. The LDL/HDL choies-
Table 3. Clinical events 
Hospitalization for unstable angina 
of whom PTCA 
of whom CABG 
Nonfatal myocardial infarction 
Death 
Claudication 
of whom PTA 
of whom bypass surgery 
Stroke / ΉΑ 
Apheresis 
3 
(1) 
(2)t 
4 
1 
2 
(1) 
(0) 
0 
Medication only 
5 
(1) 
(1) 
0 
0 
2 
(0) 
0) 
1 
P* 
0.69 
0.47 
1.00 
0.11 
1.00 
0.60 
1.00 
1.00 
1.00 
Numbers between brackets represent a subdivision, e.g. 1 of the 3 patient hospitalized for 
angina had a PTCA. *, chi2-test; f, one patient died. PT(C)A, percutanous transluminal 
(coronary) angioplasty; CABG, coronary artery bypass graft surgery; TIA, transient ischemic 
attack 
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terol ratio was reduced from 8.4 to 2.7 (-68%) in the apheresis group, versus -54% 
(from 8.5 to 3.9) in the medication group, respectively. Time-averaged Lp(a) levels 
were reduced by 19% in the apheresis group, which were significantly different in 
comparison with increased levels found in the medication group (Table 2). 
Exercise tests 
Seventeen and 15 pairs of bicycle exercise tests could be evaluated in the apheresis and 
medication group, respectively (Table 4). The patient from the apheresis group who 
died early in the study was excluded from analysis. At baseline no differences in exer­
cise tolerance by bicycle tests were found between both groups. After 1 year and after 
2 years of treatment a significant increment in time to 0.1 mV ST-depression (ST-time) 
was observed in the apheresis group, accompanied by a significant decrease of the ST-
depression at maximal load (ST-max), whereas no changes were found in the medica­
tion group (Figure 1). These differences remained highly significant when corrected for 
the product of systolic blood pressure and heart rate at maximal exercise and when the 
patients who had a PTCA, CABG, or myocardial infarction were excluded (data not 
shown). None of the patients with a negative or inconclusive test showed conversion to 
ε 
Û 
700-
600 
500-
-2.00 
1.S0 
1.00 
0.50 
ε 
e 
и 
OS 
s 
I H (Л 
LDL-Apheresis Medication 
baseline 1 year L 2 years 
Fig. 1. Time to 1 mm (=0.1 mV) ST-depression (ST-time in sec) and maximal ST-depression 
(ST-max in mm) in the LDL-apheresis group (n=l 7) versus the medication group (n=15) at 
baseline, after 1, and after 2 years of treatment; asterisks denote significant differences: 
*0.0UP<0.05; **0.00UP<0.01; ***P<0.001 (t-test) 
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a positive exercise test. 
After exclusion of the patients who had a CABG procedure, 2 and 6 paired exer­
cise thallium scintigraphies were available in the apheresis and medication group, 
respectively. The value of the analysis of the scans is limited due to the small numbers. 
However, no differences were found in the number of segments with perfusion defects 
or redistribution within and between both groups (data not shown). 
Quantitative analysis of coronary angiography 
The coronary angiograms of 20 patients could be evaluated in both groups. The two 
patients who could not be evaluated at follow-up included one assigned to the apheresis 
group who underwent CABG surgery and died within 3 months after the start of the 
study, and one patient assigned to the medication group whose film quality was insuffi­
cient for paired analysis. Bypass grafts were included in the analysis, 16 and 22 seg­
ments in the apheresis and medication group, respectively. Paired measurements were 
available on 351 segments, with a mean of 8.8±2.2 (range 4-15) segments analyzed per 
patient in both groups. No significant differences were found for the MSD and the 
MOD between and within the groups analyzed on patient or on segment basis (Table 5). 
The mean change per patient in percent stenosis was not different for both groups. The 
analysis on a segment basis of the changes in percent stenosis showed a comparable 
reduction in both minor (20-50%) and major (>50%) stenotic segments in both treat­
ment groups (Table 5). However, in the apheresis group, the total number of lesions 
was decreased due to the disappearance (<20%) of 40 minor stenoses versus 20 in the 
medication group (P=0.005), whereas 23 versus 32 new stenoses were found, respec­
tively (P=0.19). By categorical approach 9 patients in the apheresis group and 
11 patients in the medication group were classified as progressors. Two and 5 patients 
were regressors, respectively, and the remaining men showed stable disease. 
Correlations 
Of baseline variables, total cholesterol (r=-0.51, P=0.0l), LDL cholesterol (r=-0.48, 
P=0.02), ratio LDL/HDL cholesterol (r=-0.63, P=0.001), and apo В (r=-0.49, P=0.0l) 
were correlated with time to 0.1 mV ST-segment depression. Relative changes from 
baseline of total cholesterol and LDL cholesterol were also significantly correlated with 
the change in time to 0.1 mV ST-segment depression on the exercise ECG (Table 7). 
No correlations were found between baseline and in-trial lipid and lipoprotein levels 
and MSD or percent stenosis. Only mean in-trial concentrations of total cholesterol, 
LDL cholesterol, ratio LDL/HDL cholesterol, and apo В were associated with the 
percent change in MOD (Table 7, Figure 2). No correlations were found between time 
to 0.1 mV ST-segment depression on the exercise ECG and MOD. An association was 
found between maximal ST-depression on the exercise ECG and the MOD at baseline 
(r=-0.48, P=0.006) and after 2 years of treatment (r=-0.39, P=0.03). 
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Table 6. Correlations between lipids and lipoproteins and some outcome variables, 
expressed as percent change from baseline 
Change from baseline 
total cholesterol 
LDL cholesterol 
LDL/HDL ratio 
apolipoprotein В 
Mean in-trial concentrations 
total cholesterol 
LDL cholesterol 
LDL/HDL ratio 
apolipoprotein В 
Change in 
г 
0.42 
0.52 
0.39 
0.39 
-0.34 
-0.37 
-0.30 
-0.36 
ST-time 
Ρ 
0.04 
0.01 
0.06 
0.06 
0.10 
0.08 
0.15 
0.09 
Change 
г 
0.25 
0.30 
0.35 
0.22 
-0.41 
-0.43 
-0.37 
-0.35 
in MOD 
Ρ 
0.12 
0.06 
0.03 
0.16 
0.009 
0.006 
0.01 
0.03 
Data are pooled for exercise tests (n=32) and for quantitative coronary angiography 
(n=40). ST-time, time to 0.1 mVST-depression on the exercise ECG; MOD, minimal 
obstruction diameter; r, Pearson's correlation coefficient; Ρ, Ρ-value 
Treatment side-effects 
No significant differences were found between and within the groups for serum creati­
nine levels, fasting blood glucose, alkaline phosphatase, and leucocyte counts. The 
patients on apheresis experienced a significant fall in hemoglobin level from 9.2±0.6 
mmol.L'1 to 8.6±0.6 mmol.L'1 (-6.0±5.8%), due to the procedure. A nonspecific acute 
loss of 12 % of serum protein levels was observed directly post-apheresis, without trend 
in change of pretreatment levels. Twelve of 1039 (1.2%) apheretic procedures were 
complicated by an episode of hypotension (systolic blood pressure *80 mm Hg), not 
leading to discontinuation of the treatment. No bleeding complications were observed 
the first days after LDL-apheresis. Only 2 sessions in one patient had to be interrupted 
due to an 'anaphylactoid' reaction caused by the temporary administration of an ACE-
inhibitor [43,44]. During the administration of simvastatin no subjective adverse expe­
riences were observed. Episodes with aminotranferase levels >3 times the upper limit 
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Fig 2. Correlation between mean in-trial total cholesterol concentration and the change in 
minimal obstruction diameter (MOD) [a negative value depicts progression]. Open symbols 
represent the medication group and closed symbols the apheresis group 
(<;30 U.L') did not occur: 3 patients in the apheresis group and 1 patient in the medica­
tion group had *50% of the measurements of alanine aminotransferase (ALAT) be 
tween 31 and 99 U.L"1. Creatine Phosphokinase (CK) levels were elevated in 3 patients 
in both groups in *50% of the measurements (range 101-468 U.L"1; upper limit of 
normal s 100 U.L"1). None of the patients had to discontinue the administration of 
simvastatin. 
Discussion 
The LAARS trial was performed to evaluate whether aggressive lipid lowering using 
LDL-apheresis in men with extensive coronary artery disease, of whom the majority 
had a familial hypercholesterolemia, will exert better retardation of the progression of 
coronary atherosclerosis in comparison to conventional treatment. The study showed 
that the addition of biweekly LDL apheresis to lipid lowering treatment with a HMG-
CoA reductase inhibitor improved the ischemic treshhold clearly, whereas an equal 
effect in angiographically derived measures for coronary atherosclerosis was observed 
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in both groups, in whom progression of disease would be usual [45,46]. 
The accepted indication for LDL-apheresis is resistance to drug treatment in 
patients with CAD [47]. In LAARS LDL-apheresis was used as a method to lower LDL 
cholesterol more aggressively in subjects of whom some were not drug-resistant. Our 
results confirm the usefulness of extracorporeal therapy in achieving and maintaining 
extremely low levels of LDL cholesterol while preserving HDL, with an acceptable 
safety profile, as has recently been shown [38,47]. The reduction of baseline LDL 
cholesterol levels of 7.8 mmol.L'1 in the apheresis group by 63% is in keeping with 
other studies using LDL apheresis [22,48,49]. On the other hand, LDL reduction from 
7.9 mmol.L"' in the medication group by 47% may be considered as a good response in 
comparison to recent studies using HMG-CoA reductase inhibitors, which is probably 
the result of frequent monitoring of our patients [5,8,10,11]. Since LDL apheresis 
entails a major commitment for the patient and medical community, these latter results 
stress that only primary hypercholesterolemic patients with established CAD refractory 
to drug treatment should be treated with LDL-apheresis. 
Five prospective trials that include angiographic endpoints in patients with severe 
hypercholesterolemia using LDL apheresis-containing protocols to lower LDL choles-
terol have recently been described [38,48-51]. The FH Regression Study [38] and our 
study are the only randomized ones. Both studies show no further improvement of the 
angiographic endpoints by the addition of LDL-apheresis to conventional lipid lower-
ing treatment. However, changes in measures for diffuse atherosclerotic disease (MSD) 
and focal disease (MOD and % stenosis) in both studies were comparable with pooled 
data from intervention groups of 5 recent angiographic regression studies [5,7,8,10,11] 
using HMG-CoA reductase inhibitors, as has been described by Thompson et al [38]. 
Therefore, intermittent LDL reduction by apheresis induces arrest of progression of 
angiographically visible lesions comparable to drug treatment. 
Although LAARS demonstrated a correlation between the change in MOD and 
mean in-trial concentrations of LDL, it is not clear why further LDL lowering in the 
apheresis group did not result in more pronounced mean changes in angiographic 
outcome measures in comparison to the medication group. In contrast to the FH Re-
gression Study [38] LDL cholesterol levels in the apheresis group from our study were 
more reduced than in the medication group. In the first study mean LDL cholesterol 
levels were 3.2 mmol.L"1 in the apheresis group versus 3.4 mmol.L'1 in the medication 
group, whereas in our study levels of 3.0 and 4.1 mmol.L"1 were reached, respectively. 
The significance of the observed correlation between MOD and in-trial LDL in our 
study suggests that the non-sustained reduction of LDL cholesterol due to the rebound 
after LDL-apheresis does not play a role [38,52]. Sample size and the duration of the 
intervention may be more important, because expected changes in percent stenosis after 
a relative short period of intervention have been shown to be too optimistic [14]. Recent 
data from the Multicentre Anti-Atheroma Study (MAAS) and the Scandinavian 
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Simvastatin Survival Study (4S) support this view [11,16]. MAAS showed a trend to 
improvement, but no statistical differences, of the angiographic measures MOD and 
MSD after 2 years of simvastatin treatment compared to placebo, whereas after 4 years 
of treatment significant differences were observed angiographically [11]. The 4S trial 
showed that the effect of simvastatin treatment on coronary events started after 1 year 
of therapy and increased steadily thereafter [16]. Therefore, it is not unexpected that 
differences between the apheresis and medication group in LAARS were not 
angiographically detectable. 
The reduction of time-averaged levels of Lp(a) in the apheresis group from 
LAARS was much less in comparison to LDL. This may be caused by an increase of 
Lp(a) concentrations associated with the administration of simvastatin which was also 
found in the medication group, and has been confirmed by others [38,53]. However, an 
increased rebound of Lp(a) after apheresis in comparison to LDL may also play a role 
[31,54]. One of the objectives of the FH Regression Study [38] was to verify whether 
lowering of Lp(a) concentrations by apheresis was associated with further reduction of 
the percent diameter stenosis of coronary arteries. No benefit could be shown of reduc-
ing Lp(a) levels in patients whose LDL cholesterol levels had been effectively lowered 
by drug therapy or apheresis. Our data confirm these results, particularly because the 
differences in mean in-trail LDL cholesterol concentrations in the medication and 
apheresis group were greater than in the FH Regression Study, with comparable 
changes in Lp(a) levels in both studies. So, the question of the clinical relevance of 
increased Lp(a) levels during treatment with a HMG-CoA reductase inhibitor seems 
current. 
Natural occurring progression of CAD is mainly seen in the formation of new 
coronary lesions and less in growth of preexisting ones, and progression of the latter is 
correlated with high cholesterol level [46]. Most regression studies showed the greatest 
benefit in atheroma obstructing >50% of the lumen [13], and some reported that mainly 
smaller lesions responded [9-11,55]. In the present study percent stenosis remained 
almost unchanged during the 2 years of treatment (97% of stenoses showed changes in 
degree of <20%), and no preference for changes in severe (>50%) stenoses was ob-
served. It was found, however, that more aggressive lipid lowering with LDL apheresis 
resulted in the disappearance of more mild to moderate (20-50%) lesions, whereas the 
formation of new lesions appeared to be comparable between the apheresis and medica-
tion group. Therefore, our data seem to be in favor of reducing more early lesions as a 
response to aggressive lipid lowering of relatively short duration, as has also been 
shown in the Canadian Coronary Atherosclerosis Intervention Study (CCAIT) and 
MAAS [10,11]. This may be important, since early lipid-rich lesions with a fine fi-
brous cap are prone to rupture and lead to thrombotic occlusions and consequent clini-
cal events [56]. Therefore, more aggressive lipid lowering seems to improve stabiliza-
tion and regression of these lesions. 
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A remarkable observation of our study was the improvement in ergometrie bicy-
cle tests. This has also been found in some uncontrolled studies while applying LDL-
apheresis, and may be present within weeks from the start of treatment [50,51]. We 
observed significant improvement of the exercise tests after 1 year of treatment, which 
further increased after 2 years. Changes in the time to 0.1 mV ST-depression after 
2 year of treatment were also significantly correlated with the amount of LDL reduc-
tion. These findings and the angiographic ones suggest that mechanisms other than 
changes in stenosis play a role in the outcome of the exercise tests. Indeed, cholesterol 
lowering with HMG-CoA reductase inhibitors has been shown to improve 
endothelium-dependent relaxation in the coronary arteries of patients with atherosclero-
sis [57]. On the other hand, improved blood flow by changes in blood rheology induced 
by LDL-apheresis may also contribute to the improvement of coronary flow [58]. 
However, reductions of fibrinogen and most other coagulation factors last not longer 
than 24 to 48 hours [59], whereas changes in blood viscosity have been measured until 
1 week after an apheresis using dextran sulfate adsorption [60]. Since the follow-up 
assessments at the end of the study in LAARS were done 3-4 weeks after the last LDL-
apheresis, rhéologie changes did not confound our results. This indicates that functional 
improvements of the coronary vasomotor function on a level beyond the resolution of 
the angiogram may precede anatomic changes in severely stenotic coronary arteries 
[27,61,62]. Therefore, functional measures should be considered as additional, and 
possibly more sensitive outcome variables for short-term angiographic studies. In our 
study we also assessed the videodensitometric measurements of the blood flow in the 
coronary microcirculation as functional primary outcome variable. These data are 
presently being analyzed and will be published separately. 
It has been shown that culprit lesions in unstable angina have increased 
vasoreactivity, responsible for the risk of recurrence of unstable angina or infarction 
[63]. Plaque stabilization by lipoprotein manipulation may require more than 1 year of 
aggressive treatment before a significant reduction in clinical events can be documented 
[15]. In our study we were confronted with a few myocardial infarctions in the 
apheresis group in the early phase of the study, a difference with the medication group 
which may be associated with the use of anticoagulants or platelet aggregation inhibi-
tors. It must be emphasized that our study was not designed to evaluate the clinical 
events. However, combining both episodes of unstable angina and myocardial infarc-
tions no differences between both treatment groups were observed. Considering the 
natural progression of CAD, it is notable that both treatment groups showed less events 
than expected in the second year of treatment. This observation supports the notion that 
the effect of cholesterol lowering on functional improvement precedes anatomic regres-
sion of atherosclerosis [27]. 
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Combined LDL-apheresis and cholesterol lowering drugs in patients at high risk for 
cardiovascular events arrests further progression of CAD and induces functional im­
provement of the coronary blood flow. Studies of longer intervention periods are 
warranted to confirm these findings and observe the expected angiographic regression 
of CAD. However, only primary hypercholesterolemic patients with established CAD 
refractory to drug treatment should be treated with LDL-apheresis. 
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Low density lipoprotein apheresis im-
proves regional myocardial blood flow in 
patients with hypercholesterolemia and 
extensive coronary artery disease. The 
LDL-Apheresis Atherosclerosis Regression 
Study (LAARS) 
LDL-apheresis and coronary perfusion 
Provisionally accepted for publication as: 
Low density lipoprotein apheresis improves regional myocardial blood 
flow in patients with hypercholesterolemia and extensive coronary artery 
disease. The LDL-Apheresis Atherosclerosis Regression Study (LAARS) 
W.R.M. Aengevaeren, A.A. Kroon, A.F.H. Stalenhoef, G.J.H. Uijen, T. van der Werf 
JAm Coll Cardiol 1996 
Background: In patients with severe hypercholesterolaemia diet and lipid-lowering 
drugs are often insufficient to achieve optimal low density lipoprotein (LDL) choleste-
rol values. LDL-apheresis is a very effective lipid lowering therapy. Assessment of 
regional myocardial blood flow enables the evaluation of the functional state of the 
coronary circulation. 
Methods: We studied 42 patients with severe hypercholesterolemia and extensive 
coronary artery disease who were randomized to diet and simvastatin with or without 
biweekly LDL-apheresis. Regional myocardial blood flow was assessed by digital 
subtraction angiography (DSA) with videodensitometric calculation of hyperemic 
mean transit time of contrast (HMTT), at baseline and after 2 years of therapy. 
Results: LDL-cholesterol decreased by 63% (to 3.0 mmol.l·1) in the LDL-apheresis (L) 
group and by 47% (to 4.1 mmol.l·') in the medication (M) group. Paired HMTT mea-
surements were assessed in 43 regions in the L group and 35 regions in the M group. 
Baseline HMTT values of both groups were not significantly different. In the L group 
the mean HMTT of all regions decreased over 2 years from 3.35Ü.18 to 2.87±0.82 s, 
-14% (p= 0.001), whereas no change in the M group was observed, 2.95±1.06 to 
2.96±0.90 s (NS). In the patient-based comparison the mean change in HMTT was 
-0.45 s, -14% (p= 0.01) in the L group and -0.05 s, -2% (NS) in the M group, respec-
tively. 
Conclusions: Biweekly LDL-apheresis plus simvastatin decreased time-averaged LDL-
cholesterol levels by an additional 31% (1.1 mmol.l·') in comparison with medication 
alone. Regional myocardial blood flow improved in the LDL-apheresis group and 
remained unchanged in the medication group, which is in accordance with previously 
reported improvement in exercise testing. The increase in regional myocardial blood 
flow is probably explained by the improvement in endothelial dependent and/or inde-
pendent relaxation. For evaluation of lipid lowering therapy, functional assessment of 
the coronary circulation by DSA with videodensitometric calculation of the HMTT 
may be a more sensitive measure than quantitative coronary angiography, because it 
evaluates the overall effect on myocardial perfusion. 
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Introduction 
Low density lipoprotein (LDL) cholesterol levels often remain elevated in patients with 
familial hypercholesterolemia (FH) despite diet and cholesterol lowering drugs. High 
LDL-cholesterol levels are strongly associated with premature development of coronary 
artery disease especially in males with inherent risk of coronary death [1]. LDL-aphe-
resis is considered a valuable therapeutic option for patients with homozygous FH and 
for patients with coronary artery disease and hypercholesterolemia refractory to diet 
and drugs [2-4]. Plasma exchange or LDL-apheresis showed in a number of non-rando-
mized studies regression or slowing of progression of coronary atherosclerotic lesions 
and resolution of xanthomas [2,5-8]. The use of plasma exchange was also associated 
with increased survival among homozygous FH patients in comparison with their 
untreated homozygous siblings [9]. In one recently published randomized trial in 
patients with FH, biweekly LDL-apheresis versus drug therapy during two years sho-
wed no difference in coronary anatomy as measured by quantitative coronary angiog-
raphy (QCA) [10]. In the LDL-Apheresis Atherosclerosis Regression Study (LAARS), 
we neither found differences in quantitatively assessed coronary anatomy, however 
patients on LDL-apheresis had a significant improvement in exercise parameters versus 
patients on drug therapy alone [11]. Questions remained upon the cause of this functio-
nal improvement and the methods to evaluate the potential benefits in aggressive lipid 
lowering therapy. In lipid lowering trials, hard clinical endpoints such as improved 
survival and reduction of major cardiac events are generally accepted outcome measu-
res, however, they require numerous patients over a long intervention period [12-15]. 
At the moment, QCA is the best surrogate endpoint for evaluation of lipid lowering 
therapy in coronary artery disease [16-22]. The application of QCA, however, has 
several limitations such as the diffuse character of coronary artery disease, the com-
plexity of stenosis geometry, the foreshortening in non-orthogonal views, the insuffi-
cient contrast staining and the limited resolution of the radiographic chain [23-26]. 
Moreover, there seems to be a dissociation between the results of angiographic studies 
and clinical outcome. Lipid lowering therapy has shown to reduce the incidence of 
cardiovascular events without marked changes in coronary anatomy [22]. Treatment of 
hypercholesterolemia has shown to stabilize minor atheromatous plaques by depleting 
the lipid core. Therefore, not the change in angiographic lumen size, but plaque stabili-
zation appears to be related to the reduction of clinical events [27]. 
Coronary atherosclerosis and hypercholesterolemia are associated with dysfuncti-
on of endothelium mediated vasomotion which impairs coronary and myocardial blood 
flow [28-32]. Lipid lowering therapy improves the endothelium mediated vasomotion 
after relative short periods of time [33-35]. The functional improvement of the corona-
ry circulation has been shown to precede structural improvement [36]. The cumulative 
effects of all anatomical and functional abnormalities of the epicardial coronary arteries 
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in combination with possible dysfunction of conduit and resistance vessels are responsi­
ble for the ultimate effect of atherosclerosis on myocardial blood flow. In order to 
evaluate the functional state of the coronary circulation after aggressive lipid lowering 
with LDL-apheresis, we assessed regional myocardial blood flow by means of digital 
subtraction angiography (DSA) followed by videodensitometric calculation of the 
hyperemic mean transit time (HMTT) of contrast in a randomized study. 
Patients and Methods 
Subjects and treatment 
The purpose of this study was to compare the effect of aggressive lipid lowering 
treatment by LDL-apheresis versus conventional treament on the anatomy and functio­
nal state of the coronary tree. The trial design, patients characteristics, results of QCA 
and exercise testing have been described previously [11]. Briefly, consenting patients 
with extensive coronary artery disease and hypercholesterolemia were randomized to 
diet and 40 mg simvastatin once daily with or without biweekly LDL apheresis. The 
inclusion criteria were 1. male patients between 18 and 70 years, 2. family history of 
hypercholesterolemia. 3. extensive coronary atherosclerosis demonstrated with heart 
catheterization. 4. serum total cholesterol of *8.0 mmol.Γ' or LDL-cholesterol *5.8 
mmol.l"' and fasting serum triglycerides s5.0 гшпоІ.Г' during a standard lipid lowering 
diet. The study population consisted of 42 male patients with a mean age of 52.0±9.2 
years. The elevated lipid levels were due to heterozygous FH in 32 patients (76%), 16 
in each group. No homozygous FH patients were included in this study. In the LDL-
apheresis (L) group 17 patients had 3-vessel disease and 4 patients 2-vessel disease, 
whereas in the medication (M) group 19 patients had 3-vessel disease and 2 patients 
2-vessel disease (a vessel was considered as diseased when there was a ¿50% diameter 
stenosis in a major branch). Before entry into the study all patients had a two months 
run-in period. Anti-anginal medication was continued but lipid lowering medication 
was stopped. If total cholesterol remained elevated above the lower limit for inclusion 
into the study, heart catheterization and exercise testing were carried out. After heart 
catheterization patients were randomized in a stratified way, which took into account 
the total cholesterol (TC) level, Lipoprotein(a) [Lp(a)] level, age and the history of 
coronary bypass surgery. Antianginal medication was continued at the same doses 
during the trial. If adaptation in medication was necessary during the study, the original 
prescription, if possible, was restored before the follow-up heart catheterization. The 
follow-up heart catheterization was performed one month after the last LDL-apheresis. 
Hemoglobin and hematocrit were measured just before the heart catheterization. LDL-
apheresis was performed with an automated system MA-01 (Kanegafuchi Chemical 
Industry Co. Ltd, Osaka, Japan) with two small-sized dextran sulfate cellulose columns 
that were used and regenerated alternately in one procedure, permitting continuous 
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apheresis [11]. The ethical committee of the University Hospital Nijmegen approved 
the study. 
Assessment of regional myocardial blood flow 
To compare the maximal regional myocardial perfusion DSA of the coronary tree was 
followed by videodensitometry and calculation of the HMTT of contrast. Regional 
perfusion was assessed in the areas of the left anterior descending artery (LAD), 
circumflex artery (RCX) and right coronary artery (RCA) at baseline and at follow-up. 
This method has been developed in our laboratory and has been validated in animal 
model and human studies [37-41]. Before heart catheterization patients were trained to 
hold their breath, with use of a nose clamp at maximal inspiration during 15-20 se­
conds. After the completion of the left coronary angiography the left Judkins catheter 
with 7F tip (Cordis) was left in place for the DSA protocol in 60° LAO position. After 
angiography of the right coronary artery the protocol was repeated in 30° RAO position. 
Meticulous care was taken for the follow-up DSA to repeat it under exactly the same 
circumstances, with the same medication. 
At the start of the procedure a 5F stimulation catheter was positioned in the right 
atrium. During DSA the heart was triggered in synchrony with the radiographic pulses, 
slightly above its inherent rate, to provide a strictly regular heart rhythm. Iohexol-350 
(Nycomed AS, Oslo, Norway), a non-ionic low osmolar contrast agent was used. For 
all studies, 6 ml of contrast was injected, using a power injector at a speed of 4 ml.s"'. 
Twenty five seconds after administration of 8-12 mg papaverine (depending on the size 
of the vascular bed) the patient was instructed to hold his breath, and image acquisition 
was started, 5 seconds later followed by contrast injection. One image per heart cycle 
was obtained just before the onset of the QRS complex. Image acquisition was perfor­
med on a Bicor radiograph system connected to a Digitron-3 computer for digital 
subtraction angiography (Siemens AG, Erlangen, Germany). Images were generated 
with the automatic brightness control switched off after the fourth image in every study 
to enable density calculation. Subsequently, the images were digitized in a 512 χ 512 
matrix with 1,024 density levels. The image quality was checked immediately after 
image acquisition and if necessary the imaging protocol was repeated with a maximum 
of 3 times. 
Image and data processing were performed offline using a Sun SPARC station 10 
(Sun Microsystems Inc. Mountain View, USA) with programmed Khoros software. 
Circular regions of interest (ROI) of 200-600 pixels were constructed over the tip of 
the coronary catheter to record the contrast injection and over the myocardium supplied 
by the respective vessels (Fig. 1). The ROIs were chosen at the myocardial level on 
predefined localizations, carefully avoiding overlap with major sidebranches and veins. 
Close to the myocardial ROI a background ROI was chosen to analyze changes in 
background density (Fig. 1). Time-density curves were generated by sampling the 
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Fig 1. Example of the positioning of the ROIs in one of the subtracted images of the coronary 
arteries, early after contrast injection. In the left panel the left coronary artery in the 60" LAO 
projection and in the right panel the right coronary artery in the 30° RAO projection is shown 
averaged pixel density within a ROI in consecutive images. Subsequently, the time-
density curves were fitted with a gamma-variate function from the onset of the curve to 
the instant at which the descending part of the curve became less than 40% of its peak 
value [42]. In case of deviating background density, the fitted curves of the myocardial 
ROIs were corrected with the corresponding background ROI. The HMTT is the diffe-
rence of the mean transit time of the myocardial ROI and the ROI at the injection site 
(P ROI). Because of the pressure dependency of flow during maximal hyperemia, 
HMTTs were corrected for a normalized mean aortic blood pressure of 100 mmHg for 
comparison between the two studies. This correction was performed by multiplying the 
mean transit time in seconds by the ratio Pa/100, where Pâ is the actual mean blood 
pressure during image acquisition. If a pressure curve showed a pressure drop or wed-
ging during hyperemia, indicating that the catheter influenced maximal flow, the study 
was excluded from further analysis. 
Time-density curves of particular ROIs or entire videodensitometric studies of 
insufficient quality were skipped for final analysis. During the trial all DSAs were 
evaluated and ROIs were chosen. Time-density curves were made but mean transit 
times were not calculated. At follow-up videodensitometry was repeated at identical 
conditions and analysis was performed in accordance with the original ROI overlay. 
Figure 2 shows an example of paired time-density curves of a ROI. For final analysis 
paired time density curves of sufficient quality without artifacts were selected by one 
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Fig 2. Example of paired time-density curves of a ROI at baseline (upper panel) and at 
follow-up (lower panel). The HMTT values are calculated from these curves, where the 
onset of the time is derived from the time-density curve of the respective ROI at the injection 
side 
cardiologist (W.A.) blinded to treatment allocation. The final database was composed 
and subsequent HMTTs were calculated and corrected for blood pressure. Regional 
myocardial perfusion was assessed by averaging the comparative HMTTs (1-2 ROIs) in 
the area supplied by the left descending artery (LAD), the circumflex artery (RCX) and 
the right coronary artery (RCA) to one value per perfusion area per session. All perfusi­
on areas including areas supplied by bypass grafts were imaged by the DSA protocol. 
ROIs of regions supplied by bypasses were classified to the original coronary artery 
region. Effect analysis of both lipid lowering treatments was a region-based assessment 
and a patient-based assessment of the change in myocardial perfusion. The patient-
based evaluation was performed by averaging the regional HMTT values to one value 
per patient. Analysis of the patient-based HMTT was performed both with and without 
correction for change in hematocrit. For this correction the HMTT values at follow-up 
were subtracted by the % change of the hematocrit, assuming a linear relation between 
hematocrit and blood viscosity in this narrow range of actual hematocrit values [43]. 
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Statistical analysis 
Comparisons of pre-specified continuous variables within the groups were done by 
two-sided paired /-tests, between group analysis by unpaired i-tests for normally distri-
buted data. For categorical comparison a chi2 test was done when appropriate. Correla-
tions were tested by assessing the Pearson correlation coefficient. For all hypotheses 
tests, a two-sided ¿»-value of less than 0.05 was considered significant. Results are 
expressed as means ± SD, unless otherwise indicated. 
Results 
From March, 1990 to May, 1992, 42 male patients were randomized into two groups of 
21 patients in our center. The follow-up was completed in June 1994. The results of 
both groups on lipid metabolism, QCA and exercise testing have been described previ-
ously [11]. In short, LDL-cholesterol decreased in the L group from 7.78±1.86 to a 
time-averaged value of 2.95Ü.13 mmol.l·1 and in the M group from 7.85±2.34 to 
4.13Ü.58 mmol.r'. The mean change in lipid values during the study are depicted in 
Figure 3. QCA showed no changes in mean segment diameter (MSD) and minimal 
Fig 3. Bar graphs showing the change from baseline to the mean value during the study of 
total cholesterol (Tot. chol), low density lipoprotein cholesterol (LDL-chol), high density 
lipoprotein cholesterol (HDL-chol.) and triglycerides. The values are expressed as mean 
percentage change ± SEM. In the LDL-apheresis group Tot. chol. and LDL-chol. are 
presented as time-averaged values 
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Table 1 
pat· 
(nr) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
'29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
Clinical characteristics and patient based-! 
group 
L/M* 
L 
M 
M 
M 
M 
L 
M 
M 
L 
L 
L 
M 
L 
M 
L 
M 
L 
L 
M 
L 
L 
M 
M 
M 
L 
M 
L 
L 
L 
M 
M 
L 
L 
M 
L 
L 
M 
M 
L 
L 
M 
M 
age 
(yr) 
29 
59 
67 
59 
52 
43 
69 
67 
46 
65 
46 
46 
66 
58 
53 
40 
58 
52 
47 
30 
50 
45 
56 
44 
57 
56 
50 
42 
63 
49 
52 
54 
42 
56 
56 
46 
49 
50 
62 
54 
66 
42 
MI/ 
CABG 
PTCA' 
. 
I/C 
A/C 
I/ 
I/ 
NQ/ 
I/CP 
I/P 
-
-
I/C 
A/ 
I/ 
/c 
I/C 
-
I/C 
A/C 
I/C 
A/C 
A/C 
NQ/ 
A/C 
I/ 
I/P 
I/C 
I/ 
A/ 
I.A/C 
/CP 
I/ 
I/C 
-
A,A/C 
A/C 
-
NQ/ 
A/CP 
I/PC 
I/ 
A/ 
I/P 
study data 
LDL-chol 
(mmol 1 ') 
base 
12 09 
7 01 
6 62 
7 05 
5 94 
5 45 
6 28 
651 
6 63 
6 97 
7 17 
611 
6 97 
6 43 
6 80 
9 90 
671 
1136 
12 86 
10 75 
7 60 
9 20 
1165 
6 59 
7 06 
5 92 
10 84 
7 60 
6 57 
8 30 
7 60 
6 28 
7 03 
6 68 
6 66 
8 84 
731 
5 83 
6 36 
6 38 
7 16 
13 90 
during' 
5 67 
3 74 
3 90 
4 26 
3 58 
2 65 
306 
2 69 
3 00 
3 76 
2 76 
3 57 
2 14 
3 47 
198 
5 32 
2 03 
5 22 
5 62 
3 69 
3 12 
4 95 
4 93 
3 43 
2 09 
2 76 
3 36 
251 
2 09 
4 29 
4 14 
2 10 
2 00 
3 26 
2 03 
4 02 
4 48 
2 79 
2 59 
2 27 
3 16 
9 29 
change 
MSD 
(mm) 
0 39 
0 14 
0 11 
0 06 
-0 14 
-0 30 
Oil 
-0 42 
-0 12 
0 05 
0 23 
-0 08 
-0 08 
0 07 
-0 09 
0 26 
000 
-0 33 
-0 29 
-0 03 
004 
0 07 
0 17 
0 18 
-0 02 
0 08 
-0 06 
0 20 
0 00 
-0 01 
0 10 
-0 14 
-0 06 
-Oil 
0 00 
0 07 
-0 03 
0 03 
-0 02 
0 20 
change 
MOD 
(mm) 
0 20 
0 15 
0 05 
004 
-0 12 
-0 24 
-0 09 
-0 25 
-0 09 
0 07 
0 19 
-0 08 
-0 16 
0 12 
-0 14 
0 20 
-0 13 
-0 06 
-0 09 
-0 06 
0 20 
0 10 
0 07 
0 06 
-0 06 
0 05 
-0 04 
0 17 
0 03 
0 02 
0 09 
-Oil 
-0 08 
-0 13 
0 03 
-001 
0 03 
-0 01 
-0 07 
0 15 
change 
ST-time 
(s) 
-420 
0 
-30 
-360 
60 
-299 
-360 
120 
-60 
23 
-330 
0 
360 
-165 
-120 
60 
-240 
0 
-55 
-67 
-60 
-88 
-60 
5 
change 
HMTT 
(s) 
0 17 
-0 09 
0 97 
146 
-158 
-0 19 
2 57 
-0 62 
-0 14 
-0 75 
-0 38 
000 
-0 51 
-0 06 
-0 41 
041 
-0 21 
-0 62 
-0 14 
-109 
-158 
-0 30 
0 45 
-127 
-150 
0 22 
-1 51 
-0 50 
0 59 
-134 
-0 36 
0 24 
-137 
0 57 
-0 03 
*pat, patient, f L, LDL-apheresis group, M, medication group, f,all events before entrance in the study, MI, 
myocardial infarction, localization of myocardial infarction, A anterior, I inferior, NQ non-Q wave myocardial 
infarction. CABG, coronary artery bypass surgery, "C" PTCA, percutaneous transluminal coronary angioplasty, 
abbreviation "P" LDL-chol, Low density lipoprotein cholesterol §, mean time averaged LDL-cholesterol level 
(for conversion of cholesterol values to mg/dl, multiply by 38 7) Change, difference in value between follow-up 
and baseline, MSD, mean segment diameter from QCA measurements, MOD, minimal obstruction diameter, ST-
time, time to 1 mm (0,1mV) ST-segment depression, HMTT, hyperemia mean transit time Ц The patient who had 
a re-CABG 12 weeks after the start of LDL-apheresis and died post-operative due to low cardiac output 
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Table 2. Regional HMTT values in the 3 myocardial perfusion areas 
LDL-apheresis group 
baseline HMTT (s) 
follow up HMTT (s) 
p-value 
Medication group 
baseline HMTT (s) 
follow up HMTT (s) 
p-value 
Difference (p-value,)* 
LAD region 
n = 1 7 
3.28 (0.97) 
2.81 (0.86) 
0.02 
n = 1 5 
2.78 (0.78) 
2.75 (0.81) 
0.88 
0.17 
RCX region 
n = 1 8 
2.93 (0.66) 
2.66 (0.67) 
0.08 
n=13 
3.15(1.22) 
3.11(1.07) 
0.93 
0.51 
RCA region 
n = 7 
4.61 (1.85) 
3.57 (0.79) 
0.11 
n = 7 
2.95(1.35) 
3.14(0.79) 
0.74 
0.14 
All regions 
η = 42 
3.35(1.18) 
2.87 (0.82) 
0.001 
n = 3 5 
2.95(1.06) 
2.96 (0.90) 
0.96 
0.04 
Data represent means; standard deviation between brackets; HMTT, hyperemic mean transit 
time, ^difference in mean change between LDL-apheresis and medication group (t-test) 
obstruction diameter (MOD) within and between the two groups. At exercise tests in 
the L group versus the M group, time to the onset of 1 mm (0.1 mV) ST-segment 
depression was prolonged by 39% and maximal ST-segment depression was halved. 
The clinical characteristics and patient-based study data are listed in Table 1. 
Hyperemic mean transit time (HMTT) 
The DSA protocol for calculation of the HMTT was performed in all 42 patients. In the 
L group 19 patients completed the 2 years of LDL-apheresis, and 2 patients had to stop 
because of progression of angina pectoris after 3 and 10 months, respectively. Both 
patients underwent coronary artery bypass surgery (CABG). In the M group one patient 
underwent CABG after 24 months of treatment. The HMTT studies of these patients at 
follow-up were considered as end of study measurements. One patient in the L group 
who was hospitalized for unstable angina pectoris, 12 months after the start of the LDL-
apheresis, underwent percutaneous transluminal coronary angioplasty (PTCA) of the 
LAD and the RCA. After PTCA LDL-apheresis was continued, but the two perfusion 
areas were excluded for assessment of regional myocardial perfusion. In 35 patients 
(83%, 18 in the L group and 17 in the M group) comparative data of the first study and 
subsequent follow-up were available. The reasons for missing of paired data in 
7 patients were as follows: 1. insufficient image quality of one session in 2 patients and 
of both sessions in a third patient with chronic airway obstruction, 2. loss of stored 
digital images of one session in 2 patients, and 3. no comparable DSA in 2 patients due 
to abusive recordings. In total 121 comparative ROIs were available, 68 in the L group 
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Fig 4. Plots showing the changes of regional HMTT in the LDL-apheresis group (n=42) and 
medication group (n=35) 
and 53 in the M group, respectively, mean 3.5±1.7 per patient. One-hundred three ROIs 
were generated in regions supplied by native coronary arteries and 18 supplied by 
bypasses. Based on ROIs, the average HMTT decreased by 0.59±1.01 s in the L group 
(p<0.001) and decreased by 0.10±1.16 s (p=0.52) in the M group; the difference be­
tween the two groups is 0.48 s (p= 0.01). 
For analysis of the regional myocardial blood flow, ROIs (1 to 2) belonging to the 
same region were averaged. In Table 2, the results of the HMTT, based on regions are 
listed. The baseline HMTT values of the L group and M group were 3.35±1.18 s (n=42) 
and 2.95±1.06 s (n=35), respectively, and were statistically not different (p=0.52). 
Changes of all regional HMTTs in both groups are depicted in Figure 4. The relative 
changes in HMTT of the three perfusion areas of the LAD, RCX and RCA, respec­
tively, are shown in Figure 5. The distribution of regions in the L group was; LAD: 17, 
RCX: 18 and RCA: 7 regions and for the M group 15, 13 and 7, respectively. All three 
coronary perfusion areas contributed to the same extent to the results. 
In the patient based analysis the averaged HMTT value in the L group (n=18) was 
3.19±0.78 s at baseline and 2.74±0.68 s at follow-up, mean difference -0.45 s, -14% 
(p=0.01). In the M group (n=17) the averaged HMTT value was 2.99±0.84 s at baseline 
and 2.94±0.77 s at follow-up, mean difference -0.05 s, -2% (p=0.85). The mean diffe­
rence in change between the two groups was 0.40 s (ρ=0Λ9). Hematocrit measured at 
heart catheterization was in the L group 0.44±0.03 at baseline and 0.43±0.04 1.Γ1 at 
follow-up (p=0.23) and in the M group 0.45±0.03 and 0.45±0.03 LI"1, respectively 
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(p=0A4). For correction of a possible change in blood viscosity due to a change in the 
hematocrit, the mean patient based HMTT at follow-up catheterization was corrected 
by the percentage change in hematocrit from baseline to follow-up catheterization. In 
the L group (n=18) the averaged HMTT corrected for hematocrit change decreased 
from 3.19±0.78 to 2.78±0.69 s (p=0.008) and in the M group from 2.99±0.84 to 
2.97±0.84 s (p=0.94) The mean difference in HMTT between the L group and the M 
group after correction for hematocrit was 0.38 s (p=0.22). 
There were no significant correlations between the change in HMTT with the 
mean lipid levels during the trial [total cholesterol, LDL-cholesterol, high density 
lipoprotein (HDL) cholesterol, ratio LDL/HDL, Lp(a)] or change in lipid levels. No 
significant correlations were found between change in HMTT and change in MOD, 
MSD or change in time to 1 mm ST-segment depression. Categorizing patients into 
groups with improvement versus impairment of time to 1 mm ST-segment depression 
at the exercise test showed a decrease in HMTT of 16±21% in the group with improve­
ment, versus an increase in HMTT of 4±19% in the group with impairment (p=0.04). 
The change in hematocrit at heart catheterization showed no relation with the time to 
1 mm ST-segment depression nor with the change in HMTT. 
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RCA(n=14) RCX(n=31) LAD (n=32) 
Fig 5. Bar graphs showing the mean percentage change of HMTT ± SEM in the regions of the 
left anterior descending artery (LAD), the circumflex artery (RCX) and the right coronary 
artery (RCA), respectively, for the LDL-apheresis group versus the medication group 
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Discussion 
Although LAARS showed no significant change in quantitatively assessed coronary 
anatomy in both groups, the results of the HMTT measurements showed an increase in 
myocardial perfusion in the group of patients treated with LDL-apheresis, whereas 
patients on medication only remained stable. This improvement in myocardial perfusi-
on in the group on LDL-apheresis is in agreement with the improved ischemic thres-
hold as has been published before [11,44]. These results show a discrepancy between 
anatomical and physiologic parameters in the assessment of coronary atherosclerosis. 
The improved functional status in the patients on LDL-apheresis is accompanied by a 
lower LDL-cholesterol level (1.1 mmol.l"1 ) than in the group of patients on medication 
only. To explain the improvement in myocardial perfusion we hypothesized that one or 
more of the following mechanisms may be operative: 
1. Recovery of endothelial NO production and release in the conduit vessels. 
Recent studies in animals and humans associate hypercholesterolemia and increased 
Lp(a) levels with an impaired endothelium-dependent vasodilatation [28-32,45]. Lipid 
lowering during 6 months to one year may enhance the endothelial function as tested 
with acetylcholine [33-35]. Improvement in endothelial function may enhance exercise 
induced dilatation of the large epicardial coronary arteries [28,46]. The more pronoun-
ced lipid lowering in the group with LDL-apheresis may result in a better recovery of 
endothelial function and may thus improve the ischemic threshold at exercise testing. 
Assessment of HMTT reveals a time parameter that is inversely related to maximal 
myocardial perfusion. Due to the method of assessment of the HMTT (intra-coronary 
papaverine and sublingual isosorbide dinitrate), it is unlikely that endothelium depen-
dent vasodilatation is involved in the improved regional myocardial blood flow in this 
study. 
2. Remodeling of the conduit vessel wall. Regression of the atherosclerotic pla-
ques initially leads to remodeling of the vessel wall, without a significant effect on 
plaque size and/or cross-sectional area of the lumen of the epicardial coronary arteries 
[27,47,48]. The functional response of the remodeled coronary arteries to dilate in 
reaction to papaverine, however, may be enhanced and maximal myocardial perfusion 
may be increased. This view is supported by a recent publication in which the epicardi-
al response to intra-coronary nitroglycerin administration decreased significantly with 
increasing atherosclerotic wall thickening [49]. Next to obstruction of the vascular 
lumen atherosclerosis of the arterial wall also has an endothelium independent effect on 
coronary vasomotion and flow. This may explain the observation that functional impro-
vement precedes anatomical regression of atherosclerosis. 
3. Improved arteriolar vasodilatation. Resistance vessels are spared from the 
development of overt atherosclerosis. Relaxation of these vessels, however, may be 
reduced in patients with high LDL-cholesterol levels due to alterations in endothelial 
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cell function as established in primates [30]. Endothelium dependent arteriolar relaxati-
on was impaired, whereas endothelium-independent responses were nearly identical 
[30]. In the human forearm model the impairment of the microvascular vasodilator 
function in patients with hypercholesterolemia is only endothelium dependent [32]. So 
improvement in endothelium independent arteriolar vasodilatation is highly speculative. 
Another hypothesis introduced by Gould et al [50] was that the coronary flow response 
induced by a direct effect of an arteriolar vasodilator may be augmented by a further 
improved flow-mediated, endothelium dependent epicardial coronary artery vasodilata-
tion. This effect, however, was not likely to occur in this study where patients received 
prior to angiography isosorbide dinitrate for epicardial coronary artery vasodilation. 
Maximal epicardial vasodilatation after isosorbide dinitrate sublingually is known to 
persist for 30 to 60 minutes which was the time we needed to perform the angiography 
and DSA [51,52]. 
4. Changes in blood rheology. Improved myocardial perfusion may also be due to 
changes in blood rheology as a result of repeated LDL-apheresis [53,54]. Because the 
assessment of HMTT took place one month after the last LDL-apheresis, a direct effect 
of LDL-apheresis can be neglected. During the study there was a small decrease in 
hemoglobin level in the group of patients on LDL-apheresis but at heart catheterization 
the hematocrit levels were not significantly different in comparison to baseline. The 
results of the HMTT analysis after correction for change in hematocrit were virtually 
unchanged, so we decided to use the original data set for the entire analysis. During 
LDL-apheresis using dextran sulfate cellulose columns plasma fibrinogen, another 
determinant of viscosity, is lowered acutely by 26 - 35%, returning to pretreatment 
levels between 2 and 7 days [11,55]. Rigidity of red blood cells is increased in patients 
with high LDL-cholesterol values causing an increase in blood viscosity. After analysis 
of the HMTT with correction for the hematocrit and the delay between the last LDL-
apheresis and the follow-up DSA, we conclude that there was no significant effect of 
LDL-apheresis on blood viscosity at the moment of the assessment of the HMTT. 
The large individual relative change in HMTT compared with the relative change 
in MSD derived from QCA can be explained by the fact that the mean transit time is 
inversely related to the 4th power of the radius of a coronary vessel. In a model with a 
constant pressure and non-pulsatile flow, a 12% increase in coronary diameter in a 
3.0 mm coronary artery equals an 58% increase in coronary flow. Reproducibility of 
the HMTT under identical circumstances in the past has been proved to be good [40]. 
The improvement in HMTT was in agreement with the results of exercise testing, 
although there was no close correlation between the individual measurements. The 
different methodology of testing and differential effects of exercise and papaverine 
induced vasodilation may explain the individual differences in the response to LDL-
apheresis. There was also no close relation between change in coronary anatomy and 
exercise parameters. This correlation is known to be highly variable [56]. The functio-
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nal impact of lipid lowering interventions can be evaluated by other techniques such as 
intracoronary Doppler and nuclear tests such as thallium-201 single photon-emission 
computed tomography (SPECT) and positron emission tomography (PET). PET has the 
potential to measure quantitatively myocardial blood flow and lipid lowering studies 
with PET evaluation are now underway [57]. Coronary vasomotion after acetylcholine 
can be assessed by QCA. Assessment of coronary or myocardial blood flow induced by 
different vaso-active stimuli, in combination with QCA and/or intra coronary echocar-
diography, may further elucidate the mechanisms that are underlying the clinical impro-
vement in this study. 
Limitations of the present study may be the following. The hyperemic mean 
transit time is inversely related to flow if the vascular volume between the tip of the 
catheter and the regarding region of interest is constant (t = V/F where t = mean transit 
time, F = flow and V = vascular volume between the site of injection and point of 
measurement). Assessment of the HMTT was based on the assumption that the vascular 
volume after intra coronary papaverine was maximal and equal at the baseline and 
follow-up heart catheterization. Theoretically, if the vascular volume would be smaller 
due to atherosclerosis and the flow would remain the same, a shorter mean transit time 
could also be found that erroneously could be interpreted as favorable. This type of 
error is very unlikely because vascular volume is mainly determined by arterioles and 
capillaries, vessels which are not involved in the atherosclerotic process. In addition, 
the unchanged MSD in this study supports the assumption that the vascular volume of 
the conduit vessels remained unchanged. 
In this study regional myocardial perfusion was assessed as the primary endpoint 
for flow evaluation. For the patient based HMTT, regions of one patient were averaged 
to one HMTT value. However, in some patients only one region was available, in one 
patient even based on only one ROI. In other patients 8 ROIs in 3 myocardial perfusion 
areas were available (including bypass evaluation). So the patient based HMTT value is 
not always representative for the entire myocardial perfusion in that patient. 
The following conclusions can be drawn from this study. Biweekly LDL-aphere-
sis plus simvastatin improved regional myocardial blood flow in patients with severe 
hypercholesterolemia and extensive coronary artery disease. In the control group 
treated with lipid lowering drugs only, regional myocardial blood flow remained stable. 
The improvement in myocardial blood flow is in agreement with the improvement in 
ischemic threshold at exercise testing. The additional decrease in LDL-cholesterol 
levels due to LDL-apheresis may be the explanation for the functional improvement of 
the coronary circulation, although minor rhéologie changes can not be ruled out com-
pletely. The functional improvement may be due to endothelium dependent and/or 
independent changes in the coronary circulation. For the elucidation of the exact 
mechanism further studies are needed. The assessment of the regional myocardial blood 
flow by DSA and videodensitometric calculation of the HMTT is a feasible method for 
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the evaluation of lipid lowering trials. It requires some minor modifications of the 
radiographic equipment and instruction for breath holding for the patient. Assessment 
of the HMTT may be a more sensitive outcome measure than QCA for the evaluation 
of lipid lowering therapy because it evaluates the overall effect on myocardial perfusi-
on. 
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Objectives. In patients with familial hypercholesterolaemia (FH) the prevalence of 
haemodynamically significant peripheral vascular disease (PVD) was measured in 
relation to lipoproteins, general risk factors, and the presence of coronary artery dis-
ease (CAD). 
Design. A case control study. 
Setting. The outpatient lipid clinic of a university hospital (tertiary referral centre). 
Subjects. Patients with heterozygous FH [n=68; age 45.8±11.6 years; untreated LDL-
cholesterol 9.2±2.0 mmol.L'1] were compared with control subjects matched for gen-
der, age, weight, smoking and presence of hypertension [n=27; age 44.0 years; LDL-
cholesterol 3.8±1.3 mmol.L"1]. 
Main outcome measures. PVD was assessed during cholesterol-lowering treatment 
using ankle/arm blood pressure ratios and analyses of Doppler-derived blood flow 
velocities in the femoral artery at rest and during reactive hyperaemia. The diagnosis 
CAD was assessed clinically. 
Results. Haemodynamically significant PVD was found in 21 (31%) FH patients and in 
one (3.7%) control subject, predominantly localized in the femoro-popliteal vessels. 
CAD was present in 30 (44.1%) FH patients and in one (3.7%) control subject. PVD 
could be demonstrated in 50% of FH patients with CAD [relative risk 3.2 (95% CI 1.4 
to 7.2)] and in 19% as the first manifestation of vascular disease. Males and females 
were equally affected. Mean arterial blood pressure of FH patients with PVD was 
higher compared to FH without PVD. 
Conclusions. Haemodynamically significant PVD appears to be more prevalent in FH 
patients than is generally assumed, especially in those with CAD. A relation with 
lipoprotein levels could not be demonstrated. 
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Introduction 
Familial hypercholesterolaemia (FH) is an autosomal dominant disorder caused by one 
of several mutations in the gene on chromosome 19 coding for the low density lipopro-
tein (LDL) receptor [1,2]. The disorder is characterized by elevated levels of LDL 
cholesterol, tendocutaneous xanthomata and premature coronary artery disease (CAD) 
[1]. Individuals homozygous for the genetic defect have extremely high serum choles-
terol levels and they mostly develop CAD and peripheral vascular disease (PVD) in the 
first or second decade of life [1,3]. Clinical manifestations of CAD in heterozygous 
subjects appear in over 50% prior to their fifties; men develop CAD in their third to 
fifth decade and women about 10 years later [4,5]. In contrast, PVD seems to occur 
only at a slightly increased frequency and is considerably less prevalent than premature 
CAD [4,6]. The prevalence of intermittent claudication in heterozygous FH has been 
reported between 8 and 16% [7-10]. Nevertheless, the occurrence of bruits over the 
femoral arteries have been described more frequently [8,10,11]. In a few studies, a 
decreased ankle/arm systolic pressure ratio has been found in 62-65% of asymptomatic 
heterozygous FH patients [10,11]. Apparently, PVD in heterozygous FH is much more 
prevalent subclinically, only causing symptomatology in advanced cases [12,13]. 
Sophisticated non-invasive ultrasonic Doppler techniques are now available to 
facilitate the diagnosis of PVD. The ankle/arm systolic pressure ratio at rest and during 
hyperaemia is a reproducible method to determine the presence of arterial insufficiency 
in the lower limbs [14]. To differentiate between haemodynamically significant stenotic 
segments located in the aorto-iliac or the femoro-tibial tract, measurement of ankle/arm 
systolic pressure ratio should be combined with the assessment of the haemodynamic 
status of the aorto-iliac tract. Usually, invasive intra-arterial pressure measurement in 
the common femoral artery in rest and during reactive hyperaemia are used to assess 
the functional status of the aorto-iliac tract (the "golden standard"). Several studies have 
shown that these invasive pressure measurements can be replaced by analysis of the 
blood flow velocities in the common femoral artery obtained non-invasively by Dopp-
ler spectrum measurements [12,15]. This method has proven to be an accurate, non-
invasive, easy-to-perform screening-test to assess functionally and haemodynamically 
significant stenosis in the aorto-iliac tract. Moreover, the performance of Doppler 
spectrum analyses during reactive hyperaemia has been shown to enhance the sensitiv-
ity to detect haemodynamically significant aorto-iliac pathology [16]. 
The present study was undertaken to determine the prevalence of PVD by non-
invasive measurements of the ankle/arm systolic pressure ratio and a Doppler spectrum 
analysis of blood flow velocities in the common femoral artery, both at rest and during 
reactive hyperaemia, in heterozygous FH patients and matched normocholesterolemic 
control subjects. The presence of PVD will be related to lipids and lipoproteins, general 
risk factors, and the presence of CAD. 
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Materials and methods 
Subjects 
A consecutive series of 72 unrelated patients known to have definite heterozygous FH 
were recruited from the outpatient lipid clinic of the St. Radboud University Hospital of 
Nijmegen, Nijmegen, the Netherlands, to which they had been referred by either gen-
eral practitioners or hospital specialists. Four patients refused to take part in the study, 
one because of poor general health. The diagnosis familial hypercholesterolaemia was 
based on the following criteria: LDL cholesterol above ninetyfifth percentile for sex 
and age (in general >8.0 mmol.L"1); the absence of a secondary hyperlipoproteinaemia; 
the presence of tendon xanthomata; signs or symptoms of CAD before the age of 55 in 
males or the age of 60 in females, and/or a first-degree family member with 
hypercholesterolaemia or tendon xanthomata or CAD before the age of 55 and 60 in 
males and females, respectively. The criteria for CAD were the presence of angina 
(history of exercise-associated chest pain), myocardial infarction (proven by electrocar-
diogram and/or serum enzyme changes), angiographically proven disease or a history 
of coronary artery bypass surgery. Hypertension was defined as systolic blood pressure 
>160 mmHg and diastolic blood pressure >90 mmHg in supine position at rest. Patients 
with diabetes mellitus were excluded (fasting glucose >6.0 mmol.L'1 and haemoglobin 
A1C >6.4%). The control subjects consisted of 27 volunteers from the same hospital, 
matched for gender, age, weight, presence of hypertension and smoking habits. They 
were selected on the basis of their serum total cholesterol levels (below 6.5 mmol.L') 
and the absence of systemic or metabolic diseases. 
Information was recorded from 68 FH patients and 27 control subjects, including 
the presence of angina and intermittent claudication, details of past medical history, 
family history, smoking status, alcohol consumption, previous treatment for 
hyperlipoproteinaemia, and present use of drugs. Medical records of the FH patients 
were used for verification of this information, including previous lipid and lipoprotein 
levels. Vital signs were measured, the body mass index was calculated, and the pres-
ence of tendon xanthomata, xanthelasmas, arcus comealis and peripheral pulsus were 
noted. 
Lipid and lipoprotein measurements 
Fasting concentrations of total cholesterol, serum triglycerides, high-density lipoprotein 
(HDL) cholesterol, and LDL cholesterol were measured in both groups. For the FH 
group, mean levels of at least two measurements without lipid lowering treatment and 
four measurements during treatment with intervals of 2-3 months, were recorded before 
the vascular measurements were taken. Lipoprotein(a) [Lp(a)] levels were only mea-
sured during hypolipidemic drug treatment in the FH group. Serum total cholesterol and 
triglycerides were determined by enzymatic methods (CHOD-PAP, no. 237574, 
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Boehringer Mannheim GmbH, FRG and Sera-PAK, no. 6639, Miles, Milan, Italy, 
respectively). HDL-C was determined using the polyethylene glycol 6000 precipitation 
method [17]. LDL-C was calculated by subtraction. Lp(a) was measured by a specific 
radioimmunoassay (apolipoprotein(a) RIA 100, Pharmacia Diagnostics AB, Uppsala, 
Sweden). 
Doppler spectrum analysis and ankle/arm systolic pressure ratio measurement 
In one session, blood flow velocities in the common femoral arteries and ankle/arm 
systolic pressure ratios of both limbs were recorded, both at rest and during reactive 
hyperaemia, as described earlier [16]. In short, Doppler signals were obtained from the 
common femoral artery with an 8 MHz bidirectional continuous-wave Doppler appara­
tus (Medasonics Inc., Mountain View, CA, USA). The probe was placed just below the 
inguinal ligament. Reactive hyperaemia was induced by thigh cuff compression for 
5 min at a pressure of at least 50 mmHg above the systolic arterial thigh pressure. 
Doppler spectra during reactive hyperaemia were obtained approximately 15 s after 
relief of the thigh compression. Doppler signals were processed by a real-time spectrum 
analyser (Radionics SA8000; Scarborough, Ontario, Canada) and subsequently digitally 
stored on a computer for off-line analysis. Maximum-frequency waveforms were 
calculated from the spectra and several parameters were calculated that describe the 
shape of the waveforms [18]. Based on a combination of six of these Doppler parame­
ters [duration of the acceleration phase (T
milx), slope of the deceleration phase (SLd0Wn), 
maximum frequency of receding curve (F
min), and pulsatility index (ΡΙ^ ,,,,,χ-Ρ,,,,,,/Ρ,,,^ η) 
of the at-rest spectra and duration of the acceleration phase ( T ^ ) and resistance index 
(RI=F
m
„-Fdia/Fmax) of the spectra during reactive hyperaemia], the presence of 
haemodynamically significant aorto-iliac pathology can be assessed accurately [16]. 
The same Doppler probe was used to determine the ankle/arm pressure index, using the 
systolic radial artery pressure and the highest pressure in either the dorsalis pedis or 
posterior tibial artery; the side with the highest radial artery systolic blood pressure at 
rest was used as reference side for pressures during reactive hyperaemia. 
Haemodynamically significant vascular disease was defined as an ankle/arm pressure 
index at rest <0.90 and/or a decrease of the pressure index during reactive hyperaemia 
¿0.20. 
Statistical analysis 
Statistical analyses were performed with procedures available in the statistical package 
for social sciences (SPSS Inc., Chicago, IL, USA), using Student's Mest or the Mann-
Whitney U-test for differences in means, and the Yates' corrected chi-squared test for 
differences in proportions. A f-value of less than 0.05 was considered to be significant. 
All results are expressed as mean±SD, unless indicated otherwise. 
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Results 
Subjects 
A total of 68 patients (29 males and 39 females) with heterozygous FH and 27 control 
subjects (13 males and 14 females) were examined. The age distribution of the FH 
population was comparable to the control subjects (Fig. 1). The mean ages were 
45.8Ü1.6 years (range 22-68 years) for the FH patients and 44.0Ü0.9 years (range 
24-64 years) for the control group. The main cardiovascular risk factors aré summa-
rized in Table 1. No significant differences were found between the FH patients and the 
control subjects for the body mass index, smoking habits, alcohol consumption and 
hypertension. The presence of CAD in the FH population was significantly higher than 
in the control group, 44.1% versus 3.7%, respectively (PO.001) (Table 1). Twelve FH 
patients had a myocardial infarction in the past and 10 had undergone coronary artery 
bypass surgery. One subject in the control group had a myocardial infarction in the past 
and was free from angina pectoris. The cumulative frequency of CAD in FH patients as 
a function of age of onset is shown in Fig. 2 (a). The mean age of onset of CAD in the 
total FH group was 46.3Ü1.1 years (range 25-65 years, median 45 years), being 
41.8±10.0 years and 53.2±9.1 years for men and women, respectively. 
20-29 30-39 40-49 50-59 60-69 
Age (years) 
Fig. 1. Age distribution in different cohorts of patients with familial hypercholesterolemia, with 
(filled bars) and without (hatched bars) peripheral vascular disease, and control subjects (open ba 
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Table 1. Characteristics of all patients with familial hypercholesterolaemia (FHTOTAL), with (FHPVDt) and without (FHPVD.) 
peripheral vascular disease, and of control subjects' 
Sex Age BMI Smoking Hypertension MAP Angina ECG-changes Claudication 
Group (M/F) (yrs) (kg.m2) n (%) n (%) (mmHg) n(%) n(%) n(%) 
FHTOTAL 29/39 45.8Ü1.6 24.7±3.1 25(36.7) 7(10.3) 96±11 24(35.3)* 30(44.1)* 1(1.5) 
FHPVDt 8/13 47.6±11.0 25.4±3.1 9(42.8) 4(19.0) 104±9§ 11(52.4)* 15(71.4)# 1(1.5) 
FHpvD. 21/26 45.8Ü0.8 24.3±3.0 16(34.0) 3(6.4) 93±11 13(27.6)Ц 15(31.9) 0 
Controls 13/14 44.0±10.9 23.7±2.4 12(44.4) 2(7.4) 97±9 0 1(3.7) 0 
"Values are means±SD or numbers (percentages); M/F, male/female; BMI, body mass index; MAP, mean arterial pressure 
(normal range 80-100 mmHg); differences versus control subjects: \0.00UP<0.0I; *P<0.001; differences versus FHPVD.· 
#0.001 iP<0.01; §P<0.001 
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Lipids and lipoproteins 
Without lipid lowering treatment, mean basal serum total cholesterol and LDL choles­
terol levels in the FH group were strongly elevated (Table 2). HDL cholesterol concen­
trations were significantly lower and serum triglycerides did not differ in comparison to 
the control subjects. In the FH group the mean Lp(a) level of 54.8±62.1 mg.dL"' (range 
3.4-336.0 mg.dL', median 25.4 mg.dL') was higher than expected in normolipidaemic 
volunteers [19]. All FH patients were treated with lipid lowering drugs for a mean 
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Fig. 2 (a) The cumulative frequency of coronary artery disease (CAD) inpatients with familial 
hypercholesterolemia as a function of the age onset, (b) The cumulative frequency of periph­
eral vascular disease (PVD) in patients with familial hypercholesterolemia as a function of 
the age upon which PVD was detected (Ù — males, о = females) 
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Table 2. Basal and treatment levels of lipids and lipoproteins, type and duration of lipid lowering treatment of all patients 
with familial hypercholesterolaemia (FHTOTAL, n=68), with (FHPVD*, n=21) and without (FHPVD., n=47) peripheral vascular 
disease, and of normocholesterolemic control subjects (n=27)* 
Group 
Tot.chol 
(mmol.L1) 
HDL-chol 
(mmol.L1) 
LDL-chol Triglycerides Lp(a) Medication Treatment 
(mmol.L1) (mmol.L1) (mg.dL1) (inhibitor/resin) (years) 
FHT 
FHp 
FHp 
Controls 
basal 
treatment 
basal 
treatment 
basal 
treatment 
11.11±1.84* 
7.35Ü.30* 
ll.37il.79 
7.51Ü.32 
10.93il.85 
7.28Ü.29 
5.79Ü.47 
1.09i0.32* 
1.18±0.33* 
1.17±0.27 
1.26i0.34 
І.ОбіО.ЗЗ 
1.15i0.32 
1.4ІІ0.40 
9.19і2.03* 
5.51Ü.35* 
8.73i2.08 
5.54Ü.39 
9.19і2.09 
5.49Ü.33 
3.75Ü.30 
1.77i0.73 
1.50±0.62 
1.84i0.42 
1.63±0.67 
1.75±0.82 
1.45i0.61 
1.61Ü.25 
-
54.8i62.1 
-
50.3i49.0 
-
57.0i68.1 
_ 
61/28 
21/5 
40/23 
5.5i3.7 
5.2i3.2 
5.6i3.9 
"Values are means±SD; H(L)DL-chol, high (low)-density lipoprotein cholesterol; Lp(a), Lipoprotein(a); inhibitor/resin, number 
of patients on HMG-CoA reductase inhibitors and/or resins, respectively; differences versus control subjects: *Pi0.001; 
no significant differences were found between FHPVDtr and FHPVD_ 
О 
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period of 5.5±3.7 years (range 0.6-15 years, median 4.7 years); 61 of 68 (89.7%) 
patients were treated with a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase inhibitor (simvastatin or pravastatin), 28 out of 68 (41.2%) used a resin 
(cholestyramine or colestipol), and 21 out of 68 (30.9%) a combination of both groups 
of drugs (Table 2). During lipid-lowering treatment, the levels of total cholesterol, LDL 
cholesterol and HDL cholesterol in the FH group were still significantly different in 
comparison with the control subjects (Table 2). 
Peripheral vascular disease 
Vascular measurements were performed during lipid lowering treatment. The ankle/arm 
pressure ratios at rest were 1.03±0.12 and 1.08±0.11 (P=0.05) and 0.89±0.13 and 
Table 3. Prevalence of haemodynamically significant peripheral vascular 
disease (PVD) and Doppler spectrum waveform characteristics at rest and 
after reactive hyperaemia in patients with familial hypercholesterolaemia in 
comparison to normocholesterolaemic control subjects* 
Familial hypercholesterolaemia 
PVDAI+ Ρ ν ϋ π + PVD- Controls! 
Number (%) 
At rest 
AAI 
F
m
„(Hz) 
F™ (Hz) 
SL d o w n (m.s-
2) 
Τ ™ (ms) 
PI 
5 (7.4) 
0.92±0.15* 
4087±934* 
-1314±991 
-21±7* 
129±24# 
4.03Ü.96 
16(23.5) 
0.93±0.12 
7177±2645 
-1622±405 
-36±8 
102±17 
5.01Ü.49 
47(69.1) 
1.05±0.10 
6909±2077 
-1857±626 
-33±13 
101±16 
5.00±1.27 
26 (96.3) 
1.09±0.12 
6924±2496 
-1827±630 
-35±14 
100±24 
4.96Ü.64 
After hyperaemia 
AAI 0.75±0.17# 0.77±0.07 0.95±.011 0.96±0.08 
T ^ m s ) 133±54 100±39 105±36 98±32 
RI 0.60±0.10 0.65±0.08 0.68±0.10 0.68±0.08 
"Values are means±SD or numbers (percentages); PVDAI+, aorto-iliacpathology; 
PVDf-p^, femoro-tibialpathology; PVD-, no peripheral vascular disease; AAI, 
ankle-arm pressure ratio; for explanation of Doppler parameters see 'Materials 
and methods' section. JOne patient with PVD is excluded. Differences versus 
FHFVD_ and control subjects: * 0.01 sP<0.05; #0.001 UP<0.01 
oooo 
0.95±0.09 (P=0.03) after reactive hyperaemia for all the FH patients and control sub-
jects, respectively. One FH patient was known to suffer from intermittent claudication 
(a female; first symptoms at 38 years of age). Twenty-one out of 68 (30.9%, eight 
males and 13 females) FH patients had a pathological low ankle/arm systolic blood 
pressure ratio bilaterally or unilaterally (Table 3). In 39 out of 136 (28.6%) limbs, the 
pressure index was abnormal, so three patients exhibited a low ratio in only one leg. 
The patients with PVD were distributed equally within the different age groups (Fig. 1). 
The youngest patients with haemodynamically significant PVD were 31 years old (n=3) 
and most patients were found in the 40-49 year-old age cohort. The mean age at which 
PVD was found for the total group, namely 47.2±11.0 years (range 31-64 years, median 
47 years), was not different for men and women (47.8±12.4 and 46.8±10.6 years, 
respectively). The cumulative frequency of PVD as a function of the age of detection is 
shown in Figure 2(b). The total frequency in the male population of 27.6% (8/29) was 
not significantly different when compared with 33.3% (13/39) in females. 
Peripheral vascular disease was predominantly found in the femoro-tibial region 
in 16 out of 21 (76.2%) patients (Table 3). Eight of these 16 patients with a decreased 
ankle/arm index of <0.90 and a normal Doppler spectrum were detected by measure-
ments at rest, and the remaining eight patients had a decrease in the pressure index of 
¿0.20 during reactive hyperaemia. Peripheral vascular disease in the aorto-iliac vessels, 
showing an abnormal Doppler spectrum of the femoral artery, was found in five out of 
21 (23.8%) FH patients with a decreased ankle/arm index. Some parameters of the 
Doppler spectrum waveforms are shown in Table 3. Post-stenotic waveforms in pa-
tients with aorto-iliac pathology are characterized by a decreased maximum frequency 
shift (Fmax) and resistance index (RI), and an increase in the duration of the acceleration 
phase (Tmax) [16,20]. Only one out of 27 (3.7%, a female) control subjects had signifi-
cant changes in the femoro-tibial tract, showing bilaterally pathological pressure in-
dexes at rest and normal Doppler spectra. Comparison of the prevalence figures of PVD 
in the FH group and the control subjects showed significant differences, either ex-
pressed per patient (P=0.0l) or per limb (/><0.001). 
Characteristics of the FH patients with and without PVD are shown in Table 1 
and 2. No differences were found with regard to gender, age, body mass index, smok-
ing habits, alcohol consumption, lipids levels (basal or during lipid lowering treatment), 
Lp(a) concentrations, and the duration and the type of administered lipid lowering 
drugs. Hypertension in the medical history of the FH patients with PVD was found 
more often. Only the mean arterial blood pressure before the vascular measurements 
was significantly higher in comparison with the patients without PVD: 104±9 mmHg 
versus 93±11 mmHg (PO.OOl), respectively. A tendency was observed in the FH 
patients with PVD to have more clinical symptoms of CAD (angina pectoris) than in 
those without PVD. Only ECG-changes at rest or during exercise tests had a signifi-
cantly greater presence in the group with PVD: 71.4% versus 31.9% (P=0.006), respec-
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tively. Thirty out of 68 (44.1%) of the total group of FH patients had CAD, 15 (50%) of 
whom had abnormal pressure indexes, whereas only six out of 38 (19%) patients 
without CAD had PVD. Therefore, the relative risk of finding haemodynamically 
significant PVD of the lower extremities in FH patients with signs or symptoms of 
CAD compared with FH patients without CAD is 3.17 (95% confidence limits 
1.40-7.17). 
Discussion 
Peripheral vascular disease in population studies is unequivocally associated with 
dyslipoproteinaemia [21,22]. Our study addressed the question of the prevalence of 
PVD given the presence of well-defined FH. In FH populations, PVD has been reported 
in only 1.5% of cases as the first manifestation of vascular disease, whereas symptoms 
of CAD are the first feature in 94% [7]. In a prospective cohort study in subjects with 
heterozygous FH in England and Wales, a prevalence of intermittent claudication in the 
40 to 59 year-old age group has been found in 8.8 and 9.7% of men and women, 
respectively [23]. In the present study, using non-invasive measurements, haemo-
dynamically significant lesions were present in approximately one out of three asymp-
tomatic FH patients, and PVD was the first atherosclerotic manifestation in 19%. Of 
course, studies based on the detection of symptoms yield lower prevalence figures than 
those using non-invasive measurements, whereas the latter show intermediate figures 
when compared to studies using invasive angiographic methods [22,24,25]. 
The haemodynamically significant PVD prevalence figure of 31% seems lower 
than has been shown by others using pressure ratio index measurements [10,11]. How-
ever, a higher cut-off point for a pathological ankle/arm pressure ratio index <0.97 has 
been used in these studies, and this may have overestimated the presence of PVD, since 
the use of a cut-off point of <0.90 appears to be more predictive for significant obstruc-
tion [26]. 
In the past few years, there has been an increasing use of B-mode ultrasound in 
the assessment of atherosclerotic changes by measuring the intima-media thickness in 
the carotid and femoral artery [27,28]. This method may show early atherosclerotic 
manifestations of the intima-media complex which will not interfere with flow in 
contrast with Doppler spectrum analysis. However, haemodynamically significant 
changes in blood flow are comparable for both methods: in a recent study using 
B-mode ultrasound assessment in patients with heterozygous FH, plaques causing 
haemodynamically significant changes in blood flow in the femoral artery were found 
in 14 out of 36 (39%) patients, a figure that is comparable to that found in the FH 
population of our study [28]. 
There is considerable variability in the clinical manifestation of patients with 
heterozygous FH [1]. The phenotypic expression may be influenced not only by differ-
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enees in the underlying mutation, the apolipoprotein E phenotype, lipid and lipoprotein 
levels, and susceptibility to oxidative modification of LDL, but also by general risk 
factors such as gender, obesity, hypertension, and smoking [5,6,29-32]. In our study, no 
significant differences between the FH patients with and without PVD were found with 
regard to lipid and lipoprotein levels and general risk factors, with the exception of a 
higher blood pressure before the vascular measurements. Therefore, moderate hyperten-
sion may have increased the risk of development of PVD in the group of FH patients 
we studied. 
The present study also showed that PVD was mainly found in the femoro-tibial 
segments and less in the aorto-iliac vessels. Using strain-gauge plethysmography, 
Koivosto et al. also demonstrated the predominant affection of the proximal lower limb 
arteries in FH [10]. However, Rubba et al. have shown predominantly aorto-iliac 
pathology in FH using Doppler spectrum analysis of the common femoral artery at rest 
[33]. Using ultrasound methods as described in our study, only haemodynamically 
significant lesions (stenosis ¿50%) causing a decrease in arterial pressure or flow are 
documented, and addition of analyses during hyperaemia invariably increases the 
sensitivity of this method [16]. Therefore, the ultrasound measurements at rest of 
previous studies may have underestimated the presence of PVD. Since Doppler spec-
trum analysis at rest and during reactive hyperaemia accurately demonstrates the 
presence of aorto-iliac disease, even if atherosclerotic lesions of the femoral artery in 
multilevel occlusive disease exist, the presence of haemodynamically significant aorto-
iliac pathology is probably not underestimated in our study [34]. Therefore, the primary 
predilection side of PVD in FH seems to be the proximal lower limb arteries or the 
femoral-popliteal segment. Generally, a comparison between the age of onset of symp-
toms of CAD and the age at which PVD was detected in this study is debatable. Still, 
CAD and PVD can be found only when haemodynamically significant atherosclerotic 
lesions are present. Indeed, manifestations of CAD can occur coexistent with PVD in 
FH patients [5,11,13,25]. Our study showed that some patients develop CAD and PVD 
as early as the third decade of life, and that the mean age of onset of CAD was compa-
rable to the mean age upon which PVD was detected (46 versus 47 years, respectively). 
Moreover, 50% of the patients with established CAD also exhibited PVD, whereas only 
19% of the patients without CAD showed PVD. Therefore these data show that there is 
a three-fold relative risk for (asymptomatic) PVD once a patient with heterozygous FH 
exhibits signs or symptoms of CAD. 
In conclusion, haemodynamically significant PVD in patients with heterozygous 
FH is much more prevalent than is expected on clinical grounds, especially in those 
with CAD. Males and females are equally involved, and the preferential localization in 
the femoro-popliteal vessels was not related to the lipoprotein levels or general risk 
factors in this small group of patients, with the exception of hypertension. 
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with coronary artery disease 
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The effect of LDL-apheresis on peripheral vascular disease in hyperchol­
esterolemia patients with coronary artery disease 
A.A. Kroon, W.N.J.C. van Asten, A.F.H. Stalenhoef 
Ann Int Med 1996 
Objective: To compare the effect of conventional versus more aggressive lipid lower­
ing with LDL-apheresis on changes in peripheral atherosclerotic disease. 
Design: A prospective, open, randomized, single center study. 
Setting: One university hospital. 
Patients: 42 men with primary hypercholesterolemia and extensive coronary athero­
sclerosis. 
Intervention: Biweekly low density lipoprotein (LDL) apheresis plus simvastatin 
(40 mg/day) or simvastatin treatment (40 mg/day) alone for a period of 2 years. 
Measurements: ankle-arm systolic blood pressure index combined with Doppler 
spectrum analysis of the femoral artery at rest and during reactive hyperemia, and 
mean intima-media thickness (IMT) of near and far wall segments of the carotid artery, 
assessed yearly. 
Results: Baseline (mean ± SD) LDL cholesterol was reduced 63% from 7.8 to 3.0 
mmol.L"1 in the apheresis group versus 47% from 7.9 to 4.1 mmol.L"' in the medication 
group. The number of hemodynamic stenoses in the aortotibial tract in the apheresis 
group reduced from 17 to 13 (p=0.36) and increased from 11 to 23 (p=0.008) in the 
medication group. Mean IMT in the apheresis group regressed from 0.91±0.38 to 
0.85±0.29 mm (n=l 1; p=0.001) but thickened in the medication group from 0.88±0.30 
to 0.93±0.40 mm (n=ll; p=0.002). With multiple regression analysis changes in 
carotid IMT were mainly explained by changes in lipoprotein(a) and apolipoprotein Al 
levels, and aortotibial changes by mean in-trial apolipoprotein В concentrations and 
changes in total cholesterol and lipoprotein(a). 
Conclusions: Aggressive lipid lowering with medication and LDL-apheresis induced 
regression of early atherosclerotic lesions in the carotid artery and prevented increase 
of the number of hemodynamic stenosis in the lower limbs, whereas conventional 
treatment did not prevent progression of carotid and aortotibial vascular disease. 
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Introduction 
Until today intensive lipid lowering in men with established coronary artery disease 
(CAD) using HMG-CoA reductase inhibitors is the most effective means in terms of 
slowing or arrest of progression of coronary atherosclerosis and consequently reducing 
the number of clinical events [1,2]. Epidemiologic studies have shown parallel, age-
related trends of atherosclerotic lesions in the abdominal aorta, carotid, and coronary 
arteries [3-5]. In several clinical trials on plasma lipid regulation and risk factor analy-
sis measurements of peripheral vascular disease (PVD) have been performed [6-16]. 
Most of these studies have shown a slowing of progression of either carotid artery 
intima-media thickness (IMT) or the extent of femoral atherosclerosis during lipid 
lowering treatment. 
Continuous LDL-apheresis using dextran sulfate cellulose columns selectively 
removes apolipoprotein B-containing lipoproteins from plasma [17]. The performance 
of regular apheresis permits the achievement of lower levels of low density lipoprotein 
(LDL) cholesterol which is usually not possible to attain with drug therapy alone [18]. 
The application of this method may offer opportunities in the prevention of progression, 
or even inducing regression of atherosclerosis in selected patients with a primary 
hyperlipidemia and established CAD or PVD [10,19-22]. The LDL-Apheresis Athero-
sclerosis Regression Study (LAARS) was designed as a 2-years, prospective, open, 
randomized, single-center study in men with primary hypercholesterolemia and exten-
sive CAD. The objective was to determine whether more aggressive LDL cholesterol 
lowering with biweekly LDL-apheresis plus simvastatin, a potent HMG-CoA reductase 
inhibitor [23,24], exerts better an anti-atherosclerotic effect than lipid lowering to more 
conventional cholesterol levels with simvastatin alone. 
Ultrasound techniques are important surrogate variables for clinical end-points in 
quantitative measurements of atherosclerotic manifestations [25]. The ankle/arm sys-
tolic pressure ratio at rest and during hyperemia is a reproducible method to determine 
the presence of arterial insufficiency in the lower limbs [26,27]. To differentiate be-
tween hemodynamic significant stenotic segments located in the aortoiliac or the 
femorotibial tract, measurement of this pressure ratio should be combined with the 
assessment of blood flow velocities in the common femoral artery obtained by Doppler 
spectrum analyses [28,29]. It has also been found that high-resolution B-mode ultraso-
nography of the carotid artery is an effective and accurate method in the assessment of 
atherosclerotic changes of the arterial wall [30-32]. This technique has now been 
applied in a number of studies and it has been shown that the intima-media thickness 
(IMT) of the carotid artery reflects generalized atherosclerosis, indicated by its associa-
tion with coronary and lower extremity atherosclerosis [33-39]. 
In this article the results from LAARS of the sequential assessments of 
hemodynamic stenosis in the lower extremities and the carotid artery IMT are presented 
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and related to the lipid and lipoproteins levels. The results of the quantitative analysis 
of sequential coronary angiographies and exercise tolerance tests have been described 
recently [40]. 
Materials and Methods 
Subjects and treatment 
The design of the trial has been described previously [40]. Briefly, eligibility criteria 
included: a) men aged between 30 and 67 years, b) a mean of two successive serum 
total cholesterol determinations above 8.0 mmol.L'1 or LDL cholesterol above 
5.8 mmol.L', and a mean of two successive fasting serum triglycerides measurements 
below 5.0 mmol.L"1 on a standard lipid lowering diet (American Heart Association step 
I) without other lipid lowering treatments, and c) extensive coronary atherosclerosis as 
shown by visual assessment of the baseline coronary angiogram. Excluded were pa­
tients with a myocardial infarction or percutaneous transluminal coronary angioplasty 
(PTCA) or coronary artery bypass grafting (CABG) within the previous 3 months, 
impaired hepatic (>30% above normal range) or renal function (plasma creatine 
i 150 μπιοΙΧ"1), hypertension (diastolic blood pressure * 100 mmHg), diabetes mellitus, 
severe obesity (BMI *30 kg.m"2), hyperhomocysteinemia, homozygous familial 
hypercholesterolemia, heavy smokers (>10 cigarettes per day), and any secondary 
hyperlipidemia. During a 2-months run-in period a coronary angiogram and vascular 
measurements of the aortotibial tract and the carotid artery were performed. Those 
patients who proved to be eligible were allocated at random to either biweekly LDL-
apheresis plus simvastatin (40 mg/day) or simvastatin treatment (40 mg/day) alone. 
Randomization was stratified for the level of serum total cholesterol and lipoprotein(a) 
[Lp(a)], age, and CABG status. 
LDL-apheresis was performed with an automated system (MA-01 unit, 
Kanegafuchi Chemical Industry Co. Ltd., Osaka, Japan) with 2 small-sized dextran 
sulfate cellulose columns (Liposorber®), selectively absorbing apolipoprotein (apo) B-
containing particles. A volume of 5000 mL (approximately 1.5 plasma volume) was 
treated per session. The combination therapy of LDL-apheresis and simvastatin can be 
expected to slow down the post-apheresis rebound in serum cholesterol, which permits 
prolongation of the intervals between the apheresis procedures [41,42]. Patients allo­
cated to lipid lowering with drugs attended the outpatients clinics each month; those on 
LDL-apheresis were seen fortnightly. In both groups a resin in the highest tolerable 
dose was added to the treatment if (pre-apheresis) serum cholesterol levels in 2 consec­
utive months remained above 8.0 mmol.L'1, since it was considered not appropriate to 
continue single drug treatment above this level. At each visit the patients were sub­
jected to a brief physical examination and dietary instruction was repeated frequently. 
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Lipids, lipoproteins, and other measurements 
In the apheresis group lipids and lipoproteins were measured biweekly, before and 
immediately after each LDL-apheresis, and in the medication group monthly. Apo Al, 
apo B, and Lp(a) were measured bimonthly. Serum total cholesterol and fasting triglyc­
erides were determined enzymatically (CHOD-PAP, no. 237574, Boehringer 
Mannheim GmbH, FRG and Sera-PAK, no. 6639, Miles, Italy, respectively). High 
density lipoprotein (HDL) cholesterol was determined using the polyethylene glycol 
6000 precipitation method [43]. LDL cholesterol was calculated by subtraction. Sam­
ples for apo Al, apo B, and Lp(a) were stored at -80°C, and determined at the end of 
the study. Apo Al and apo В were quantified in serum by immuno-nephelometry [44]. 
Lp(a) was measured by a specific radioimmunoassay [apolipoprotein(a) RIA 100, 
Pharmacia Diagnostics AB, Uppsala, Sweden]. 
The selective removal of apo B-containing lipoproteins with LDL-apheresis 
causes sawtooth-like alterations in lipoprotein concentrations [45]. The increase of 
lipoprotein levels after the treatment can be explained by first order kinetics [22,46]. 
Therefore, time-averaged concentrations (C A V G) or interval means of total cholesterol, 
LDL cholesterol, apo B, and Lp(a) were calculated by applying a formula derived from 
rebound curves which were constructed for each patient at one occasion: 
CAVG^MIN+O-^CCMAX-CMJN), where Смдх is the pre-treatment level and CM,N the levels 
immediately after apheresis. For serum triglycerides and HDL cholesterol only pretreat­
ment levels were used in the analysis, because triglycerides reach pretreatment levels 
within 1 to 2 days after apheresis and HDL cholesterol is not influenced by LDL-
apheresis. Apheresis produced an acute reduction of 35% in fibrinogen levels, returning 
to pre-treatment concentrations between 2 and 7 days (n=l 1, data not shown). Fibrino­
gen concentrations at baseline did not differ between both groups. 
Ankle/arm systolic pressure ratio measurements and Doppler spectrum analyses 
The analysis of blood flow velocities in the common femoral artery obtained by Dopp­
ler spectrum measurements has proven to be an accurate, non-invasive, easy-to-perform 
screening-test to assess functionally and hemodynamically significant stenosis in the 
aortotibial tract [28,29]. Measurements were performed at baseline, after 1 year, and 
after 2 years of treatment. In one session blood flow velocities in the common femoral 
arteries and ankle/arm systolic blood pressure ratios of both limbs were recorded, both 
at rest and during reactive hyperemia. The performance of Doppler spectrum analysis 
during reactive hyperemia has shown to enhance the sensitivity for detection of 
aortoiliac pathology [47,48]. Doppler signals were obtained from the common femoral 
artery with an 8 MHz bidirectional continuous-wave Doppler apparatus (Angiodine 2, 
D.M.S. Montpelier, France) by placing the probe just below the inguinal ligament, as 
described previously [49]. Reactive hyperemia was induced by thigh cuff compression 
for 5 minutes at a pressure of at least 50 mmHg above the systolic arterial thigh pres-
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sure. Doppler spectra during reactive hyperemia were obtained approximately 
15 seconds after relief of the thigh compression. Maximum-frequency waveforms were 
calculated from the spectra and several parameters were used that describe the shape of 
the waveforms [50]. Based on a combination of 6 of these Doppler parameters [dura-
tion of the acceleration phase (Tmax), slope of the deceleration phase (SLdown), 
maximum frequency of receding curve (Fmin), and pulsatility index (PI=Fmax-
Fmin/Fmean) of the at-rest spectra and duration of the acceleration phase (Tmax) and 
resistance index (RI=Fmax-Fdia/Fmax) of the spectra during reactive hyperemia] the 
presence of hemodynamic significant aortoiliac pathology was assessed, and could be 
expressed as a continuous variable [47]. The same Doppler probe was used to deter-
mine the ankle/arm pressure index, using the systolic radial artery pressure and the 
highest pressure in either the dorsalis pedis or posterior tibial artery. Hemodynamic 
significant vascular disease was defined as a ankle/arm pressure index at rest <0.90 
and/or a decrease of the pressure index during reactive hyperemia i0.20. 
For evaluation of the results patients were categorized as follows. Patients with at 
least one new hemodynamic significant lesion in the aortoiliac or femorotibial tract of 
either sides were defined as worsened. Improved were patients with a reduced number 
of lesions and stable patients showed no difference in number or location of 
hemodynamic stenosis. If a patient had to undergo an angioplasty procedure (PTA) or 
vascular surgery for progressive claudication, he was considered to be worsened irre-
spective of the outcome of the test. 
Measurements of carotid artery intima-media thickness (IMT) 
Two-sided high resolution B-mode ultrasound examinations of the carotid arteries were 
performed at baseline, after 1 year, and after 2 years of treatment. Baseline measure-
ments could not be done in the first patients of the study since the method was not 
available at the start of the study. Therefore, three sequential assessments, including 
baseline, of 11 patients in both groups could be evaluated and two measurements in the 
remaining men. Scannings were done with a duplex apparatus (ACUSÓN 128XP, 
Cardia-Acuson B.V., Mountain View, CA, USA) equipped with a 7 MHz L7384 linear 
array /5.0 MHz Doppler transducer combination. In order to enhance reproducibility, 
longitudinal scans were performed from a fixed latero-lateral angle, using the dilation 
of the common carotid artery and the flow divider in the carotid artery as anatomical 
landmarks. Greatest care was taken to obtain a double-line pattern both from the near 
and far wall. The IMT was defined as the distance (mm) between lumen-intima and 
media-adventitia interfaces of the arterial far wall. Although, near and far wall do not 
represent identical anatomical correlates [51], combined measurements can be used in 
an intervention study since rates of progression between both wall measurements do not 
differ [52]. Moreover, the inclusion of the near wall reduces the variability of the 
measurement. If a plaque was located where IMT measurement should be performed, 
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the plaque thickness was included in the IMT value. The ultrasound images of the 
arterial segments were stored in real-time on a S-VHS videotape. Follow-up scans from 
each patient were made by the same sonographer, who was specially trained. At the end 
of the study off-line analysis of the IMT was performed at the CORE Laboratory of the 
Interuniversity Cardiology Institute (ICIN, Utrecht, the Netherlands) by professional 
readers blinded for the treatment. The IMT of the common carotid artery (the segment 
10 mm proximal to the dilation), the bifurcation (the segment between the flowdivider 
and the dilation), and the internal carotid artery (the segment 10 mm distal to the 
flowdivider) was measured by a semi-automated contour detection program. For each 
subject a mean IMT from 12 combined arterial sections (2 sides, 2 arterial walls, 
3 segments) per patient was taken as a measure for wall thickness. Effects on individual 
carotid segments were also investigated. To estimate the intraobserver variability 
10 randomly selected patients were invited for a repeated IMT assessment 7 days after 
the original one. The coefficient of variation, computed as the proportion of the stan-
dard deviation of the overall mean, was 11.5% (intraobserver error 0.10 mm). 
Table 1. Baseline characteristics 
Apheresis Medication only P* 
(n=21) (n=21) 
Age [years] 50.2±9.6 53.9±8.7 0.43 
Weight [kg] 81.5±9.7 80.8±8.6 0.88 
BMIfkg.m"2] 26.6±2.0 26.2±2.0 0.64 
Blood pressure [mmHg] 
systolic 
diastolic 
Current smoking 
Myocardial infarction 
CABG 
PTCA 
Hypertension 
Stroke 
Claudication 
129.3±17.3 
78.2±8.9 
3 (14.3) 
16 (76.2) 
10(47.6) 
2(9.5) 
2(9.5) 
1 (4.8) 
3 (14.3) 
126.3±18.1 
76.5±9.0 
4 (19.0) 
18(85.7) 
10(47.6) 
5 (23.8) 
5 (23.8) 
3 (14.3) 
5 (23.8) 
0.56 
0.63 
1.00 
0.69 
0.75 
0.41 
0.41 
0.60 
0.69 
Values indicate numbers (percentages) or means ± SD; * t-test or chF-test where 
appropriate. BMI, body mass index; CABG, coronary artery bypass graft; PTCA, 
percutaneous transluminal coronary angioplasty 
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Table 2. Changes in lipids and lipoproteins: baseline and treatment levels 
Apheresis(n=21) Medication only (n=21) Difference 
basal interval mean % change basal mean % change 
Total cholesterol (mmol.L1) 
Triglycerides (mmol.L1) 
LDL cholesterol (mmol.L1) 
HDL cholesterol (mmol.L 1) 
Lipoprotein(a) (mg.dL1) 
Apolipoprotein В (g.L'1) 
Apolipoprotein Al (g.L1) 
9.72±1.84 4.63Ü.18 -52.9±6.6 9.85±2.17 5.95±1.60 -39.5±7.7 0.005 
2.32±1.03 1.83±0.76 -17.4±24.4 2.64Ü.33 1.84±0.89 -26.5±20.3 0.38 
7.78Ü.86 2.95Ü.13 -62.9±8.3 7.85±2.34 4.13±1.58 -47.4±8.1 0.01 
0.93±0.18 1.09±0.20 +17.7Ü3.6 0.92±0.19 1.05±0.22 +13.7Ü0.9 0.23 
57.0±63.9 44.5±54.3 -18.6±18.0 38.4±39.7 44.5±45.7 +14.9±16.3 0.02 
2.59±0.47 1.32±0.35 -49.0±7.6 2.60±0.61 1.74±0.47 -31.0±17.0 0.003 
1.43±0.29 1.34±0.17 -5.3±13.0 1.46±0.38 1.33±0.21 -5.4±16.8 0.89 
Data represent means ± SD. Apheresis group: 52 measurements per patient. Medication group: 26 measurements per patient. Interval 
mean, time-averaged levels, calculated by estimation of the area under the rebound curve (see text); % change, difference between basal 
and mean levels; P, p-values of differences between interval mean in the apheresis group and mean levels in the medication group (t-test 
or Mann-Whitney U-test where appropriate). To convert values for total cholesterol to mg/dL, multiply by 38.67, and to convert values 
for triglycerides to mg/dL, multiply by 88.57 
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Statistical analysis 
The sample size of the study was limited for logistic reasons to approximately 
40 patients. Sample size calculations were based on expected changes in the coronary 
arteries [40]. Analyses were performed with procedures available in the statistical 
package for social sciences (SPSS Inc., Chicago, IL.), using Student's Mest, 
multivariate ANOVA (with correction for repeated measures) for normally distributed 
data, or Mann-Whitney U-test for differences in means of not normally distributed data. 
Differences in proportions were analyzed with the (Yates') corrected chi2-test, and 
analyses for trends in proportions were done with the extended Mantel-Haenszel ehr-
test. A two-sided Fisher's exact test was employed when the total number of cases was 
less than 15. For measures of agreement the Pearson product-moment correlation 
coefficient was used. Stepwise least-squares multivariate regression analysis was 
performed using a maximal p-value in the F-test of 0.05 before a variable could be 
added and a minimal tolerance (collinearity) of 0.01. Analyses were based on random-
ization assignment (intention-to-treat); data forgoing peripheral vascular surgery or 
angioplasty were used as end-point measurements. A two-sided p-value of less than 
0.05 was considered to be significant. Results are expressed as means ± SD, unless 
otherwise indicated. 
Results 
Baseline characteristics 
Twenty-one men were enrolled in each group of whom the baseline characteristics are 
shown in Table 1. In both groups 16 patients were heterozygous for familial hyperchol-
esterolemia (76% of the study population). Risk factors for atherosclerosis were equally 
distributed. All patients had severe angiographically demonstrated coronary atheroscle-
rosis. By the criterion of a stenosis of ¿50% being considered significant, 17 of 21 men 
in the apheresis group, and 19 of 21 men in the medication group had 3-vessel disease 
of the coronary arteries. The other patients had 2-vessel coronary artery disease. A 
previous history of stroke or intermittent claudication was present in 4 men of the 
apheresis group versus 8 in the medication group. None of the patients were hyperten-
sive at the start of the study. Basal cholesterol levels were high, and predominant 
elevation of apo B-containing lipoproteins were found in agreement with the inclusion 
criteria (Table 2). Lp(a) levels showed a skewed distribution with median baseline 
levels of 28.8 and 19.8 mg.dL'1 in the apheresis and medication group, respectively. 
The treatment groups were well balanced and no significant differences were found 
with respect to baseline characteristics and baseline lipid and lipoprotein concentra-
tions. 
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Table 3. Number of sides with hemodynamic significant stenoses in the aortoiliac and femorotibial tract as measured with 
Doppler spectrum analyses of the femoral artery and ankle-arm systolic blood pressure ratios at rest and after reactive 
hyperemia, at baseline, after 1 year, and after 2 years of treatment 
Location 
Aortoiliac 
Femorotibial 
Whole tract 
Testi 
7 
15 
17 
Apheresis (n=40) 
Test 2 
4 
13 
16 
Test3 
2 
11 
13 
PA 
0.07 
0.34 
0.36 
Testi 
7 
6 
11 
Medication 
Test 2 
8 
14 
18 
only (n=42) 
Test3 
- 11 
18 
23 
PM 
0.28 
0.004 
0.008 
Difference 
PD 
0.003 
<0.001 
0.002 
Test 1, 2, and 3: assessments at baseline, after 1 year, and after 2 years of treatment, respectively; PA and Pu p-values of 
trends in proportions in Apheresis (A) group and Medication (M) group; P& p-value of difference (D) in trends between 
both treatments (extended Mantel-Haenszel chi2-test) 
Table 4. Ankle-arm systolic blood pressure ratios and some Doppler spectrum waveform characteristics at rest and after reactive 
hyperemia at baseline, after 1 year, and after 2 years of treatment 
Apheresis (n=40) Medication only (n=42) Difference 
Testi Test 2 Test3 Testi Test 2 Test3 PM PD 
At rest 
AAI 
Fmax (Hz) 
Fmin (Hz) 
Sldown (m.s'2) 
Tmax (ms) 
PI 
After hyperemia 
AAI 
Tmax (ms) 
RI 
1.07±0.11 
5950±1696 
-1962±620 
-33±10 
101±15 
5.00±0.99 
0.87±0.17 
98±27 
0.59±0.07 
1.05±0.12 1.07±0.13 0.48 
5927±1693 5934±1375 0.99 
-1853±437 -1985±406 0.18 
-29±10 -31±9 0.05 
98±16 96±13 0.32 
5.25Ü.36 5.83±1.14 0.001 
0.89±0.17 0.90±0.17 0.64 
95±30 96±15 0.86 
0.60±0.07 0.61±0.10 0.19 
1.02±0.14 0.99±0.18 0.98±0.18 0.03 0.34 
5529±1490 5433±1697 5409±2051 0.90 0.97 
-1801±609 -1584±584 -1598±540 0.02 0.28 
-29±8 -26±9 -27±9 0.25 0.74 
112±26 114±20 115±23 0.61 0.25 
5.02Ü.22 5.00±1.31 4.90±0.97 0.84 0.005 
0.86±0.22 0.84±0.20 0.84±0.22 0.55 0.39 
102±32 113±44 114±43 0.98 0.90 
0.62±0.09 0.61±0.08 0.59±0.10 0.19 0.04 
О 
О 
О 
Data represent means ± SD. AAI, ankle-arm systolic blood pressure ratio; for explanation of Doppler parameters see Materials and 
Methods section; Test 1, 2, and 3: assessments at baseline, after 1 year, and after 2 years of treatment, respectively; PA, PM and P& 
P-values in Apheresis (A) group, Medication (M) group, and of the difference (D) between both groups, respectively (multivariate 
ANOVA) 
LDL-apheresis and peripheral vascular disease 
Clinical events and patient evaluation 
Two patients, one in each group, had progressive intermittent claudication. The patient 
from the apheresis group had to undergo an angioplasty (PTA) of the left common iliac 
artery at 5 months after the start of the study. In the same patient a coronary artery 
bypass graft (CABG) procedure had to be performed for unstable angina at 9 months, 
after which he continued only treatment with simvastatin. In the medication group the 
other patient with progressive claudication had abdominal aortic graft surgery after 
12 months of treatment and another patient had a cerebral transient ischemic attack 
(TIA) at 11 months. In the apheresis group one patients was lost to follow-up, due to 
death immediately after coronary surgery for unstable angina within 3 months after the 
start of the study. So, the results of 20 patients in the apheresis group and 21 in the 
medication group could be evaluated. 
Lipid and lipoprotein profiles 
Three patients in the apheresis group and 4 in the medication group received additional 
resin treatment, 8-24 g cholestyramine per day. LDL-apheresis caused an acute reduc-
tion of 62%, 78%, 71%, and 72% of the mean concentrations of total cholesterol, LDL 
cholesterol, Lp(a) and apo B, respectively. HDL cholesterol levels were not influenced 
by this procedure. Differences in treatment effects were established by comparison of 
interval mean concentrations in the apheresis group and mean concentrations in the 
medication group. During the whole course of the study apo B-containing lipoproteins 
were significantly lower in the apheresis group compared to the medication group 
(Table 2). In both groups a comparable increase of HDL cholesterol levels and a de-
crease of serum triglyceride levels was observed while on treatment with simvastatin 
(Table 2). The LDL/HDL cholesterol ratio was reduced from 8.4 to 2.7 (-68%) in the 
apheresis group, versus -54% (from 8.5 to 3.9) in the medication group. The interval 
mean Lp(a) level was reduced by 19 % in the apheresis group, which was significantly 
different in comparison with the 15% increased levels found in the medication group 
(Table 2). 
Hemodynamic significant lesions in the aortoiliac and femorotibial tract 
At baseline no significant differences in number of patients with stenoses in the whole 
aortotibial tract were observed between both groups: an abnormal low ankle/arm 
systolic blood pressure ratio was found in 9 patient in the apheresis group versus 6 in 
the medication group, on 17 versus 11 sides, respectively (Table 3). The ankle/arm 
pressure ratios at rest were 1.07±0.11 and 1.02±0.11, respectively, and after reactive 
hyperemia 0.87±0.17 and 0.86±0.22, respectively (Table 4). An abnormal Doppler 
spectrum of the femoral artery and a decreased ankle/arm ratio, representing aortoiliac 
hemodynamic significant lesions, were observed on 7 sides in both groups (Table 3). 
Femorotibial lesions, as shown by a normal Doppler spectrum and a decreased an-
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kle/arm pressure ratio, were found in 15 limbs in the apheresis group and in 6 of the 
medication group (p=0.01). At the end of the study the number of patients with 
hemodynamic stenoses in the medication group was increased from 6 to 13 (p=0.03). 
This was predominantly based on a significant increase of femorotibial lesions 
(Table 3). In the apheresis group a not statistically significant trend was observed 
towards reduction of the number of patients (from 9 to 7) and sides (aortoiliac and 
femorotibial) with hemodynamic lesions, causing significant differences in trends 
between both groups at the end of the study (Table 3). 
In general, post-stenotic waveforms in patients with aortoiliac pathology are 
characterized by a decreased maximum frequency shift (Fmax-Fmin) and resistance 
index (RI), and an increase in the duration of the acceleration phase (Tmax) [47]. Some 
characteristics of the Doppler spectrum waveforms, addressing only changes in the 
aortoiliac tract, are shown in Table 4. Significant differences in trends of the pulsatility 
index [PI=(Fmax-Fmin)/Fmean] and resistance index [RI=(Fmax-Fdia)/Fmax] between 
both groups were observed, which is in accordance with the decrease in the apheresis 
group of aortoiliac hemodynamic significant stenoses and their increase in the medica­
tion group. In the apheresis group 18 of 20 (90%) patients showed improvement or no 
change in the number hemodynamic significant stenoses in the whole aortotibial tract, 
versus 8 of 21 (38%) patients in the medication group (p=0.002, relative risk 2.36 [95% 
CI: 1.34 to 4.15]). Categorization of all patients in those who showed increase in the 
number of lesions versus those who showed no change or a reduction in the number of 
hemodynamic stenoses demonstrated significant more reduction of total cholesterol, 
LDL cholesterol, Lp(a) and apo В in the group that did not change or improved 
(Table 5). 
Intima-media thickness (IMT) of the carotid arteries 
Baseline concentrations of lipids and lipoproteins of the group of 22 men who had 
3 IMT measurements, including baseline, were not different in comparison to the whole 
study group (data not shown). At baseline the IMT of the bifurcation and the internal 
carotid were significantly different between both groups (Table 6). However, during the 
study a gradual significant decrease in mean IMT of all segments was observed in the 
apheresis group compared to an increase in the medication group (Table 6). These 
changes were due to significant different trends in IMT of the segments in the common 
carotid artery and the bifurcation between both groups (Fig. 1). Categorization of all 
patients who showed reduction or no change of mean IMT (n=ll) versus those who 
showed increased thickening (n=l 1) again demonstrated significantly more reduction of 
total cholesterol, LDL cholesterol, Lp(a) and apo B, comparable to the data shown in 
Table 5, and no differences in HDL cholesterol, serum triglycerides, and apo Al levels 
were found (data not shown). 
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F/g. 7. Change in mean intima media thickness (mean±SEM) of the bifurcation, the common 
and internal carotid artery in 11 subjects from the apheresis group versus 11 subjects from the 
medication group at baseline, after 1, and after 2 years of treatment. (Asterisks denote signifi­
cant difference versus baseline: *0.01sP<0.05; **0.001sP<0.01) 
Correlations 
Absolute changes from baseline and mean in-trial concentrations of total cholesterol, 
LDL cholesterol, and apo В were significantly correlated with worsening or improve­
ment of hemodynamic lesions in the aortotibial tract, indicating that more aggressive 
lipid lowering was associated with reduction in presence of hemodynamic stenoses 
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(Table 7). Multiple regression showed that only mean in-trial apo В (variance RH). 19, 
p=0.005), absolute change from baseline of total cholesterol (variance RM). 19, 
p=0.005), and absolute change from baseline of Lp(a) (variance RM). 16, p=0.01) 
explained the changes in the aortotibial tract. Stepwise addition of other variables did 
not further improve the explained variance significantly (total R2=0.36, p=0.001). Early 
atherosclerotic lesions, expressed as changes in mean IMT, were correlated with abso­
lute changes in apo Al (variance R2=0.25, p=0.02) and Lp(a) (variance R M ) ^ , 
p=0.004). Using stepwise multiple regression no other variables further improved the 
explained variance of the mean IMT significantly (total R2=0A9, p=0.002). A positive 
correlation was found between the reduction in mean IMT of the carotid artery and the 
Table 7. Correlations between lipids and lipoproteins and changes in 
hemodynamic significant aortotibial lesions and mean carotid artery 
intima-media thickness 
Absolute change from baseline 
Total cholesterol 
LDL cholesterol 
HDL cholesterol 
Lipoprotein(a) 
Apolipoprotein В 
Apolipoprotein Al 
Mean in-trial concentrations 
Total cholesterol 
LDL cholesterol 
HDL cholesterol 
Lipoprotein(a) 
Apolipoprotein В 
Apolipoprotein Al 
Aorto-tibial tractf 
г 
0.46 
0.38 
0.20 
0.44 
0.30 
0.07 
-0.36 
-0.30 
0.12 
-0.09 
-0.41 
0.12 
Ρ 
0.003 
0.01 
0.22 
0.005 
0.06 
0.66 
0.02 
0.06 
0.46 
0.57 
0.009 
0.47 
Change 
г 
0.25 
0.17 
0.17 
0.59 
0.18 
0.50 
-0.35 
-0.35 
0.09 
-0.14 
-0.32 
0.15 
inIMTí 
Ρ 
0.27 
0.46 
0.45 
0.004 
0.42 
0.02 
0.11 
0.11 
0.71 
0.54 
0.14 
0.50 
Data represent Pearson's correlation coefficient (r) and corresponding 
p-values (P) from pooled data of aortotibial lesions (n=41), expressed as 
categoria! changes (worsened, unchanged, improved) f, and mean 
intima-media thickness (IMT) of the carotid artery (n=22)f 
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reduction of hemodynamic significant stenoses in the aortotibial tract, expressed as 
categorial changes (worsened, stable, improved) (r=0.44, p=0.048) or as change in a 
continuous score for the Doppler spectrum waveform (r=0.54, p=0.009) (Fig. 2). 
Discussion 
LAARS was performed to evaluate whether more aggressive lipid lowering in men 
with extensive CAD exerts better retardation of the progression of atherosclerosis. The 
primary outcome measures showed equal arrest of progression of CAD in both groups 
as assessed by sequential quantitative coronary angiography. However, LDL-apheresis 
plus simvastatin treatment further reduced the number of early coronary lesions and 
significantly reduced exercise-induced myocardial ischemia [40]. The present study 
showed the secondary outcome measures. We demonstrated that aggressive cholesterol 
lowering prevented increase of the prevalence of hemodynamic stenosis in the 
aortotibial tract and reduced the mean IMT of the carotid arteries. In other words, 
2 years of more aggressive lipid lowering regressed early peripheral atherosclerotic 
lesions and arrested progression of advanced ones, whereas conventional treatment did 
m 
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Fig. 2. Correlation between the change (baseline-end of study) in mean intima media 
thickness (IMT) of the carotid artery and the change (baseline-end of study) in the score of the 
Doppler spectrum analysis (DOSA) [negative figures depict worsening]. 
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not prevent progression of early and advanced peripheral lesions. 
It has been shown that natural occurring progression of CAD is mainly seen in the 
formation of new lesions and less in growth of preexisting ones, whereas progression of 
the latter is correlated with high cholesterol levels [53]. Most coronary regression 
studies showed the greatest benefit in atheroma obstructing >50% of the lumen. How-
ever, more recent trials reported also that the formation of new lesions was reduced 
[54-57]. The present results from LAARS, showing arrest of progression of advanced 
aortotibial lesions and regression of early carotid lesions, suggest a parallel effect of 
cholesterol lowering on both CAD and PVD. 
The effect of lipid lowering on femoral atherosclerosis has been shown by several 
studies [7-10]. CLAS was the first placebo-controlled study showing significant reduc-
tion of angiographically determined femoral PVD during treatment with colestipol and 
niacin in men with previous CABG [9]. POSCH showed that fewer subjects in the ileal 
bypass surgery group developed intermittent claudication and angiographically demon-
strated PVD [8]. Only one uncontrolled study showed the beneficial effect of LDL-
apheresis in severe atherosclerotic obstruction of the lower extremities in patients 
refractory to drug treatment [10]. A reduced progression or regression of the carotid 
artery IMT has been demonstrated in CLAS, MARS, ACAPS, KAPS and PLAC-II 
[11,12,14-16]. The observed reduction in mean IMT of the common carotid artery after 
two years in the apheresis group of our study is comparable with the findings of the 
active treatment groups of CLAS and MARS, which showed a reduction of 
-0.05±0.06 mm and -0.06±0.11 mm, respectively [11,12]. Remarkable are the observa-
tions of the medication group in LAARS which do not seem to benefit from cholesterol 
lowering. However, the placebo groups of CLAS, MARS, and PLAC-II, all with a 
mean in-trial LDL cholesterol comparable to our medication group, also showed pro-
gression of carotid IMT [11,12,16]. The recently published population-based primary 
prevention studies ACAPS and KAPS, using lovastatin and pravastatin treatment, 
respectively, support these results [14,15]. Moreover, ACAPS has shown that reduction 
of LDL cholesterol to 2.9 mmol.L"1 significantly reduced the cardiovascular and all-
cause mortality. So, although we analyzed only a small group of subjects in LAARS, 
our data underline that more aggressive reduction of apo B-containing lipoproteins is 
necessary to induce regression of atherosclerosis in different peripheral vascular beds. 
The accepted indication for LDL-apheresis is resistance to drug treatment in 
patients with CAD [18]. In LAARS, LDL-apheresis was used as a method to lower 
LDL cholesterol more aggressively in subjects of whom some were not drug-resistant. 
Our results confirm the usefulness of extracorporeal therapy in achieving and maintain-
ing low LDL cholesterol levels, as has also been shown recently by Thompson et al 
[22]. The reduction of baseline LDL cholesterol levels by 63% (95% CI: 59 to 68%) is 
in keeping with other studies using lipid lowering drugs plus dextran sulfate LDL-
apheresis columns [21,58]. On the other hand, LDL reduction in our medication group 
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by 47% (95% CI: 44 to 51%) may be considered as a good response to simvastatin 
treatment [23,24] which is probably the result of frequent monitoring of the patients. 
Since LDL apheresis entails a major commitment for the patient and the medical 
community, our results affirm the observations from others that hypercholesterolemic 
patients with established CAD and/or PVD should be treated with a combination of 
lipid lowering drugs to LDL cholesterol levels < 3.0 mmol.L"' [1]. Consequently, LDL-
apheresis should be considered in patients with hypercholesterolemia who are refrac­
tory to drug treatment. 
It is accepted that the impact of risk factors for the development of atherosclerosis 
differs among the various arterial segments [59,60]. Cigarette smoking, hypertension, 
and age have been shown to be more powerful predictors for the presence of PVD than 
lipids and lipoproteins. The observed differences in effects of risk factor intervention on 
different arterial segments or between studies may be associated with different visual­
ization technics or different durations of the intervention. Moreover, individual biologi­
cal susceptibility for risk factors due to lesions of different age and therefore different 
physicochemical and histological characteristics may also be contributory [16,61]. In 
LAARS only the effects of changes in lipids and lipoproteins could be analyzed, since 
no other risk factors were influenced. Changes in the aortotibial tract were explained by 
absolute reduction of total cholesterol and Lp(a) and by in-trial apo В levels, whereas 
changes in carotid IMT were explained by absolute change in Lp(a) and apo Al levels. 
These findings concerning apolipoproteins and total cholesterol accord with data from 
population-based and intervention studies [37,62-64]. The influence of Lp(a) as a risk 
factor should be discussed more in detail with relation to LDL-apheresis. Our study 
showed a significant reduction of Lp(a) levels in the apheresis group. The role of Lp(a) 
as an independent risk factor for CAD and cerebrovascular disease, but also for PVD, 
has been confirmed [65]. However, only recently the FH Regression Study showed that 
further reduction of Lp(a) levels by LDL-apheresis did not induce more regression of 
CAD in comparison with drug treatment which lowered LDL cholesterol levels to the 
same extent [22]. Moreover, in LAARS we also did not observe differences between 
both treatment groups with regard to changes in coronary anatomy. The present results, 
however, show a different risk factor relationship between Lp(a) and PVD, especially 
for early carotid lesions. 
One may criticize the results from Doppler spectrum and ankle/arm pressure 
index measurements by presuming that rhéologie changes induced by LDL-apheresis 
have influenced the results. Indeed, early improvements in the clinical symptoms of 
claudication and pectoral angina are assumed to be initially induced by correction of 
rhéologie properties of blood [10,66]. Acute reductions by dextran-sulfate adsorption of 
fibrinogen, factor VIII, and other coagulation factors have been described to last no 
longer than 1 to 2 days [67]. Still, whole blood and plasma viscosity have been shown 
to be reduced for a period as long as 1 week [68]. So indeed, it can not be excluded that 
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improved rheology influenced the measurements of hemodynamic stenosis after 1 year 
of treatment, while apheresis was still going on. However, at the end of the study the 
assessments were done 3 to 4 weeks after the last treatment, at the time rhéologie 
changes have disappeared. 
In conclusion, the results of LAARS support the evidence that aggressive lipid 
lowering is beneficial in patients with hypercholesterolemia and coronary atherosclero-
sis. Combined LDL-apheresis and cholesterol lowering drugs in patients with high risk 
for cardiovascular events induced regression of the IMT in the carotid arteries and 
arrested progression of hemodynamic significant stenosis in the aortotibial tract. These 
findings are consistent with the concept that atherosclerosis is a generalized condition, 
although the impact of various risk factor interventions may be different. 
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gous familial hypercholesterolemia 
treated with long-term low-density 
lipoprotein apheresis 
LDL-apheresis dwing pregnancy in homozygous FH 
Published as: 
Pregnancy in a patient with homozygous familial hypercholesterolemia 
treated with long-term low-density lipoprotein apheresis 
A.A. Kroon, D.W. Swinkels, P.W.J, van Dongen, A.F.H. Stalenhoef 
Metabolism 1994;43:1164-70 (reprinted with permission) 
The pregnancy and delivery of a subject with homozygous familial 
hypercholesterolemia (FH) and coronary artery disease (CAD) were monitored 
closely for signs of maternal and fetal distress. Biweekly treatment with low-density 
lipoprotein (LDL) apheresis using dextran-sulfate cellulose columns was continued 
throughout the pregnancy, and lipid and lipoprotein levels were evaluated. During the 
course of the pregnancy and delivery, no signs of maternal coronary insufficiency 
developed. Serial ultrasonographic measurements of fetal growth indices and the 
blood flow velocity waveforms (FVWs) of the uterine and umbilical artery did not 
reveal any sign of fetal growth retardation or insufficiency of the uteroplacental 
circulation, respectively. During pregnancy, time-averaged concentrations of serum 
total cholesterol (TC), LDL cholesterol (LDL-C), apolipoprotein (apo) B, and lipo-
protein^) [Lp(a)] showed a gradual decline. Notwithstanding LDL-apheresis, a 
gradual twofold increase of serum triglyceride (TG) levels was found. In the second 
and third trimester, high-density lipoprotein cholesterol (HDL-C) levels showed a 
55% increase that coincided with a 75% reduction in hepatic lipase activity in 
postheparin plasma, normalizing after parturition. After delivery, Lp(a) levels showed 
an almost twofold increase, which could not be explained by the interruption of LDL-
apheresis alone, and may be caused by changes in gonadal steroids. Histologic exami-
nation of the placenta and the umbilical arteries revealed no atherosclerotic changes, 
infarctions, or lipid deposits. In general, long-term LDL-apheresis in homozygous FH 
can delay the onset and complications of severe CAD. In case of a pregnancy, LDL-
apheresis seems feasible and should be continued during the pregnancy to prevent 
superimposed hyperlipidemia and placental insufficiency. 
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Introduction 
Familial hypercholesterolemia (FH) is an autosomal dominant disorder caused by a 
mutation in the gene coding for the low-density lipoprotein (LDL) receptor, and 
characterized by elevated levels of LDL cholesterol (LDL-C), tendocutaneous xan-
thomas, and premature coronary artery disease (CAD) [1]. Approximately one in 500 
subjects in the population inherits a single copy of the mutant gene of the LDL 
receptor. These heterozygous patients may develop CAD from the third decade of 
life. Homozygous patients, usually carrying two different mutant genes for the LDL 
receptor, are very rare, with a frequency of one in one million persons. In these 
patients, serum cholesterol levels are extremely high, and they mostly develop CAD 
in the first or second decades of life. Due to the inability to induce functional LDL 
receptors, treatment with diet and cholesterol-lowering drugs is never sufficient in 
these patients, although homozygous patients with some remaining receptor activity 
can show a certain degree of cholesterol reduction [1,2]. Alternative treatments 
include portocaval shunting, liver transplantation, and plasmapheresis [3-5]. The 
latter has been shown to reduce the mortality of CAD [6]. New techniques have been 
developed to replace plasmapheresis that selectively remove apolipoprotein (apo) 
B-containing particles extracorporally. These methods make use of immunoabsorption 
columns, chemical-affinity columns, precipitation with heparin at low pH, and 
doublefiltration techniques [7-11]. 
During pregnancy in normal women, the concentrations of all lipids and lipo-
protein fractions undergo striking increases due to changes in the levels of estrogens, 
progestogens, insulin, and human placental lactogen [12,13]. The major lipid incre-
ment is in serum triglyceride (TG) levels, usually twofold to threefold, mainly due to 
an estrogen-induced augmentation of very-low-density lipoprotein synthesis in the 
liver and probably also by a decrease in lipoprotein lipase activity in the vascular bed 
and skeletal muscles [14]. Total cholesterol (TC) levels increase up to 60% above 
nonpregnant levels, an effect that can be ameliorated by a low-cholesterol diet [15]. 
The LDL-C level increases steadily to term (45 to 50%) and is the only fraction to 
remain elevated in the Puerperium. High- density lipoprotein cholesterol (HDL-C) 
concentration reaches its maximum at midgestation (+45%) and shows a subsequent 
decline thereafter. 
Pregnancy in homozygous FH women is extremely rare because of the morbid-
ity and mortality of the disease. A few cases have been reported in the literature 
[16-19]. The main point of concern has been the aggravation of coronary insuffi-
ciency of the mother, mainly due to the hemodynamic changes in pregnancy [20,21]. 
High lipid levels may also affect placental vasculature and cause fetal growth retarda-
tion [17,18]. 
We report the case of an uncomplicated term pregnancy of a 20-year-old woman 
in whom the diagnosis homozygous FH and severe CAD was established [22]. She 
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continued treatment with continuous LDL-apheresis using dextran-sulfate cellulose 
columns throughout her pregnancy [9]. We monitored signs of maternal and fetal 
distress closely and evaluated lipid and lipoprotein levels. 
Subject and methods 
Patient 
The patient, a young woman of Turkish descent, presented at age 14 with multiple 
xanthomas, serum TC levels ranging from 15 to 20 mmol/L, and normal serum TG 
during dietary therapy, and use of resins. After referral to our hospital 1 year later, the 
diagnosis homozygous FH was made by the presence of hypercholesterolemia in both 
parents and all six siblings (Table 1), a history of premature myocardial infarction in 
both parents, fibroblastbinding studies showing a low specific association of LDL of 
30%, and a decreased fractional catabolic rate of LDL-apo В of 0.213 pools/d in an 
LDL turnover study [22]. Family investigation was in accordance with the diagnosis 
homozygous FH in her youngest sister and heterozygous FH in all the other subjects 
[22]. The patient had developed angina pectoris during exercise some months before 
referral. Coronary angiography was performed, which revealed a two-vessel disease 
among which a 50 to 70% main-stem stenosis of the left coronary artery, making 
Table 1. Serum lipid levels (mmol/1) of the proband and the kindred. 
1-1 
1-2 
П-1 
П-2 
П-3 
П-41 
П-5 
П-6 
Sex/Age* (yr) 
M/49 
F/43 
M/24 
F/21 
F/16 
F/15 
F/12 
F/6 
Normal adult 
TC 
9.56 
7.22 
9.54 
7.45 
7.38 
16.93 
7.43 
16.40 
<6.5 
TG 
6.00 
1.30 
1.86 
0.94 
1.44 
3.86 
1.50 
1.12 
<2.0 
HDL-C 
0.44 
0.90 
1.02 
1.19 
1.28 
0.54 
1.13 
0.89 
1.0-1.4 
LDL-C 
6.82 
5.98 
7.85 
6.05 
5.68 
14.39 
5.75 
15.24 
<4.5 
*Age at the moment the family has been investigated. 
»Density 1.006-1.063 g/mL 
\Proband 
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coronary artery bypass grafting necessary. Since then, at the age of 16, biweekly LDL-
apheresis (dextran sulfate cellulose columns, MA-01 unit, Kanegafuchi Chemical 
Industry, Japan) was begun and continued until now, 4 years later. Concomitant treat­
ment with acetylsalicylic acid 160 mg/d and simvastatin was instituted. The latter drug, 
a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor [23], was administered 
in an attempt to limit the rebound in serum cholesterol after LDL-apheresis, and was 
stopped 4 months before conception. Anginal attacks did not recur. Planar and tubero-
eruptive skin xanthomas on the elbows disappeared within 6 months after the start of 
LDL-apheresis. At the age of 18, a repeated coronary angiogram revealed no progres­
sion of the atherosclerotic lesions [22]. On physical examination at the beginning of the 
pregnancy, a 20-year-old woman (length 1.55 m, weight 68 kg) with normal blood 
pressure (135/55 mm Hg) was seen, with inferior corneal lipoid arcs and marked thick­
ening of the Achilles tendons. The electrocardiogram was unremarkable. The patient's 
spouse had serum lipid levels as follows: TC 6.2 mmol/L, TG 0.89 mmol/L, HDL-C 
1.13 mmol/L and LDL-C 4.70 mmol/L. 
mmol/L 
τ 1 1 1 г 
4 В 12 16 20 24 28 32 36 40 44 48 
weeks after start of pregnancy 
tot.cholesterol triglycerides 
Fig. 1. Concentrations of serum TC and TG (mmol/L) during the course 
of pregnancy of a patient with homozygous FH, treated with LLDL-aphe-
resissis. Shown are TC levels before and immediately after LDL aphere-
sis and pretreatment TG levels. LDL-apheresis was not performed from 6 
to 14 weeks' gestation and for 6 weeks after parturition, from 38 to 44 
weeL· ' amenorrhea 173 
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Study protocol 
During pregnancy, vital signs were monitored before each treatment with LDL-
apheresis, and an electrocardiogram at rest was performed each month. Lipid and 
lipoprotein levels were determined as described below. Laboratory safety parameters 
were measured each month, and postheparin lipase activities were measured every 
2 months. Fetal growth was determined serially by ultrasonographic measurements of 
the biparietal diameter, femur length, and abdominal circumference. Starting at 
22 weeks' gestation, ultrasonography of the umbilical artery was performed to measure 
blood flow velocity waveforms (FVWs), both before and after LDL-apheresis using 
two flow indices, the systolic to diastolic ratio (S/D) and the resistance index 
([RI]=(SD)/S), to monitor placental function [24,25]. The maternal placental circulation 
was also studied by blood FVWs of the left and right uterine artery [25,26]. After 
parturition, both macroscopic and microscopic aspects of the placenta and umbilical 
cord were examined. Gestational age was calculated as the number of weeks from the 
last menstrual period. 
Lipid and lipoprotein determinations 
After an overnight fast, blood samples were drawn for measurement of serum lipids 
and lipoproteins, apo Al and apo B, and lipoprotein(a) [Lp(a)] every 2 weeks. Serum 
TC and TG were determined by enzymatic methods (CHOD-PAP, no. 237574, 
Boehringer, Mannheim, Germany, and Sera-PAK, no. 6639, Miles, Italy, respec­
tively). HDL-C was determined using the polyethylene glycol 6000 precipitation 
method [27]. LDL-C was calculated by subtraction. Samples for apo Al, apo B, 
Lp(a) and postheparin lipase activities were initially stored at -80°C and determined 
after the pregnancy. Apo Al and apo В were quantified in serum by 
immunonephelometry [28]. Lp(a) was measured by a specific radioimmunoassay 
(apolipoprotein(a) RIA 100, Pharmacia Diagnostics, Uppsala, Sweden), and lipopro­
tein lipase and hepatic lipase activities were determined with an immunochemical 
technique in plasma samples taken 15 minutes after injection of 50 U heparin/kg body 
weight [29]. 
The selective removal of apo B-containing lipoproteins with LDL-apheresis 
causes sawtooth-like alterations in lipoprotein concentrations (Fig 1) [22]. The in­
crease of lipoprotein levels after the treatment is more rapid in the first than in the 
second week and can be explained by first-order kinetics [5,30]. TC, LDL-C, apo B, 
and Lp(a) all reach pretreatment levels within 7 to 10 days after apheresis, and have 
almost identical recovery half-times. Time-averaged concentrations (C„Yg) of TC, 
LDL-C, apo B, and Lp(a) can be estimated by the following formula: C,
vg = Cmin -Ι­
Ο. 73 ( С ^ - С ^ , where C„,„ is the pretreatment level and C
rain the level immediately 
after the apheresis [31]. We used this formula for the calculation of time-averaged 
levels of serum TC, LDL-C, apo B, and Lp(a). Serum TG reach the pretreatment 
levels within 1 to 2 days after apheresis, and HDL-C is not influenced by LDL-
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apheresis. Therefore, pretreatment concentrations (C^J of triglycerides and HDL-C 
were given. 
Statistical analysis 
Statistical analyses were performed with procedures available in the personal com­
puter software package "Statistix" (NH Analytical Software, St Paul, MN), using the 
Wilcoxon signed-rank test for paired data and a one-way ANOVA for additional 
trend analyses. A P-value of less than 0.05 was considered significant. All results 
are expressed as the mean ± SD unless indicated otherwise. 
Results 
Clinical course 
LDL-apheresis was not performed from 6 till 14 weeks' gestation because of the 
patient's refusal, but was resumed thereafter. The procedures were tolerated well and 
no adverse effects were apparent. The mean plasma volume treated was 4,583 mL 
(n= 12). The cholesterol-lowering diet was not changed and controlled by a dietician. 
The patient's body weight increased 11.3 kg during the pregnancy. At 37 weeks' 
gestation, hospitalization was required because of moderate hypertension and edema 
of the hands and feet, which subsided within 1 day of bed rest. No signs of cardiac 
failure or proteinuria were present. Ultrasonography revealed no signs of fetal dis­
tress or growth retardation. At 38 weeks' gestation, after spontaneous rupture of the 
fetal membranes, labor was induced by intravenous synthetic oxytocin. An epidural 
catheter was inserted and injected with bupivacaine and fentanyl, resulting in an 
adequate sensory block. Twelve hours after the start of the oxytocin infusion, she 
delivered a healthy female infant of 3,300 g. Angina pectoris did not occur during 
labor or in the postpartum period. The infant's 1- and 5-minutes Apgar scores were 
9 and 10, respectively. Both mother and infant were discharged from the hospital on 
the third day postpartum and have subsequently done well. At birth, the neonate's 
cord blood TC was 1.1 mmol/L and at 2 months of age, while being breast-fed, the 
serum TC and LDL-C were 5.5 and 4.05 mmol/L, respectively (>95th percentile for 
controls), confirming obligate heterozygosity for FH [32]. 
Lipids and lipoproteins 
Before and during pregnancy, LDL-apheresis was performed once every 2 weeks. 
Pretreatment and posttreatment levels of serum TC are presented in Fig 1, showing 
the typical sawtooth-like changes in concentration. For purposes of clarity, in Fig 2 
only the time-averaged levels of LDL-C, Lp(a), and apo В are shown. The concentra­
tions of TC and LDL-C followed the course of treatment with LDL-apheresis (Figs 1 
and 2, respectively). LDL-apheresis was not performed from 6 to 14 weeks' gestation 
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mmol/L or g/L mg/dL 
8 12 16 20 24 28 32 36 40 44 48 
weeks after start of pregnancy 
LDL-C Lp(a) Apo В 
Fig. 2. Time-averaged concentrations of LDL-C (mmol/L), Lp(a) 
(mg/dL), and apo В (g/L), during the course of pregnancy of a patient 
with homozygous FH, treated with LDL-apheresis. LDL-apheresis was 
not performed from 6 to 14 weeks' gestation and for 6 weeks after par­
turition, from 38 to 44 weeks' amenorrhea 
and for 6 weeks immediately following parturition. In these periods, both TC and 
LDL-C showed a precipitous increase. After resumption of LDL-apheresis during the 
pregnancy, TC levels immediately before apheresis (C
max
) were lower than pretreat­
ment levels, before the pregnancy (11.22+0.84 ν 12.76±0.73 mmol/L, P<.05), 
respectively). Posttreatment TC levels (C
min) were higher in comparison to treatments 
before the pregnancy (4.27±0.49 ν 3.32±0.63 mmol/L, P<.05), respectively), 
although the same plasma volume was treated biweekly (Fig 1). Time-averaged levels 
of TC were not significantly different in comparison to those in the period before 
pregnancy (Table 2). Time-averaged levels of LDL-C showed a gradual decline 
during the pregnancy, and were significantly lower in the third trimester as compared 
with the prepregnancy levels (Table 2). Apo В levels followed the course of LDL-C 
during the treatment with LDL-apheresis, showing an increase both in the first tri­
mester and after delivery, the periods in which no apheresis was performed (Fig 2). 
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Table 2. Mean (±SD) time-averaged concentrations of serum TC, LDL-C, Apo B, and Lp(a) and pretreatment levels of serum TG, HDL-C, 
and Apo Al during the course of pregnancy of a patient with homozygous FH, treated biweekly with LDL-apheresis 
pre-pregnancy (n=4) 
1st trimester (n=5) 
2nd trimester (n=7) 
3rd trimester (n=5) 
post-pregnancy (n=4) 
TC 
(mmol/L) 
9.88±0.24 
12.78±2.80 
9.78±1.04 
9.46 ±0.43 
13.17±2.37 
TG 
(mmol/L) 
2.21±0.18 
2.61 ±0.49 
3.29±0.40* 
4.33 ±0.45* 
3.03 ±0.99 
LDL-C 
(mmol/L) 
8.21 ±0.38 
11.10±2.58 
7.64±1.18 
6.91 ±0.58* 
11.64±2.18 
HDL-C 
(mmol/L) 
0.66±0.05 
0.65 ±0.05 
1.02±0.11* 
l.O2±0.03* 
0.68±0.03 
Apo Al 
(g/L) 
1.52 ±0.24 
1.42±0.18 
1.92±0.23* 
1.88±0.08* 
1.04±0.09 
Apo В 
(g/L) 
3.01 ±0.29 
4.03 ±0.98 
3.81 ±0.62 
2.89±0.26# 
3.51±1.01 
Lp(a) 
(mg/dL) 
18.5±2.8 
18.4±1.8 
14.7±2.31 
13.3±2.51 
30.8±7.2' 
NOTE. LDL-apheresis was not performed during most of the first trimester and 6 weeks after parturition. 
Differences: *P<0.05 ν prepregnancy (Wilcoxon signed-rank test), #P<0.05 ν 1st and 2nd trimester (ANOVA), V>< 0.001 ν prepregnancy 
and 1st trimester (ANOVA) 
LDL-apheresis during pregnancy in homozygous FH 
In the third trimester, apo В concentrations were significantly lower in comparison to 
the levels in the first and second trimester (Table 2). Trend analysis of time-averaged 
levels of Lp(a) showed a significant decline of 25% to the end of the pregnancy 
(Fig 2 and Table 2). In the period during pregnancy in which no apheresis was 
performed, no increases of Lp(a) concentrations were found, but after parturition, 
during breastfeeding, Lp(a) showed the same precipitous increase as was found for 
LDL-C. 
Notwithstanding LDL-apheresis, there was a gradual increase of serum TG levels 
in the third trimester to twice the concentration present before pregnancy (Table 2). 
After delivery TG levels declined to normal within 2 months (Fig 1). In the second 
trimester, HDL-C showed a 55% increase to a plateau level, remaining constant in the 
last trimester (Fig 3). After parturition, HDL-C concentrations returned to prepregnancy 
levels (Table 2). Apo Al showed the same change in concentrations as HDL-C (Fig 3 
and Table 2). The results of postheparin plasma lipolytic activities are shown in Table 
3. At 10 weeks' gestation, lipoprotein lipase activity was within the range for normal 
female controls [29], showed a decline thereafter, and was still on that lower level 
10 weeks after delivery, during breastfeeding. Hepatic lipase activity showed a 75% 
reduction in the second and third trimester as compared with normal controls, and 
returned to normal levels after parturition (Fig 3). 
Ultrasonic measurements 
Fetal growth appeared normal for the biparietal diameter, femur length, and abdomi­
nal circumference and ran along the 50th percentile during pregnancy. There were no 
Table 3. Postheparin plasma lipoprotein lipase and hepatic lipase activities 
during the course of pregnancy of a patient with homozygous FH, 
compared with normals (mean ± SD) 
Weeks' gestation 
week 10 
week 16 
week 28 
week 34 
post-pregnancy 
normal females (n= = 15) (29) 
Lipoprotein lipase 
7.7 
4.6 
3.9 
3,0 
3.7 
8.9±2.2 
Hepatic lipase 
7.4 
4.7 
3.7 
3.8 
19.4 
16.2±6.4 
Results are μπιοί FFA/mL/h 
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signs of increased placental resistance as measured by the blood FVW of the umbili-
cal artery. Both the S/D and the RI showed a normal gradual decline with the pro-
gression of gestation from 2.8 to 1.7 (normal values, 3.9±1.1 to 2.2±0.3) and 0.64 
to 0.41 (normal values, 0.75 ±0.06 to 0.52 ±0.05), respectively (Table 4) [33]. No 
differences were found between the RI in the pre- and post-LDL-apheresis state (data 
not shown). The uterine artery blood FWV indices, only measured in the last trimes-
ter, were also within the normal range (data not shown) [26]. 
Placental examination 
The placenta weighed 540 g. Histologic examination of the placenta and umbilical ar-
teries after delivery revealed no atherosclerotic changes, infarctions, or lipid deposits. 
Discussion 
Pregnancy and delivery in patients with homozygous FH are rare. Only four cases 
have been reported in the literature (Table 5). Pregnancy in homozygous FH patients 
treated with long-term LDL-apheresis using dextran-sulfate cellulose columns has not 
been reported yet. We describe the first pregnancy of a woman with homozygous FH 
and severe CAD who started treatment with LDL-apheresis 4 years before she be-
came pregnant. 
Clinically, we were concerned about the recurrence of angina pectoris and the devel-
opment of fetal growth retardation. Indeed, there are increased stresses on the cardio-
Table 4. FVWs of the umbilical artery in the preapheresis state, 
quantitated by the S/D and RI during the course of the pregnancy 
of a patient with homozygous FH, treated with LDL-apheresis 
Weeks'gestation 
week 22 
week 26 
week 30 
week 32 
week 34 
week 36 
normal values (33) 
S/D 
2.80 
2.40 
2.28 
2.25 
2.25 
1.70 
3.90±1.05 
to 
2.20±0.32 
RI 
0.64 
0.58 
0.56 
0.55 
0.55 
0.41 
0.75 ±0.06 
to 
0.52±0.05 
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mmol/L or g/L umol FFA/h/mL 
2.5 
2 
1.5 
1 
0.5 
0 
0 4 8 12 16 20 24 28 32 36 40 44 48 
weeks after start of pregnancy 
""&~ HDL-C —$~ apo Al ""*~ hep. lipase 
Fig. 3. Pretreatment concentrations of HDL-C (mmol/L) and apo Al 
(g/L) and activities of postheparin hepatic lipase (umol FFA/h/mL) 
during the course of pregnancy of a patient with homozygous FH, trea-
ted with LDL apheresis. LDL apheresis was not performed from 6 to 
14 weeks' gestation and for 6 weeks after parturition, from 38 to 44 
weeks' amenorrhea 
vascular system throughout pregnancy and particularly at delivery. Both blood vol 
urne and cardiac output increase by 40% to 50%, and during labor cardiac output 
increases another 25% to 80% [34]. It is clear that these hemodynamic alterations in 
pregnancy seriously compromise women with ischemic heart disease. In these 
women, maternal mortality due to myocardial infarction or its complications during 
pregnancy and within 7 days of delivery is as high as 37% [34]. One case report of a 
pregnant heterozygous FH patient describes myocardial infarction and death of the 
mother early in gestation; she had suffered a myocardial infarction 4 years before the 
pregnancy and had been without complaints until then [20]. The hemodynamic 
changes in labor are less dramatic during caudal and epidural analgesia, implying that 
pain is an important component of the cardiovascular stress of labor. Nevertheless, 
cesarean section also causes serious acute hemodynamic stress [34]. Therefore, 
vaginal delivery can be accomplished safely during epidural anesthesia [34]. Follow-
J I I I I I 1 I I I I I L 
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up evaluation during pregnancy and postpartum of our patient revealed no increment 
of coronary insufficiency, and even labor with epidural anesthesia resulted in an 
uneventful vaginal delivery. Given the course of this pregnancy and delivery, it is 
likely that long-term LDL-apheresis has prevented further progression of coronary 
atherosclerosis. Indeed, LDL-apheresis has the potential to prevent progression or 
even cause regression of CAD in patients with FH [35,36]. 
Analysis of the uterine and umbilical artery blood FVW has been shown to be a 
sensitive method for predicting fetal distress during pregnancy and subsequent growth 
retardation [25]. In normal pregnancy, the arterial blood FVW shows a low-resis­
tance flow pattern, with the S/D and the RI gradually decreasing with advancing 
gestational age [26,33]. Pathological pregnancy is characterized by increasing resis­
tance in the placental vascular bed, causing a decrease of the end-diastolic flow 
velocity, and therefore an increment of the S/D and the RI is found [25]. Advanced 
atherosclerotic changes have not been shown to be the cause of placental insufficiency 
during the pregnancy of homozygous FH patients (Table 5). Yet, intrauterine growth 
retardation has been reported in two of four cases [17,18], probably because of 
hyperviscosity and vasoconstriction in the placental vasculature due to the hyper-
lipidemic state [18]. Indeed, Beigel et al. reported an increase of the S/D of the 
umbilical artery during the course of a pregnancy, which became almost normal after 
plasma exchange [18]. LDL-apheresis has also been shown to change hemodynamics 
favorably by improving the rheological properties of the blood, and probably also by 
restoring the endothelium-dependent vasodilation [37,38]. In our case, i.e. continuing 
biweekly LDL-apheresis during the course of the pregnancy, no signs of fetal growth 
retardation were recorded, and the studies of the uteroplacental blood FVW did not 
demonstrate any abnormality. There was a normal decline with the progression of 
gestation, and even no increase in the pre-LDL-apheresis phase was found, indicating 
that there were no signs of placental insufficiency due to increased vascular resistance 
under these metabolic conditions. Additionally, LDL-apheresis was very well toler­
ated without any maternal or fetal adverse effects. Therefore, these data confirm the 
observations of Beigel et al. [18] and seem to stress the importance of continuing 
plasmapheretic treatment in general in homozygous FH patients during pregnancy. 
Patients with homozygous FH appear to retain the ability to increase the lipo­
protein production in response to the hormonal changes in pregnancy [16]. In our 
patient, concentrations of TC and LDL-C showed no pregnancy-induced increase, 
and apo В concentrations paralleled the course of LDL-C levels. Evidently, these 
changes were due to the biweekly treatment with LDL-apheresis. Serum TG levels 
instead showed a normal estrogen-induced twofold increase, which is also known in 
pregnant normocholesterolemic women [12,14]. We did not observe the tremendous 
11-fold increase in TG levels that has been described in a homozygous FH case by 
Tsang et al. [16]. It is not likely that the treatment with LDL-apheresis prevented 
such an increase, because serum TG returns to pretreatment levels within a few days 
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Table 5. Characteristics of homozygous FH patients during the course of pregnancy and delivery, as reported in the literature. 
Medical 
Change in Lipid Levels (%) 
Author history TC TG HDL LDL Treatment 
Fetal 
Cardiac Placental growth 
Delivery events insufficiency retardation 
Tsang, 1978 (16) 
Barss, 1985 (17) 
Beigel, 1990 (18) 
MI 
CABG 
-
AP 
+ 19 +1095 +39 +12 diet section ischemia no (hist) 
cholestyramine 37 weeks postpart. 
no 
induced no 
38 weeks 
normal 
39 weeks 
no 
Goldstein, 1991 (19) PTCA 
Kroon (present study) CABG 
+28 - diet 
+ 147* - - - diet 
plasma ex­
change 
diet 
plasma ex­
change 
-9* +96* +55* -17* diet normal no 
LDL-apheresis 38 weeks 
normal no 
no (hist) 
no (echo) 
no (hist) 
no 
(echo+hist) 
yes, 2250 g 
yes, 2700 g 
no 
no, 3300 g 
Abbreviations: MI, myocardial infarction; CABG, coronary artery bypass graft; AP, angina pectoris; PTCA, percutaneous transluminal 
coronary angiography; hist, histological examination of placenta and umbilical cord; echo, ultrasound analysis of blood FVW of the umbilical 
artery. Concentrations determined immediately before LDL-apheresis have been used for comparison 
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after an apheresis [31,39]. 
Notwithstanding the performance of LDL-apheresis, the gradual decrease of 
LDL-C and apo В in comparison to prepregnancy levels may be caused by the action 
of estrogens, which are known to increase LDL degradation through induction of 
LDL receptors [40,41]. In a case report, Mabuchi et al. described the estrogen-
induced normalization of TC and LDL-C, together with the reduction of tendon 
xanthomas, during pregnancy in a heterozygous FH female due to increased expres­
sion of LDL receptors [42]. Our patient was known to have a small percentage of 
(mutant) LDL receptor activity, and treatment with simvastatin (an hepatic 
hydroxymethyl-glutaryl-coenzyme A reductase-inhibitor) at a dose of 40 mg/d had 
been shown to induce a limited decrease of TC of 11% [22]. Therefore, increasing 
concentrations of estrogens during her pregnancy may have caused the further de­
crease of LDL-C and apo В levels in the second and third trimester as compared with 
prepregnancy levels. 
In two studies, Lp(a) levels have been monitored during pregnancy [43,44]. The 
first one reported an increment of Lp(a) levels to a maximum in the middle of the 
second trimester [43]. In contrast, the second found an increase of Lp(a) until the end 
of pregnancy, which paralleled the changes well known for plasma TG, TC, and apo 
B, suggesting modulation by endogenous hormones [44]. Lp(a) levels in our patient 
did not increase and even showed a 25% decrease in the second and third trimester. 
These changes are caused by LDL-apheresis, which has been shown to induce an 
acute decrease of 70% of Lp(a) concentrations and to decrease time-averaged Lp(a) 
levels by 20% depending on the frequency and volume of plasma treated [31]. The 
almost twofold increase of Lp(a) levels after delivery in comparison to the period in 
which no LDL-apheresis was performed in the first trimester is of interest. Hormonal 
changes after parturition may have caused the increase of Lp(a) levels at that time, 
since interruption of treatment in the first trimester was not followed by such an 
increase. This observation also suggests a role for gonadal steroids in the regulation 
of Lp(a) levels, as has been reported recently [45-47]. 
The pattern of HDL-C increase - a 55% increment to a plateau in the second 
and third trimester - was greater than previously reported for normal subjects [12,13] 
and a homozygous FH case [16], but the subsequent decrease after parturition to 
preconception levels in the homozygote paralleled that reported for normals. In 
pregnancy, estrogens have been shown to cause an increase of very-low-density 
lipoprotein synthesis and a decrease in overall plasma TG removal capacity as mea­
sured by postheparin lipolytic activity [14,48]. Although redistributed within certain 
tissues, lipoprotein lipase activity decreases with the progression of gestation, which 
occurs when maternal TG levels are highest. Hepatic lipase activity shows an even 
more pronounced reduction during the course of pregnancy. Both lipoprotein lipase 
and hepatic lipase contribute significantly to the variation in HDL-C levels in a 
reciprocal manner [49,50]. In our case, the estrogen-induced decrease of hepatic 
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lipase activity may have caused the observed increase of HDL-C. This is supported 
by the simultaneous increase of apo Al, which is known to be increased by high 
estrogen levels [51]. 
In summary, the pregnancy and delivery of this patient with homozygous FH 
and severe CAD, who was treated with LDL-apheresis throughout her pregnancy, did 
not coincide with maternal and fetal distress or gross deterioration of lipid metabo-
lism. In general, long-term LDL-apheresis seems feasible in pregnant homozygous 
FH women. This form of apheresis can delay the onset and progression of CAD and 
may allow the patients to have offspring. Nevertheless, pregnancy and delivery in 
women with ischemic heart disease is hazardous and should be monitored very 
closely. LDL-apheresis should be continued during the pregnancy course to control 
superimposed hyperlipidemia and placental insufficiency and subsequent intrauterine 
growth retardation. 
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The main issue of the present thesis was to study the effect of aggressive lowering of 
low density lipoprotein (LDL) cholesterol on the severity of established cardiovascular 
disease. The mechanisms by which LDL-cholesterol lowering promotes arrest of 
progression of atherosclerotic vascular disease includes a combination of reduction of 
atherogenic LDL-particles, decreased susceptibility of LDL to oxidative modification, 
reduction of the atherosclerosis-associated inflammatory responses in the vessel wall, 
improvement of the endothelium-dependent vasodilation, and stabilization of rupture-
prone lesions. 
More effective lipid lowering has become available with the introduction of 
HMG-CoA reductase inhibitors, e.g. pravastatin or simvastatin. In chapter 2 we showed 
that a 51% reduction of plasma total cholesterol by the administration of high doses of 
pravastatin for 9 months in young Watanabe heritable hyperlipidemic (WHHL) rabbits 
reduced the incidence of both coronary and aortic atherosclerotic plaques in comparison 
with untreated animals. Basal coronary flow and bradykinin-induced increase in coro­
nary flow were higher than in the control animals and comparable with normochol-
esterolemic New Zealand white rabbits. Moreover, the change in bradykinin-induced 
flow was greater in the animals with lower plasma total cholesterol levels. This indi­
cates that in this model cholesterol lowering with pravastatin not only retards the 
progression of plaque formation, but also preserves endothelium-dependent relaxation 
of the coronary arteries. 
An alternative approach of cholesterol lowering is LDL-apheresis using dextran 
sulfate cellulose columns. This treatment selectively removes large amounts of 
apolipoprotein B- (apo B) containing lipoproteins from plasma, i.e. VLDL and LDL, by 
chemical binding of apo В to dextrans. We applied biweekly LDL-apheresis in combi­
nation with the administration of simvastatin in an open randomized 2-years trial, the 
LDL-Apheresis Atherosclerosis Regression Study (LAARS), as has been described in 
the chapters 3 to 7 and 9. The effects of this more aggressive cholesterol lowering 
treatment in comparison to conventional treatment with simvastatin alone were evalu­
ated in 42 hypercholesterolemic men with extensive coronary artery disease (CAD). 
Primary outcome measures were changes in CAD, as measured by quantitative coro­
nary angiography and the angiographic assessment of the regional myocardial blood 
flow, whereas secondary outcome measures were changes in peripheral vascular dis­
ease (PVD), as measured noninvasively by ultrasound techniques (chapter 3). 
LDL-apheresis causes sawtooth-like alterations in plasma lipoprotein concentra­
tions. The efficacy of the treatment depends on the pre- and posttreatment lipid levels, 
and on the rate of return to pretreatment levels, the so-called rebound. In chapter 4 the 
rebound of lipids and lipoproteins from the subjects of LAARS were described. We 
showed that a single LDL-apheresis removed roughly 5 to 6% of the total exchangeable 
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cholesterol body stores. Although all patients were treated concomitantly with the 
cholesterol synthesis inhibitor simvastatin at a dose of 40 mg/day, the pretreatment ratio 
of lathosterol to cholesterol was increased to 3.60±1.45, indicating that long-term 
aggressive lipid lowering had increased whole-body cholesterol synthesis. By nonlinear 
regression analysis of the rebound curves the recovery half-times of LDL and Lp(a) 
were comparable, 4.0 and 3.5 days, respectively, whereas return to pretreatment levels 
took 13 and 12 days, respectively. This indicates that the interval of biweekly treat-
ments is acceptable. Additionally, in this chapter a simple uniform formula was pre-
sented for the estimation of the mean plasma levels between two apheresis procedures 
using only pre- and posttreatment levels . 
In chapter 5 we described that a single LDL-apheresis improved all parameters for 
in-vitro copper-induced LDL-oxidizability, lag-time, maximal rate of diene production, 
and time to maximal diene production, until the 3rd day after apheresis. This could be 
explained by changes in the fatty acid composition, since the linoleic acid and 
arachidonic acid content of LDL were reduced by 11 and 18%, respectively. Although 
large amounts of the main lipophilic antioxidant of LDL, vitamin E, were removed, the 
vitamin E content per LDL-particle did not change acutely, nor in the days of the 
recovery period. Since the biological consequences of the rather short time-span of less 
susceptibility to LDL-oxidation are unknown, it is concluded that LDL-apheresis at 
least does not affect LDL-oxidizability in a negative way. 
In chapter 6 and 7 we described the outcome of long-term aggressive lipid lower-
ing treatment on CAD. Baseline LDL-cholesterol was lowered by an average of 63% 
(from 7.8±1.9 to 3.0±1.1 mmolTL) and by 47% (from 7.9±2.3 to 4.1±1.6 mmol/L) in the 
apheresis and medication group, respectively. Quantitative coronary angiography 
showed no differences between both groups in coronary artery mean segment diameter 
(MSD), -0.01±0.16 versus 0.03±0.16 mm, respectively, nor in minimal obstruction 
diameter (MOD), -0.01±0.13 versus 0.01±0.11 mm, respectively. This means that 
complete arrest of progression of CAD was achieved in both groups after 2 years of 
treatment. However, bicycle exercise tests in the apheresis group showed a significant 
prolongation of the ischemic threshold on the ECG, the time to 0.1 mV ST-depression, 
from 461±47 to 641±50 sec, in comparison with no change (485±81 to 442±60 sec) in 
the medication group. This may indicate that functional improvements preceded ana-
tomical changes (chapter 6). Indeed, regional myocardial blood flow assessed by digital 
subtraction angiography with videodensitometric calculation of the hyperemic mean 
transit time (HMTT) showed a significant improvement from 3.4± 1.2 to 2.9±0.8 sec in 
the apheresis group versus no change (3.0±1.1 to 3.0±0.9 sec) in the medication group 
(chapter 7). Categorizing patients into groups with increased versus reduced time to 
0.1 mV ST-depression showed a 16% decrease of HMTT in the group with an im-
proved versus a 4% increase in HMTT in the group with a worsened ischemic threshold 
(P=0.04). Therefore, more aggressive lipid lowering increased the ischemic exercise-
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induced threshold by improving the myocardial blood flow, i.e. restoring the 
endothelialdependent and/or independent relaxation in the coronary circulation. 
Assessments of peripheral vascular atherosclerosis were performed in the 
aortotibial tract and in the carotid arteries. In the aortotibial tract a combination of the 
ankle/arm systolic blood pressure index (AAI) and Doppler spectrum analysis (DOSA) 
of the femoral arteries, at rest and during reactive hyperemia was used to measure 
hemodynamically significant pathology. In the carotid arteries early atherosclerotic 
changes were assessed by B-mode echography of the intima-media thickness (IMT) of 
the near and far wall of the common carotid artery, the bifurcation, and the internal 
carotid artery. In chapter 8 we showed that the prevalence of hemodynamically signifi­
cant PVD in the lower extremities in patients with heterozygous familial 
hypercholesterolemia (FH) was 31% compared to 4% in age-matched normochol-
esterolemic control subjects. The first manifestations of PVD were already present at 
the age of 30. These data indicate that PVD is much more prevalent in FH patients than 
is generally assumed. We also showed that men and women were equally affected at all 
ages in contrast to the prevalence of CAD in FH which presents approximately 10 years 
earlier in men compared to women. 
Sequential measurements of PVD in LAARS were performed and described in 
chapter 9. The number of sites with hemodynamic stenoses in the right and/or left 
aortotibial tract was reduced from 17 to 13 in the apheresis group and increased from 
11 to 23 in the medication group (/'=0.002). Categorization of all patients in those who 
showed an increase in the number of hemodynamic aortotibial stenoses (n=15) versus 
those who improved or showed no change (n=26) revealed that the latter group had 
significantly lower LDL-cholesterol, lipoprotein(a) [Lp(a)], and apo В levels. The 
analyses of the IMT of the carotid arteries showed comparable changes: mean IMT of 
all carotid segments in the apheresis group regressed from 0.91±0.38 to 0.85±0.29 mm 
but thickened from 0.88±0.30 to 0.93±0.40 mm in the medication group (PO.OOl). 
Changes in IMT were predominantly found in the common carotid artery and the 
bifurcation, and were associated with changes in Lp(a) levels (r=0.59, P=0.004). So, 
both early and hemodynamically significant atherosclerotic lesions regressed by more 
aggressive lipid lowering. This indicates that although atherosclerosis is a generalized 
condition, the impact of lipid lowering may be different for the coronary and the pe­
ripheral vascular beds. 
Finally, in chapter 10 we described a patient with homozygous FH on long-term 
LDL-apheresis treatments during a pregnancy. She was known with severe CAD from 
the age of 15 and treated with biweekly LDL-apheresis and simvastatin since then. 
Mean time-averaged LDL-cholesterol levels during treatment forgoing the pregnancy 
were 8.2±0.4 mmol/L. During the course of the pregnancy, while apheresis was contin­
ued, she developed no signs of coronary insufficiency, neither during delivery. Serial 
Doppler spectrum measurements of the uterine and umbilical artery did not show signs 
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of insufficiency of the uteroplacental circulation. It is postulated that long-term LDL-
apheresis is the therapy of choice in homozygous FH and is able to prevent atheroscle­
rotic complications, even during pregnancy. 
Conclusions that were drawn from these studies: 
1. In WHHL rabbits lipid lowering with high doses of pravastatin retards the progres­
sion of atherosclerosis and preserves endothelium-dependent vasodilation. 
2. In hypercholesterolemic patients (total cholesterol >8.0 mmol/L) with extensive 
coronary atherosclerosis lipid lowering with simvastatin alone is able to arrest the 
progression of CAD, but apparently insufficient to improve myocardial blood flow 
or prevent the progression of PVD. 
3. More aggressive lipid lowering with LDL-apheresis and simvastatin in the same 
population arrests the progression of CAD and also improves myocardial blood flow, 
and moreover, induces regression of PVD. 
4. Functional improvements of endothelial vasomotion precede anatomical changes in 
the process of regression of atherosclerosis. 
5. The impact of lipid lowering is different between coronary and peripheral vascular 
beds. 
6. Biweekly long-term LDL-apheresis is a safe and effective therapy, which should be 
considered in drug refractory hypercholesterolemic patients with established CAD. 
7. During LDL-apheresis time-averaged concentrations of total cholesterol, LDL-
cholesterol, Lp(a), and apo В can be uniformly estimated by the following formula: 
CAVG^MIN^-^-HCMAX-CMN). 
8. A single LDL-apheresis procedure induces short-term, favourable changes in LDL-
oxidizability by changes in the composition of the LDL particles. 
9. Hemodynamically significant PVD is present in approximately one third of subjects 
with heterozygous FH without differences in gender. 
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Samenvatting en conclusies 
Het belangrijkste onderwerp van dit proefschrift was het bestuderen van het effect van 
rigoreuze verlaging van het lage dichtheidslipoproteïne (low density lipoprotein, LDL, 
dat grotendeels uit cholesterol bestaat), op de progressie van reeds bestaand hart- en 
vaatlijden. De mechanismen die leiden tot een afname van de voortgang van atheroscle-
rotisch vaatlijden ('aderverkalking') zijn diverse. Te weten: amarne van de concentratie 
van de atherogene LDL-deeltjes, verminderde gevoeligheid van LDL voor oxidatieve 
verandering, vermindering van de met athérosclérose samenhangende ontstekingspro-
cessen in de vaatwand, verbetering van endotheel-afhankelijke bloedvatverwijding, en 
het stabiliseren van atherosclerotische lesies van de bloedvatwand die makkelijk kun-
nen ruptureren. 
Effectievere verlaging van het cholesterolgehalte in het bloed is beschikbaar 
geworden met de introductie van een groep geneesmiddelen die de aanmaak van cho-
lesterol remmen, HMG-CoA reductase remmers genoemd, zoals bijvoorbeeld prava-
statine of simvastatine. In hoofdstuk 2 staat een studie beschreven met jonge Watanabe 
konijnen, een speciale stam met een erfelijke aandoening waardoor het cholesterolge-
halte in het bloed sterk verhoogd is. Een deel van deze konijnen werd gedurende 
9 maanden behandeld met hoge doses pravastatine. In die studie laten we zien dat een 
vermindering van 51% van het totale cholesterolgehalte in het bloed zowel het optreden 
van atherosclerotische afwijkingen in de bloedvaten van het hart (de coronairarterieën) 
als in de lichaamsslagader (aorta) verminderd heeft in de behandelde dieren. Ook de 
basale bloeddoorstroming in het hart en de door bradykinine geïnduceerde toename van 
de bloeddoorstroming in het hart waren hoger in de behandelde konijnen in vergelijking 
met de controle groep. Deze waarden waren vergelijkbaar met die van konijnen met een 
normaal cholesterolgehalte. Bovendien was de verandering die teweeg gebracht werd 
door bradykinine groter in die dieren die een lager cholesterolgehalte in het bloed 
hadden. Dit betekent dat, in deze proefopstelling, het verlagen van cholesterol met 
pravastatine niet alleen de verdere progressie van het vormen van atherosclerotische 
afwijkingen tegengaat, maar dat ook de endotheel-afhankelijke verwijding van de 
bloedvaten van het hart behouden blijft. 
Een alternatieve manier om het cholesterolgehalte te verlagen is LDL-aferese met 
behulp van dextraansulfaat cellulose kolommen ('vetspoeling van het bloed'). Deze 
behandeling verwijdert selectief grote hoeveelheden lipoproteïnen uit het bloed die het 
eiwit apolipoproteïne В (apo B) bevatten, namelijk VLDL en LDL. Dit gebeurt door 
chemische binding van apo В aan dextranen, In een open, gerandomiseerde, 2 jaar 
durende studie, de LDL-Apheresis Atherosclerosis Regression Study (LAARS) behan­
delden wij patiënten met LDL-aferese, lx per 2 weken, in combinatie met het medica-
ment simvastatine. Dit staat beschreven in de hoofdstukken 3 t/m 7 en 9. De effecten 
van deze meer agressieve manier om het cholesterolgehalte te verlagen werden vergele-
195 
Samenvatting en conclusies 
ken met de gebruikelijke behandeling met alleen simvastatine. Het onderzoek werd 
uitgevoerd bij 42 mannen met een sterk verhoogd cholesterolgehalte en met uitgebreid 
vaatlijden van het hart (coronary artery disease, CAD). De effecten van de behandeling 
werden gemeten met kwantitatieve coronaire angiografie en met bepaling van de 
regionale bloeddoorstromüig in de hartspier gemeten met digitale subtractie technieken. 
Tevens werden de veranderingen in perifere bloedvaten (in hals en benen, peripheral 
vascular disease, PVD) gemeten met echografische methoden (hoofdstuk 3). 
LDL-aferese veroorzaakt zaagtandachtige veranderingen in de concentraties van 
lipoprotéines. De effectiviteit van de behandeling hangt af van de bloedwaardes vóór en 
na de behandeling en van de snelheid waarmee de concentraties van vóór de behande-
ling weer bereikt worden, de zogenaamde rebound. In hoofdstuk 4 wordt de rebound bij 
de patiënten uit LAARS beschreven. We toonden aan dat door een eenmalige LDL-
aferese ongeveer 5 tot 6% van het uitwisselbare cholesterol in het lichaam, daadwerke-
lijk verwijderd wordt. Hoewel alle patiënten tegelijkertijd behandeld werden met de 
cholesterol synthese remmer simvastatine in een dosis van 40mg/dag, was de ratio van 
lathosterol/cholesterol vóór de aferese verhoogd tot 3.60±1.45. Dit geeft aan dat lang-
durige agressieve cholesterolverlaging de totale synthese van cholesterol in het lichaam 
doet toenemen. Niet lineaire regressieanalyse van de rebound grafieken van LDL en 
Lp(a) liet zien dat de halveringstijd voor de toename van de concentratie na aferese 
vergelijkbaar was (respectievelijk 4.0 en 3.5 dagen). Het duurde respectievelijk 13 en 
12 dagen voordat de waarden van vóór de behandeling weer bereikt waren. Dit geeft 
aan dat de tweewekelijkse intervallen voor de aferese acceptabel zijn. Daarnaast is in 
dit hoofdstuk een eenvoudige formule beschreven waarmee uit de concentratie vóór en 
direct na de behandeling de gemiddelde concentratie tussen twee afereses bepaald kan 
worden. 
In hoofdstuk 5 beschrijven we dat een eenmalige LDL-aferese alle parameters 
verbeterd van de door koper geïnduceerde oxideerbaarheid van LDL. Dit bleef aanwe-
zig tot de derde dag na de aferese. Het kon verklaard worden door veranderingen in de 
vetzuur samenstelling van LDL, omdat de hoeveelheid linoleenzuur en arachidonzuur 
verminderd waren met respectievelijk 11 en 18%. Hoewel grote hoeveelheden van het 
lipofiele antioxidant van LDL, vitamine E, verwijderd waren, veranderde het gehalte 
van vitamine E per LDL-deeltje niet. Omdat de biologische gevolgen van de vrij korte 
tijd van verminderde gevoeligheid voor oxidatie van LDL niet bekend is, concludeer-
den we dat LDL-aferese de LDL-oxideerbaarheid in ieder geval niet negatief be-
ïnvloedt. 
In hoofdstuk 6 en 7 worden de resultaten van LAARS beschreven ten aanzien van 
het coronairlijden. Het LDL-cholesterol in de aferesegroep was gemiddeld verminderd 
met 63% (van 7.8±1.9 tot 3.0±1.1 mmol/L) en in de medicatiegroep met 47% (van 
7.9±2.3 tot 4.1±1.6 mmol/L). De kwantitatieve coronaire angiografie liet geen verschil-
len tussen de twee groepen zien in de gemiddelde segment diameter van de coronair 
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arterieën (MSD), -0.01±0.16 in vergelijking met 0.03±0.16 mm. En ook niet in de 
gemiddelde diameter van de ergste sténose (MOD), -0.01±0.13 in vergelijking met 
O.OÜO.l 1 mm. Dit betekent dat volledige stilstand van de progressie van het coronair 
vaat lij den was bereikt in beide groepen na 2 jaar behandeling. Echter, bij de fietstesten 
bleek in de aferesegroep een significante verlenging te zijn opgetreden van de tijd 
voordat zuurstoftekort in de hartspier ontstond. Dit werd gemeten op het ECG als de 
tijd totdat een daling optrad van 0.1 mV in het ST-segment. In de aferesegroep nam 
deze tijd toe van 461±47 tot 641±50 sec, terwijl er in de medicatiegroep geen verande-
ring werd gezien (485±81 tot 442±60 sec). Dit zou er op kunnen wijzen dat verbete-
ringen in de functie van de bloedvaten vooraf gaan aan anatomische veranderingen 
(hoofdstuk 6). Inderdaad bleek de regionale bloeddoorstroming van de hartspier, bere-
kend aan de hand van de gemiddelde passagetijd van het contrast tijdens maximale 
vaatverwijding (HMTT), significant verbeterd te zijn in de aferese groep (van 3.4±1.2 
tot 2.9±0.8 sec) en niet veranderd in de medicatiegroep (van 3.0±1.1 tot 3.0±0.9 sec). 
Als de patiënten ingedeeld werden in een groep die een verbetering liet zien bij de 
fietstest en in een groep die geen verbetering liet zien, dan werd in de verbeterde groep 
16% reductie van de HMTT en in de niet verbeterde groep een toename van 4% van de 
HMTT gevonden (P=0.04). Dus het agressiever verlagen van het cholesterolgehalte 
verminderde het zuurstoftekort van het hart bij inspanning door de bloeddoorstroming 
van de hartspier te verbeteren. Dit wordt waarschijnlijk verklaard door het verbeterde 
vermogen van de bloedvaten om zich te verwijden onder invloed van endo-
theel-afhankelijke en -onafhankelijke factoren (hoofdstuk 7). 
Metingen van athérosclérose in de perifere vaten werd gedaan in de grote slag-
aders naar de benen (aortotibiale gebied) en in de slagaders in de hals (arteria carotis). 
Voor de benen werd een combinatie gebruikt van de ratio van de systolische bloeddruk 
in de enkel en de arm (enkel/arm druk) en van Doppler spectrum analyse (DOSA) van 
de bloedvaten in de bovenbenen (arteria femoralis). Dit werd gemeten zowel in rust als 
tijdens maximale vaatverwijding (hyperemie) en is een maat voor vernauwingen die de 
bloeddoorstroming belemmeren (hemodynamisch belangrijke Stenosen). In de halsva-
ten werden juist vroege atherosclerotische afwijkingen gemeten door middel van 
echografische bepaling van de intima-media dikte (IMT) van de vaatwand. Dit werd 
uitgevoerd op 3 plaatsen in de halsslagader. Gebruik makend van de enkel/arm druk en 
de DOSA van de arteria femoralis laten we in hoofdstuk 8 zien dat bij patiënten met 
een heterozygote vorm van familiaire hypercholesterolemie (FH) hemodynamisch 
belangrijke Stenosen in de bloedvaten naar de benen veel frequenter voorkomen (31%) 
dan bij een groep van gelijke leeftijd en met een normaal cholesterolgehalte (4%). De 
eerste verschijnselen van perifeer vaatlijden bij deze groep FH-patiënten waren reeds 
aanwezig op de leeftijd van 30 jaar. Deze gegevens laten zien dat perifeer vaatlijden 
veel vaker voorkomt bij FH-patiënten dan algemeen wordt aangenomen. We toonden 
ook aan dat er bij deze patiënten geen verschil is tussen mannen en vrouwen in de 
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leeftijd waarop zij zich presenteren met de eerste verschijnselen van perifeer vaatlijden 
in tegenstelling tot vaatlijden aan het hart dat bij mannen ongeveer 10 jaar eerder 
begint. 
De diverse metingen van het perifere vaatlijden bij LAARS zijn beschreven in 
hoofdstuk 9. Het aantal hemodynamisch belangrijke vernauwingen in de vaten naar de 
benen nam af van 17 tot 13 in de aferese groep en nam toe van 11 tot 23 in de medica-
tiegroep (P=0.002). Als alle patiënten werden verdeeld in een groep die een toename in 
het aantal vernauwingen liet zien (n=15) in vergelijking met de patiënten die geen 
verandering of een amarne lieten zien, konden we vaststellen dat de onverander-
de/verbeterde groep een significant lager LDL-cholesterol, lipoproteïne(a) [Lp(a)] en 
apo В gehalte had. De analyses van de IMT van de halsslagaders liet vergelijkbare 
veranderingen zien: de gemiddelde IMT van alle segmenten van de halsslagaders 
verminderde in de aferesegroep van 0.9Ü0.38 tot 0.85±0.29 mm maar werd dikker in 
de medicatiegroep (van 0.88±0.30 tot 0.93±0.40 mm, PO.001). Veranderingen in IMT 
waren geassocieerd met veranderingen in het Lp(a) gehalte (r=0.59, P=0.004). Dus 
zowel hemodynamisch significante atherosclerotische Stenosen als vroege afwijkingen 
namen af tijdens agressieve cholesterolverlaging maar niet onder de gebruikelijke 
therapie. Hoewel athérosclérose een gegeneraliseerde ziekte is, is het effect van choles-
terolverlaging verschillend voor de perifere bloedvaten en voor de bloedvaten van het 
hart. 
Tenslotte hebben we in hoofdstuk 10 een patiënte beschreven met een homozygo-
te FH behandeld met langdurige LDL-aferese tijdens de zwangerschap. Vanaf haar 
1 Sde jaar was zij bekend met ernstig vaatlijden van het hart en wordt sindsdien behan-
deld met tweewekelijks LDL-aferese en simvastatine. De gemiddelde LDL-cholesterol 
gehaltes onder behandeling voorafgaande aan de zwangerschap waren 8.2±0.4 mmol/L. 
Tijdens de zwangerschap, terwijl de LDL-aferese werd voortgezet, ontstonden er geen 
angineuze klachten. Dit gebeurde ook niet tijdens de bevalling. Herhaalde Doppler 
spectrum metingen van de vaten van de baarmoeder en de navelstreng gedurende de 
zwangerschap lieten geen tekenen zien van onvoldoende doorbloeding van de uterus en 
placenta. Deze casus toont aan dat langdurige LDL-aferese de behandeling van keuze is 
bij patiënten met homozygote FH en dat hiermee belangrijke cardiovasculaire compli-
caties werden voorkomen, zodat deze patiënte zelfs een zwangerschap kon voldragen. 
Conclusies die uit deze onderzoeken getrokken kunnen worden: 
1. Verlaging van het cholesterolgehalte bij jonge Watanabe konijnen met hoge doses 
pravastatine remt de progressie van athérosclérose en houdt de endotheel-afhanke-
lijke verwijding van de bloedvaten in stand. 
2. Cholesterolverlaging met simvastatine alleen bij patiënten met een sterk verhoogd 
cholesterolgehalte (>8.0 mmol/1) en uitgebreid coronarialijden remt de progressie 
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van coronarialijden maar verbetert niet de doorbloeding van de hartspier noch voor-
komt het progressie van het perifere vaatlijden. 
3. De meer agressieve wijze van het verlagen van het cholesterolgehalte met LDL-
aferese en simvastatine in eenzelfde populatie remt de progressie van coronarialij-
den, verbetert de doorbloeding van de hartspier en veroorzaakt regressie van het 
perifere vaatlijden. 
4. Tijdens het proces van regressie van athérosclérose lopen functionele veranderingen 
vooruit op de anatomische. 
5. De verlaging van het cholesterolgehalte heeft verschillende effecten op de vaten van 
het hart en de perifere vaten. 
6. Langdurige behandeling met LDL-aferese is een veilige en effectieve therapie. Deze 
behandeling moet overwegen worden bij patiënten met coronarialijden bij wie het 
cholesterolgehalte niet adequaat kan worden verlaagd met medicatie alleen. 
7. Tijdens LDL-aferese kunnen gemiddelde concentraties over de tijd van het totaal 
cholesterol, LDL-cholesterol, Lp(a) en apo В allemaal met dezelfde formule geschat 
worden: Со^^м^+О.ТЗССмдх-Смпд). 
8. Een eenmalige LDL-aferese veroorzaakt kortdurige, gunstige veranderingen in de 
oxideerbaarheid van LDL door veranderingen in de samenstelling van de 
LDL-deeltjes. 
9. Bij één op de drie patiënten met heterozygote FH treft men hemodynamisch signifi-
cant perifeer vaatlijden aan, onafhankelijk van het geslacht. 
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Dankwoord 
Velen hebben aan de totstandkoming van dit proefschrift bijgedragen. Graag maak ik 
van de gelegenheid gebruik om een aantal van hen hiervoor te bedanken. 
De bijdrage van de patiënten aan LAARS is het meest essentieel geweest. Het 
fanatisme waarmee zij het 2 jaar lang volhielden om iedere keer weer op de polikliniek 
of de aferesekamer te verschijnen en het schijnbaar probleemloos ondergaan van 
allerlei meer of minder invasieve onderzoeken bewonder ik zeer in hen allen. Door de 
lange periode van intensief contact zijn velen van hen personen voor mij geworden 
waar ik bijzondere herinneringen aan heb. 
Dorothé Kampschreur, research verpleegkundige, verdient eigenlijk de meeste 
hulde. Jij was het die op onnavolgbare wijze de patiënten stimuleerde en motiveerde. 
Voor iedereen had je een brede (luide) lach paraat. Je was naar mijn smaak de centrale 
figuur bij LAARS en jij zorgde met woord en daad voor alle afspraken, om niet te 
spreken over je talenten op de cath-kamer en jouw vermogen om computers te laten 
crashen. 
De meiden van de aferesekamer, Gaby, Margriet, Mariette en Suzanne hebben de 
patiënten die geafereerd moesten worden steeds bijgestaan als er weer eens een schier 
oneindige sessie van problematische venapuncties op maandagmorgen plaatsvond. De 
patiënten waren in goede handen als ik de snelheid van de bloedpomp flink omhoog 
had gedraaid. Het was altijd een genot om even bij te praten en stoom te kunnen afbla-
zen. 
Vele andere afdelingen hebben meegewerkt aan de verschillende onderzoeken 
voor onze patiënten. Alle medewerkers van het klinisch vasculair laboratorium wil ik 
bedanken voor hun ondersteuning en bereidheid om weer eens een afspraak te verzetten 
of juist "even gauw tussendoor", maar met de grootste nauwkeurigheid, een IMT-
meting te doen. Wim van Asten bedankt voor het geduld dat je toonde om me wegwijs 
te maken op het gebied van hemodynamiek. Ook wil ik de medewerkers van de cathete-
risatiekamer hartelijk bedanken voor de wijze waarop jullie met alweer een andere 
onderzoeker omgingen. Het was altijd heel plezierig vertoeven bij jullie. De functieaf-
deling van de afdeling cardiologie wil ik ook niet vergeten. Daar was ik een kind aan 
huis als het ging om fietstesten en wat dies meer zij. Een lipidenonderzoek kan niet 
zonder lipidenlaboratorium. Anneke, Heidi, Magda en Pietemei ontzettend bedankt 
voor de zeer goede professionele en vooral intermenselijke ondersteuning. Doordat 
mijn onderzoek zo sterk klinisch gericht was, heb ik maar weinig lab-handelingen zelf 
hoeven te doen. Desalniettemin was het lab toch altijd een veilige thuishaven. Pierre 
Demacker, jij geeft op bijzondere wijze leiding aan dit "zootje". Ik wil je bedanken 
voor al de kritische noten die jij hebt toegevoegd aan mijn proefschrift. Een revisie van 
een artikel van jouw hand was nooit een pretje; het werd er wel beter van. 
De cardiologen Nico Pijls, Evert Lamfers en Wim Aengevaeren zijn allen in 
successie actief betrokken geweest bij mijn onderzoek en verdienen mijn speciale dank. 
Wim, jij hebt het leeuwendeel van de cardiologische input voor je rekening genomen. 
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Bedankt voor de samenwerking. 
Anton Stalenhoef is de initiator en drijvende kracht achter LAARS geweest. Beste 
Anton, jij bent een gedreven onderzoeker, en ik heb veel van je geleerd. Het onderzoek 
heeft mede de basis gelegd voor mijn huidige functie. Prof. dr. Ab van 't Laar was altijd 
op de achtergrond aanwezig. Beste Ab, door jouw emeritaat zijn onze discussies over 
mijn onderzoek enigszins achterwege gebleven. Dejaren dat ik bij jou in opleiding was, 
waren heel plezierig. Jij bent voor mij als arts een groot voorbeeld. Uiteraard gaat mijn 
dank ook uit naar Paul Stuyt, Mare Mol en Bas Bredie van wie en met wie ik de lipido-
logie in de vingers kreeg. Mare, we waren een goed team. 
Alle collegae en secretaresses werkzaam op de Interne Geneeskunde van de 
Radboud dank ik langs deze weg voor de prettige werksfeer. Samen hebben we heel 
wat gezellige uren doorgebracht. Ook mijn huidige collegae in het AZM wil ik bedan-
ken voor de momenten dat ze me uit de wind hielden om te kunnen schrijven. 
Dank aan mijn ouders die mij de gelegenheid hebben gegeven om te gaan stude-
ren en altijd vertrouwen in mij hebben gehad, ook als ik het anders deed dan de ande-
ren. 
Verder wil ik iedereen bedanken die de afgelopen jaren voor Féline en Maxime 
hebben gezorgd, zodat aan het proefschrift gewerkt kon worden. Hierbij wil ik met 
name mijn schoonouders noemen als echte rotsen in de branding. 
Lieve Désirée, dank je wel voor al je steun, onzichtbaar en zichtbaar in de layout 
van dit boekje. Je bent een reus die veel meer kan dragen dan een instabiel bekken doet 
vermoeden. Beiden full-time werken en veel reizen maakt het er zeker niet rustiger op, 
maar nu lijkt toch echt de periode aan te breken dat we meer tijd voor elkaar en de 
kinderen krijgen. 
Lieve Féline en Maxime, jullie weten niet beter dan dat papa aan zijn boekje moet 
werken. Nu is het eindelijk af en gaan we met z'n vieren een heleboel leuke dingen 
doen. 
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Stellingen 
behorende bij het proefschrift 
'Aggressive cholesterol lowering and regression of atherosclerosis 
Studies on LDL-apheresis' 
Bram Kroon, 9 oktober 1996 
1. Bij secundaire preventie van hart- en vaatziekten geldt t.a.v het serumcholesterolgehalte: 
hoe lager hoe beter. 
Dit proefschrift 
2. Voorafgaande aan de angiografische afname van athérosclérose treedt functioneel herstel 
op van de reactiviteit van de vaatwand. 
Dit proefschrift 
3. Aan het arsenaal van uitkomstvariabelen van toekomstige regressiestudies dienen functio-
nele testen te worden toegevoegd. 
Dit proefschrift 
4. Het gebruik van een HMG-CoA reductase remmer voorkomt de toename van de choleste-
rolsynthese tijdens behandeling met LDL-aferese niet. 
Dit proefschrift 
5. LDL-aferese moet alleen overwogen worden als medicamenteus het serumcholesterolge-
halte niet voldoende kan worden verlaagd. 
Dit proefschrift 
6. De prevalentie van perifeer vaatlijden bij familiaire hypercholesterolemie is veel hoger 
dan klinische verschijnselen doen vermoeden. 
Dit proefschrift 
7. Hypercholesterolemie induceert en cholesterolverlaging herstelt de endotheeldysfunctie 
van macroscopisch normale bloedvaten. 
Stroes et al, Lancet 1995;346:467-71 
8. In het licht van de relatie tussen Helicobacter pylori en peptische ulcera verdient de 
associatie van athérosclérose met Chlamydia pneumoniae infecties en de aanwezigheid 
van dit microorganisme in plaques nader onderzoek. 
Kuo et al, PNAS USA 1995;92: 6911-4 
9. Ondanks de negatieve publicaties ten aanzien van de behandeling van hypertensie met 
Calciumantagonisten is er op dit moment geen enkele reden om de behandeling te herzien. 
van Zwieten et al, Ned Tijdschr Geneeskd 1995;139:2715-21 
10. Elke patient met een recent ontstane reumatoïde artritis moet verwezen worden naar een 
reumatoloog voor agressieve ziektemodulerende behandeling. 
11. Absence of evidence is not evidence of absence. 
Altman & Bland, BMJ1995;311:485 
12. Voor veel betawetenschappers geldt maar al te vaak dat ze betwetenschapper zijn. 
13. De Nederlandse taal is wetenschappelijk gezien een dialect. 
14. 'Bekkeninstabiliteit' t.g.v. toegenomen laxiteit van de ligamenten in de zwangerschap kan 
een zeer invaliderende aandoening zijn die langdurige, intensieve revalidatie vereist. 
Eigen waarneming 
15. Elke academisch werkende specialist wordt geacht evenredig te participeren in kliniek, 
onderwijs en wetenschappelijk onderzoek. Hierdoor wordt geen optimaal gebruik ge-
maakt van ieders specifieke kwaliteiten. 



